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Introduction 
Ύοιι might reason that a matter of such vital importance as prognosis must have been 
the subject of careful study, and that generations of physicians must, by the time the 
twentieth century has been reached, have so thoroughly investigated the subject that (he 
basis of a safe and sure progiwsis must have been laid, at all events for the more common 
diseases. You wil not be long in practice before you find that this is not so. ' 
This quotation of Sir James MacKen-
zie in 1916 is still up to date in the nine­
ties of the twentieth century for many dis-
eascs and certainly for rheumatoid 
arthritis. The prognosis of rheumatoid 
arthritis is (he focus of this thesis. 
onset after the age of 60, RA is more 
equally distributed over the sexes. Be­
cause of the chronicity, RA is a major 
problem in the elderly: 1.5% of the men 
and 4.7% of the women in the Nether­
lands above the age of 65 arc suffering 
from RA.5 
Rheumatoid arthritis 
Rheumatoid arthritis (RA) is a systemic 
illness with chronic, symmetric polyar­
thritis as its most important clinical fea­
ture. The term 'rheumatoid arthritis' was 
first used by Sir Alfred Baring Garrod in 
1876." The first convincing, clear descrip­
tion of the disease is that of Landre-
Bcauvais in 1800. However, famous per­
sons such as the emperor Constanlinc IX 
(980-1055) and some Flemish painters, 
including Rubens, suffered from a rheu­
matoid-like polyarthritis. The evidence 
for the existence of RA before 1500 is cer­
tainly sparse and unconvincing. There­
fore Boyle and Buchanan postulated that 
RA is a disease of the modern era. 
The prevalence of seropositive (a posi­
tive rhcumafactor test in scrum), erosive 
RA appears to be similar all over the 
world, if data are corrected for the age of 
the population. Seronegative RA is not a 
distinct entity and therefore a wide range 
of prevalence is given, connected with the 
divergent definition of the disease. The 
overall prevalence of RA in the Nether­
lands is 1-2%. Women are affected more 
frequently than men at a ratio of 2:1 in 
younger patients. In patients with disease 
Clinical manifestations 
The clinical features of RA include a 
symmetric polyarthritis nearly always af­
fecting the small joints. Longslanding ar­
thritis leads to irreversible joint damage. 
Typical of RA is the development of ero­
sions (discrete defects in the cortex of the 
bone). Approximately 70-75% of the pa­
tients develop erosions in hands and feet 
as shown by prospective studies in 
specialised departments of rheumatol­
ogy. Joint space narrowing is a common 
feature beside the erosions. This is due to 
loss of cartilage. Juxta-articular osteopo­
rosis and bony cysts arc also often seen. 
Extra-articular manifestations includ­
ing pericarditis, pleuritis, Felly's syn­
drome, subcutaneous nodules, vasculitis 
exist in a minority of the patients. Beside 
localised symptoms of painful and stiff 
joints, generalised morning stiffness, sys­
temic complaints of weakness and fatigue 
are usually present during active epi­
sodes of the disease. 
Laboratory features may include pres­
ence of rheumatoid factors in the serum, 
anaemia and elevated sedimentation 
rate. The course of the disease is variable 
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and capricious, ranging from one episode 
of (mild) polyarthritis with spontaneous 
remission to (rapidly) progressive and 
destructive polyarthritis with extensive 
extra-articular manifestations. The ma-
jority of the patients (70%) have a varying 
course with flare-ups and remissions. 
Onset of the disease ranges from acute 
(within a day) to insidious (months). In 
some patients there is an apparent preci-
pitating event, e.g. physical, psychic, in-
fectious or traumatic stress. 
Aetiology 
The aetiology of rheumatoid arthritis is 
still unknown. A genetic predisposition is 
strongly suggested: the frequency of 
HLA-DR4 among seropositive RA pa-
tients is twice that of the general popula-
tion to which the RA patients belong. A 
hypothesis is that an (unknown) initiating 
factor causes immunological reactions 
and inflammation in the presence of a 
certain genetic predisposition. Environ-
mental, social, psychological, economic 
and genetic factors may play a part in the 
expression of the disease. 
Treatment 
Not only is the aetiology unknown, no 
curative treatment of RA is known, ci-
ther. The treatment of RA is directed to-
ward 1. alleviation of the signs and symp-
toms of active inflammation 2. prevention 
of tissue destruction 3. preservation of 
function and 4. reversal of phenomena 
threatening organ function, such as mo-
noneuritis, myopericarditis and lung fi-
brosis. 
Several treatment modalities are nee-
ded and workers of different disciplines 
are involved in the treatment of RA. Im-
portant aspects of the treatment of RA 
are patient education and counselling, 
physical therapy, pharmacotherapy, sur-
gical therapy and occupational therapy. 
The pharmacotherapy, which is still the 
mainstay of the treatment of RA, is di-
vided in first- and second-line drugs. Next 
to this, systemic low-dose corticosteroids 
are given in case the first- and second-line 
drugs are insufficient, or cause side ef-
fects, or to overcome the delayed effect 
of the second-line drugs. Intraarticular 
corticosteroids arc injected to control a 
localised arthritis. 
The first-line drugs include non-steroi-
dal anti-inflammatory drugs (NSAIDs) 
e.g. indomclhacin, naproxen, diclofenac. 
These drugs give immediate relief of pain 
and stiffness. They inhibit the joint in-
flammation but do not influence the nat-
ural history of the disease. NSAIDs are 
combined with second-line drugs, if the 
effect of NSAIDs alone is not sufficient. 
The second-line drugs, e.g. hydroxy-
chloroquine, sulphasalazine, gold salts, 
d-pcnicillamine, azathioprinc, and meth-
otrexate are also called disease-modify-
ing antirheumatic drugs (DMARDs), re-
mission-inducing drugs (RIDs) or slow 
acting antirheumatic drugs (SAARDs). 
These names indicate two general as-
pects of the second-line drugs: firstly, 
they have the capacity to alter the course 
of the disease. Secondly, most second-
line drugs have a delayed onset of action 
and efficacy can only be evaluated after 
3-6 months. The onset of action of the 
newest SAARDs, such as sulphasalazine 
and methotrexate is earlier. The first ef-
fects may be seen after 4-6 weeks. There-
fore the name slow-acting drug is not fully 
correct for these two drugs. On the other 
hand, the efficacy in slowing down the ra-
diographic progression is not evident for 
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all second-line drugs. Therefore is it 
questionable whether these drugs are re­
ally 'disease modifying' or 'remission in­
ducing'. However, in the literature all 
these terms are used frequently and inter­
changeable. 
Risk/benefit 
The SAARDs differ widely from each 
other in respect to efficacy and toxicity. 
In general, the more effective drugs cause 
more toxicity. Lack of efficacy and toxic­
ity arc major problems in the treatment 
of RA patients with second-line drugs. In 
trials of SAARDs with a duration of 48 
weeks the dropout rates due to inefficacy 
and toxicity were 40% for antimalarials, 
30% for sulphasalazinc, 52% for oral 
gold, 57% for injectable gold, 20% for 
methotrexate, and 64% for azathio-
R 1Ω 
princ. " Especially the reason for with­
drawal, inefficacy versus toxicity, is dif­
ferent for the various drugs. A minority 
oflhc patients still benefit from SAARDs 
after 5 years. In life-table analysis 81 % of 
(he patients treated with sulphasala/inc, 
83% with penicillamine and 92% with 
gold had to stop therapy due to lack of 
effect and/or toxicity after 5 years. 
These figures arc disappointing. As long 
as no other drugs are available we might 
try to improve the risk/benefit ratio. 
What do we have to know to improve 
the risk/benefit ratio? 
1. The prognosis of the patient. If we 
should know the prognosis of a particular 
patient, the choice oflhc SAARD could 
be adjusted. Palicnts with a good overall 
prognosis could be treated with an 
NSAID only or with a less effective, so 
less toxic SAARD. No extra risks have to 
be taken with little chance of benefit, as 
the patient has a good prognosis. Patients 
at bad risk could be treated with very ef­
fective drugs. The possible benefit bal­
ances the risks of toxicity. 
2. Prognostic factors of a beneficial ef­
fect of the drug. If we could predict which 
patients have a reasonable chance to im­
prove on a particular drug, only these pa­
tients could be selected for treatment 
with this drug. Consequently, patients 
who will have no benefit will not be ex­
posed to toxicity. 
3. Risk factors for developing toxicity. 
The discerning of patients with determi-
nanls which imply a great risk of toxicity 
could prevent exposure of these patients 
to the drug, resulting in a decrease of the 
toxicity with an equal chance of benefit. 
Prognosis of RA 
The present study deals with the first 
item: the prognosis. The knowledge of 
prognostic factors for the outcome has 
obvious advantages. To start wilh, pa­
tients with a good or moderale prognosis 
may be reassured. Nearly even palieni 
wilh rccenl-onsct RA is afraid of becom­
ing crippled. The wheelchair is a dreadful 
vision for most patients, while only few 
patients have to worry about this. 4 we 
know which patients arc at bad risk, the 
majority oflhc palicnts can be relieved of 
a needless fear. 
The second major advantage is the 
above-mentioned improvement of the 
risk-benefit ratio of the SAARDs. Re­
cent studies indicate lhat in 90% of ihc 
patients wilh erosive disease, erosions 
occur within 2 years of onset of joint 
symptoms. This means that radiogra­
phic damage is a relatively early symptom 
and noi a late consequence as has was 
long believed. Therefore effective ther­
apy has to be insliluled soon aflcr onset. 
5 
Chapter I 
This makes it necessary to select patients 
at bad risk for development of erosions at 
an early stage of the disease. Hence, 
prognostic factors must be known in the 
initial phase of the disease. Otherwise ir-
reversible damage already exists before 
action can be taken. 
Finally, prognostic factors may be used 
in clinical trials. Evaluation of the effi-
cacy of the drugs under study may be 
much easier if the patients can be divided 
in different prognostic subclasses. It is 
possible that there is no overall differ-
ence between two treatment groups, 
however, analysis of separate prognostic 
subclasses may reveal a difference. Con-
sequently, the results can be translated 
better for clinical practice: for physicians 
it is desirable to know if a particular pa-
tient with certain prognostic factors may 
benefit from a drug. 
Review of the literature 
As the citation of Sir James MacKenzie 
indicates 'You might reason that 
prognosis must have been the subject of 
careful study'. Certainly, many studies 
have been undertaken. Nevertheless, 
only few studies were 'careful' studies. 
The results of a review of the literature 
are described in Chapter VII. It is re-
markable that many conclusions are 
based on cross-sectional and retrospec-
tive studies and on studies of patients 
with established RA. These designs are 
not suitable for the study of prognosis due 
to all kinds of possible bias (e.g. selection, 
recall). Beneath the weak design of most 
studies, endpoint measures were unsatis-
factory. Both variables to measure dis-
ease activity and variables to assess more 
structural damage such as radiographic 
damage and loss of function have been 
used arbitrarily as endpoint measures. 
Process vs outcome variables 
In recent years a discussion has been 
going on in the literature about endpoint 
measurements in RA. A difference has to 
be made between socalled 'process' vari-
ables and Outcome' variables. Process 
variables measure the actual disease ac-
tivity. Most clinical and laboratory vari-
ables are process variables. Functional 
capacity and radiographic damage in 
hands and feet are mostly used as 'out-
come' measurements. " Ideally, vari-
ables which measure the 'process' (dis-
ease activity) have to correlate with the 
In 
'outcome'. However, both arc impor-
tant to know. For example, corticoste-
roids diminish disease activity measured 
by process variables such as the number 
of painful joints. In the long term, they 
may be hazardous and influence the out-
come unfavourable by causing osteopo-
rosis and complicating fractures with ac-
companying disability. The use of 
outcome variables in short-term trials is 
not always possible because they are in-
sensitive to measure change in a short pe-
riod. Consequently, the process variables 
may be used to evaluate short-term trials 
of SAARDs, but only if they correlate 
with outcome variables. Ideally, outcome 
variables should be included also in me-
dium- and long-term trials. Moreover, 
these outcome variables are needed to 
determine the long-term prognosis. 
Numerous variables arc used to mea-
sure disease activity and to evaluate clin-
ical trials. This causes many problems in 
the analysis of a clinical trial: 1. multiple 
testing has to be done and consequently 
a correction in the statistical analysis has 
to be made. This decreases the power of 
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the study and therefore more patients arc 
needed to determine the same effect; 
2. trials are not comparable because of 
divergence of outcome variables. In addi­
tion 3. insensitive measurements for 
change are used. To resolve the problem 
of multiple testing indexes to measure 
disease activity have been developed. Lit­
tle research has been done on the reliabil­
ity of the single and the composed in­
dexes to measure disease activity. 
Design of the study 
Before the start of the evaluation of the 
prognosis we developed and validated 
process and outcome variables. First we 
developed a Disease Activity Score, 
based on the clinical judgment of rhcu-
matologists (Chapter II). This is a com­
posed score to measure disease activity 
intended to resolve the problems of the 
use of many single process variables, as 
described before. 
Methods to score radiographic damage 
of hands and feet and a questionnaire to 
evaluate functional capacity were devel­
oped as outcome variables. The radio­
graphic scoring was based on Sharp's 
method. Sharp scored erosions and 
joint space narrowing of the hands only. 
However, some studies indicate that 
damage in the feet is an early feature and 
may be even more pronounced than in 
the hands. ' Therefore we developed 
and validated an analogous method for 
scoring abnormalities in the feet. The 
sensitivity of the radiographic method 
has been tested in a parallel, double-
blind, comparative study of hydroxychlo­
roquine and sulphasalazinc after 1 and 
after 3 years (Chapter HI and IV).8 
To measure the functional capacity we 
constructed a questionnaire. We used an 
American and a Canadian questionnaire 
as the basis and translated and adjusted 
Λ·} l ' I 
these for the Dutch situation. ' There­
after we tested the reproducibility and re­
liability of the questionnaire in a group of 
clinic and outclinic RA patients. The sen­
sitivity was tested in the above-mentioned 
trial (Chapter V). 
Only if process variables correlate with 
outcome are they valid measures for as­
sessing disease activity. After the devel­
opment of the outcome variables we 
could use these variables to evaluate the 
validity of clinical and laboratory vari­
ables and composed indexes to measure 
disease activity (Chapter VI). 
Course of RA and prognostic 
factors 
A review of the literature on prognostic 
factors for the final outcome in RA is de­
scribed in Chapter VII. As staled before, 
the most important cause of the divergent 
results might be shortcomings in study 
designs. To overcome several problems, 
we based our study on prognosis on a pro­
spective follow-up of patients with early 
RA. In addition, we used the variables to 
measure disease activity and outcome 
which were validated before. 
A large prospective follow-up of pa­
tients with classical or definite RA with 
disease duration shorter than 1 year at 
entry was started in 1985. Patients were 
followed in two clinics: the departments 
of rheumatology of University Hospital 
Nijmegen and University Hospital Gro­
ningen. Every 4 weeks clinical variables 
were assessed and blood was sampled for 
laboratory measurements. Biannual X-
rays of hands and feet were made and the 
questionnaire on functional capacity was 
completed. All patients were treated by a 
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rheumatologist. At the time of the last 
analysis for this thesis, 213 patients took 
part in the follow-up. 
In studying prognosis, not only the ulti­
mate outcome is important but also the 
way in which this outcome is reached. Es­
pecially for the decision to start treat­
ment with SAARDs, it is important to 
know if there is a gradual increase in ab­
normalities or if some phases show an ac­
celerated decline. However, the course of 
radiographic damage of RA is still un­
clear Many studies are based on retro­
spective or cross-sectional data or on pa­
tients with a wide variety of disease 
duration. Therefore, we studied the cour­
se of radiographic damage in this pros­
pective follow-up of patients with early 
RA (Chapter VIII). 
RA with onset at later age is often con­
sidered a different subset, with a more fa­
vourable outcome. Again, there is no 
unanimity in the literature However, one 
of the findings is that there is less sero-
positivity in older-age RA. Seropositivity 
might be the most dominant prognostic 
factor for a worse prognosis. Therefore, 
we evaluated solely the effect of age on 
the presentation and prognosis of RA 
(Chapter IX). 
As our Final step, we evaluated which 
factors predicted a worse outcome in our 
study. Outcome was defined as radio­
graphic damage and functional capacity. 
The choice of prognostic factors to be in­
cluded, was based on the review of the 
literature. In this analysis age was in­
cluded as a continuous variable, in con­
trast with the study of the age at onset, 
which compared patients over and under 
60 years at onset (Chapter X). 
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Summary 
Introduction 
In rheumatoid arthritis disease activity 
cannot be measured by one single vari-
able. In clinical practice an opinion of dis-
ease activity is formed from a combina-
tion of information, such as laboratory 
and clinical variables, radiological assess-
ments, and overall impression of the pa-
tient. This clinical judgment of the dis-
ease activity varies considerably among 
different rhcumatologists as has been 
shown by Kirwan. In addition, there is a 
discrepancy between what doctors be-
lieve their clinical behaviour to be and the 
way they really act in practice. ' 
If this clinical judgment can be for-
malised to provide a quantifiable disease 
activity index it would provide an oppor-
tunity to study and influence this process. 
In addition, such an instrument could be 
Clinical judgment: Disease activity score 
used to compare the efficacy of treat-
ments in clinical trials. 
In a large prospective study the decision 
of rhcumatologists to start treatment with 
a slow acting antirheumatic drug or to 
stop such treatment because of disease 
remission were equated with high and 
low disease activity respectively. The clin-
ical and laboratory variables that explain 
most of the variance of the rhcumatolo-
gists' decisions were composed by vari-
ous statistical methods into a 'disease ac-
tivity score'. 
The result of such implicit judgment 
may be the first step in composing a dis-
ease activity index. The next step is vali-
dation: Is the judgment of the rhcumatol-
ogists in practice a good reflection of 
'real' disease activity? 
An investigation of clinical and laboratory variables which might form the basis for 
judging disease activity by six rheumatologists in clinical practice was made in a 
prospective study of up to three years' duration of 113 patients with early rheumatoid 
arthritis. Decisions to start treatment with slow acting antirheumatic drugs were equated 
with moments of high disease activity. If treatment with slow acting antirheumatic drugs 
was not started or if the slow acting antirheumatic drug remained unchanged for at least 
one year, or if treatment was stopped because of disease remission, this was equated with 
periods of low disease activity. Two groups, one with high and one with low disease 
activity according to the above criteria, were fanned. Factor analysis was performed to 
enable easy handling of the large number of clinical and laboratory variables without 
loss of information; this resulted in five factors. Next, discriminant analysis was done to 
determine to what extent each factor contributed to discrimination between the two 
groups of differing disease activity. Finally, a multiple regression analysis was carried out 
to determine which laboratory and clinical variables underlie the factors of the discri-
minant function, resulting in a 'disease activity score'. Tins score consisted of the 
following variables: Ritchie index, swollen joints, erythrocyte sedimentation rate, and 
general health, in declining importance. The rheumatologists'decisions to prescribe slow 
acting antirheumatic drugs, or not, were mainly based on articular symptoms. 
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Patients and methods 
Patients 
All patients met the following criteria: 
they had classical or definite rheumatoid 
arthritis according to American Rheu­
matism Association criteria, disease du­
ration of less than one year, and had not 
previously been treated with slow acting 
antirheumatic drugs. All consecutive pa­
tients eligible for the prospective follow 
up from January 1985 were asked to par­
ticipate. Eight patients were not included 
(refusal, fatal accompanying disease). At 
the time of analysis 113 patients partici­
pated in the study and the follow up 
ranged from two to 39 months (number 
of check ups 1816). 
Methods 
Two specially trained research nurses 
assessed all the patients every four weeks 
in the rheumatology outpatient depart­
ment of the University Hospital, Nijme­
gen. Furthermore, all patients were fol­
lowed by their rheumatologists, inde­
pendently of the evaluations of the re-
Table I. Characteristics of the 113 patients at the 
start of the study 
Male/female (n) 
Mean (SD) age (years) 
Range 
Median 
Mean (SD) disease du­
ration (months) 
Range 
Median 
IgM RF- >5 lU/ml (n) 
43/70 
54.2 (14.5) 
16-81 
55.3 
5.5(3.6) 
0-21 
4.9 
89 
•RF = rheumatoid factor 
search nurses, on average four to six times 
a year. The rhcumatologist made all the 
decisions to start or withdraw slow acting 
antirheumatic drugs independently of the 
clinical assessments of the research 
nurses. The rheumatologists were not in­
formed of the fact that their decisions 
were part of the investigation. Six rheu­
matologists were working at the outpa­
tient department. The sequence of the 
start of the various slow acting antirheu­
matic drugs follows a fixed schedule: first 
step hydroxychloroquine or sulfasala­
zine, second step intramuscular gold, 
thereafter d-pcnicillamine or azathio-
prine or methotrexate. Corticosteroids 
and non-steroidal anti-inflammatory-
drugs are allowed as adjuvans at all 
stages. The rheumatologists' policy is to 
start treatment with slow acting antirheu­
matic drugs if the disease is not adequate­
ly controlled after two months' treatment 
with non-steroidal anti-inflammatory-
drugs only. 
iAssessmenis 
The following assessments were made 
every four weeks: number of tender 
joints, number of swollen joints, Ritchie 
articular index, morning stiffness (min­
utes), fatigue (hours after rising), pain 
(on a visual analogue scale of 10 cm, 
0 = no pain, 10 = worst pain possible), 
general health (visual analogue scale of 
10 cm, 0 = best possible, 10 = worst possi­
ble), grip strength with a vigorimeter 
(mm Hg) and the bodyweight (kg), eryth­
rocyte sedimentation rate (ESR) accord­
ing to Westergren (mm in 1st hour), 
haemoglobin (g/1), leucocyte count 
(109/1), thrombocyte count (109/1), total 
protein, albumin, ai-globulin,a2-globu-
lin,/J-globulin,y-globulin (all g/1), С reac-
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Table II Minimum, maximum, and skcwness of Ihe variables 
Variable 
ESR· (mm/lsl h) 
Albumin (g/1) 
a\ Globulin (g/1) 
02 Globulin (g/1) 
β Globulin (g/1) 
γ Globulin (g/1) 
Haemoglobin (g/1) 
rhrombocyles (xl09/I) 
CRP' (g/1) 
IgM RF· 
Morning stiffness (mm) 
Pain (100 mm scale) 
General health (100 mm scale) 
Grip strength right (mm Hg) 
Gnp strength left (mm I Ig) 
Ritchie score 
Tender joints (n) 
Swollen joints (n) 
Mean 
31 
444 
24 
71 
7 3 
12 7 
127 
313 
30 
215 
52 
33 
31 
40 
38 
9 
11 
14 
SD 
25 
5 0 
08 
17 
14 
41 
16 
100 
40 
412 
74 
22 
22 
22 
22 
8 
9 
7 
Range 
(1-140) 
(265-64 6) 
(0 5-81) 
(17-17 6) 
(4 0-14 7) 
(4 0-37 2) 
(76-174) 
(103-845) 
(3-260) 
( < 5-3200) 
(0-360) 
(0-100) 
(0-100) 
(0-158) 
(0-131) 
(046) 
(040) 
(0-36) 
Skewness 
1367 
-0 474 
0 980 
0 734 
0515 
1146 
-0 214 
1 126 
2455 
3 078 
2 394 
0 433 
0 423 
1031 
0 830 
0 997 
0 618 
0 381 
Skewness after 
transformation 
-0 460 
-0474 
-0 249 
-0182 
0175 
-0177 
-0 214 
0102 
0 231 
0 238 
0284 
0 433 
0 423 
-0 037 
-0 228 
-0 152 
-0 252 
0381 
*bSR = erythrocyte sedimentation rate, CRP = C reactive protein, ΚΓ= rheumatoid factor 
live protein (g/1), IgM rheumatoid factor 
(normal <5IU/ml). Albumin and glucose 
were determined in the urine. Creatinine 
(wmol/l), alkaline phosphatase (U/1), an­
tinuclear antibodies, IgA, IgM and IgG 
(g/1) were measured every three months 
and serum iron and total iron binding ca­
pacity (мтоі/і) every six months. Every 
six months plain anterior radiographs of 
the hands and feet were obtained, all pa­
tients completed a questionnaire on their 
physical and psychosocial wellbeing, and 
the production of tears was assessed with 
a Schirmertest (normal > 10mm). Serum 
and plasma were stored at -20°C at every 
visit. Some measurements were made for 
control purposes because of the slow act­
ing antirheumatic drugs, others to follow 
the course of rheumatoid arthritis or to 
search for complications or systemic 
manifestations. Variables, previously re­
ported as possible disease activity mark­
ers, were included in the analysis: number 
of tender joints, number of swollen joints, 
Ritchie articular index, morning stiffness, 
fatigue, pain, general health, grip 
strength right and left, ESR, haemoglo­
bin, thrombocyte count, total protein, al­
bumin, ai-globulin,a2 -globulins-globu­
lin, y-globulin, С reactive protein, and 
IgM rheumatoid factor. 
Statistical procedure 
Initially, all selected variables were as­
sessed for their suitability for multivariate 
statistical analysis. If necessary, transfor­
mation to a reasonably normal distribu­
tion was performed. To find some struc­
ture in the large number variables, factor 
analysis was performed, resulting in a few 
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factors to be used in the further analysis. 
The patients' records were then divided 
(according to explicit rules) into a group 
with high and one with low disease activ­
ity. This selection was the basis of a dis­
criminant analysis to determine how the 
factors might best be combined to pro­
duce a score which reflects the disease 
activity most accurately: the disease ac­
tivity score. The reproducibility of the 
factors was studied with an interperiod 
correlation matrix analysis. Subsequent­
ly, a multiple regression analysis was per­
formed to determine how the disease ac­
tivity score might best be measured in 
practice. 
Table III Three 
Factor 1 
libR' 
Thrombocytes 
Haemoglobin 
Albumin 
αϊ Globulin 
аг Globulin 
γ Globulin 
CRP· 
IgM RI" 
factor model of all dala 
Factor 2 
Ritchie 
Tender joints 
Swollen joints 
Morning stiffness 
Grip strength right 
Gnp strength left 
Factor 3 
Pain 
General 
health 
β Globulin 
*CSR = ciytrhocy1c sedimentation rate; CRP = C 
recaclive protein, RF= rheumatoid factor 
Factor analysis 
Results 
Table 1 shows some general character­
istics of the patients. Table II summarises 
the variables used in the analysis. Be­
cause of a high skewness some variables 
were transformed to approximate a nor­
mal distribution. These transformed val­
ues were used in the analysis. As the vari­
able 'total protein' depends fully on the 
other components of the protein analysis, 
and the variable 'fatigue' showed no 
change over the lime, these two variables 
were excluded from the analysis. 
Initially, a factor analysis on the com­
plete data was performed. Three factors 
with Eigen values higher than 1 and a cu­
mulative percentage of explained vari­
ance of 59% were analysed further. Table 
III shows the factors and corresponding 
variables. Factor 1 consists of inflamma­
tory variables in the blood, factor 2 in­
cludes the scmiobjcclive measures of 
joint examination, and factor 3 subjective 
variables and β globulin. To obtain result 
which could be interpreted more easily a 
factor analysis on the individual data was 
performed. For this purpose Pearson 
correlations between all longitudinal sc­
ries of observations in each individual pa­
tient were calculated. A correlation ma­
trix of the median correlations over all 
Fable IV Five factor model of the individual data 
Factor 1 
ESR-
Thrombocytes 
Haemoglobin 
CRT* 
I g M R F * 
Factor 2 
Ritchie 
Tender joints 
Swollen joints 
Factors 
Albumin 
αϊ Globulin 
«2 Globulin 
β Globulin 
γ Globulin 
Factor 4 
Pain 
General health 
Morning stiffness 
Factors 
Grip strength, right, left 
*IiSR = erythrocyte sedimentation rate, CRP = С reactive protein; RF= rheumatoid factor 
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patients was composed as the basis of the 
factor analysis. Five factors have an Eigen 
value higher than 1 with a cumulative per­
centage of explained variance of 66%. 
Table IV summarises the five factors with 
the variables with the highest loadings on 
these factors. In conclusion, factor analy­
sis of individual data gives the most easily 
interpreted results and the greatest ex­
plained variance. The factors can be la­
belled as variables of inflammation in the 
blood (factor 1), variables of joint exam­
ination (factor 2), protein analysis (fac­
tor 3), subjective complaints (factor 4) 
and grip strength (factor 5). Two factors 
(1 and 3 ) are objective measurements, 
factor 2 is a semiobjcclivc assessment, 
factor 4 reflects the subjective complaints 
of the patient, and factor 5 combines dis­
ease activity and structural (irreversible) 
damage of the hand. 
Calculation of the factor values 
The standard deviation score (Z-score 
= (observed valuc-mcan)/standard devi­
ation) was calculated for all variables at 
each visit. The mean of the Ζ scores of the 
variables corresponding with one factor 
gave the factor value for that visit. The 
factor values are the basis of the subse­
quent calculation. (For the sake of sim­
plicity we used sum scores rather than the 
actual factor scores, resulting in slightly 
different values: the factor values.) 
Reliability of the factor values 
Cronbach's alpha, computed to deter­
mine the reliability of the factorvalucs, 
ranges from 0.73 (factor 2) to 0.92 (fac­
tor 5) which may be considered fairly re­
liable. 
Course of the factor values 
To determine the progression of the 
factor values with time the mean autocor­
relations of the 5 factors were deter­
mined. Factor 1 had an autocorrelation 
of 0.61, which means that the factor pro­
ceeded smoothly with time. On the other 
hand, factor 3 had an autocorrelation of 
0.21 and accordingly, a capricious course. 
The autocorrelations of the other three 
factors varied from 0.42 to 0.48. 
Reproducibility of the factor values in 
the longitudinal study 
The measurement quality of the factors 
is very important in longitudinal studies. 
Fortunately, owing to the repetition of 
the mcasurcmenls, it was possible to esti­
mate this quality in the study using the 
interperiod correlation matrix. Thus the 
intercorrelation of five periods (months) 
was plotted against the intervening time 
intervals (one to four months). When the 
short time interval was taken into account 
the correlations were linearly related to 
time, which may be represented by a well 
fitting regression line (correlation ν time 
interval). Extrapolation of this line to a 
time interval of/его gave the direct mca-
surcmcnt-rcmeasuremcnt correlation, 
which may be interpreted as a quality 
Tabic V Mcasurcmcnt-rcmcasurcment 
correlations of the faclors estimated from the 
inlerpcnod correlation matrix 
factor 1 
Factor 2 
Factor 3 
Factor 4 
Factor S 
ro 
0 94 
0 87 
0 70 
0 74 
0 94 
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Table VI. Pooled correlation of discriminant functions of three, four, and five factors 
Гасюг 1 
Factor 2 
Factor 3 
Factor 4 
Factor 5 
Canonical correlation 
Correctly classified (%) 
5 Factors 
051 
0 86 
051 
0 47 
-0 54 
0 658 
83 2 
4 Factors 
051 
0 86 
051 
0 47 
0 662 
83.9 
3 Factors 
0 53 
0 91 
0 51 
0 630 
83 6 
measure of the factor. Tabic V presents 
the results of the estimations. 
Definition of disease activity 
The overalljudgmcnt of the rhcumatol-
ogist was the starling point in assessing 
disease activity. Indeed, the decision to 
start or terminate slow acting antirheu­
matic drugs was used as the criterion. The 
decision to start slow acting antirheu­
matic drugs was taken by the rheumalolo-
gists independently of the clinical assess­
ments of the research nurses. 
The definition of high disease activity 
was (a) start of a slow acting antirheu­
matic drug; (b) termination of treatment 
with slow acting antirheumatic drugs be­
cause of lack of effect. The definition of 
low disease activity was (a) termination of 
treatment with slow acting antirheumatic 
drugs because of remission of the rheu­
matoid arthritis; (b) not changing a slow 
acting antirheumatic drug for at least one 
year; (c) not starting treatment with a 
slow acting antirheumatic drug for at 
least one year. If a patient met the above 
criteria more than once only the observa­
tions made at an interval of at least five 
months were included. Ultimately, 78 pa­
tients met these conditions, with the num­
bers of records ranging from one to four. 
In all, 177 assessments were analysed: 138 
observations in the group with high dis­
ease activity and 39 in those with low dis­
ease activity. 
Discriminant analysis 
The factor values of the five factors of 
the assessments were used in the discrim­
inant analysis, restricted to the group 
with high disease activity and the group 
with low disease activity. Moreover, an 
analysis without factor 5 was made be­
cause grip strength reflects not only dis­
ease activity but also (irreversible) de­
struction. A discriminant analysis on 
three factors, leaving out factor 3 and 5, 
was also performed, as factor 3 (protein 
analysis) has the lowest reproducibility 
(Table V). Table VI shows the relative 
importance of the variables used in three, 
four and five factor groups. When factor 
3 or 5 or both, was omitted this did not 
affect the canonical correlation or the 
discriminating power. In the subsequent 
analysis the discriminant function based 
on three and four factors was used. The 
joints scores (factor 2) contributed most 
to the discriminant score. The other fac­
tors were equally important but at a lower 
level. 
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Table VII Compulation of the disease activity scores The units used in the formulas arc given in 
Table II 
Disease activity score (four variables) = 
Ώ4 = 0 53938*sqrt(Rilchie score) + 0 06465*(number of swollen joints) + 0 330*ln(ESR) + 
0 00722* (general health) 
Disease activity score (three variables) = 
D3 = 0 53938'sqrt(Rilchie score) + 006465"(питЬсгоГ swollen joints) +0 330*ln(ESR) + 0224 
Multiple regression analysis 
The discriminant function contains fac­
tor values which in turn arc composed of 
several clinical and laboratory variables. 
A multiple regression analysis was used 
to determine which variables contribute 
most to the discriminant function, to ob­
tain a disease activity score which could 
be used easily in practice. 
A stepwise forward multiple regression 
analysis was performed on all 1816 re­
cords, with the discriminant function on 
three factors as the dependent variable 
and ESR, hacmoglobulin, thrombocytes, 
morning stiffness, number of tender 
joints, number of swollen joints, Ritchie 
score, pain, general health, С reactive 
protein and IgM rheumatoid factor as in­
dependent variables. As the first step the 
Ritchie sore was included (multiple 
R = 0.852), thereafter the number of 
Table VIII Relative contribution of the variables 
to the equation of disease activity, expressed as 
the partial correlations of the initial and final 
steps in the regression analysis 
Variable 
Ritchie score 
Swollen joints 
LSR 
General health 
Initial par­
tial correla­
tion 
0 80 
0 69 
049 
0 50 
Final partial 
correlation 
0 85 
0 74 
0 63 
0 39 
swollen joints (multiple R = 0.951), ESR 
(multiple R = 0.977), general health 
(multiple R =0.984), thrombocytes (mul­
tiple R = 0.988), and number of lender 
joints (multiple R =0.993). On the basis 
of these results, we decided to compose a 
disease activity score using the variables 
Ritchie score, number of swollen joints, 
ESR and general health. In practice the 
variable of general health is not always 
determined. Therefore the regression 
comparison was also calculated with the 
remaining three variables. Both the 
Ritchie score and the ESR were trans­
formed. Table VII shows the disease ac­
tivity scores of four and three variables 
after conversion. From these data I he rel­
ative contribution to the equation of each 
variable is not clear. Therefore we deter­
mined the partial correlations of the vari­
ables when used as the first step and when 
used as the final step in the regression 
analysis. Table VIII shows these correla­
tions. 
The constant of the function of three 
variables (D3) was chosen so that the 
mean of this score equalled the score 
based on four variables without a con­
stant to ensure the possibility of ex­
change. 
The mean disease activity scores of all 
records were 3.57 (SD 1.18, range 0.51-
7.26, four variables) and 3.57 (SD 1.12, 
range 0.59-7.05, three variables). 
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Reproducibility of the disease activity 
score 
The reproducibility of the disease activ-
ity score was determined by an intcr-
pcriod correlation matrix of five periods 
(months), as described for the reproduc-
ibility of the factor values. The mcasurc-
ment-remeasurement correlation was 
0.89 for the disease activity scores with 
both three and four variables. 
Discussion 
Clinical judgment of disease activity in 
rheumatoid arthritis is a complex process 
of combining clinical and laboratory vari-
ables as well as radiological assessments 
and overall impression. This clinical 
judgment is hard to formalise. Kirwan de-
scribed the great difference exists be-
tween what doctors believe about their 
clinical behaviour and their actual bcha-
viour in practice. ' Most rheumatolo-
gisls are unable lo describe their policies 
in judging disease activity. Kirwan's stud-
ies were executed on 'paper patients' on 
single occasions. Though these 'paper 
patients' correlated well with the real sit-
uation, a survey of judging disease activity 
on such patients does not necessarily re-
flect the process of actual decision mak-
ing in practice. ' ' This study describes 
judging disease activity in actual practice. 
We opted for a real decision point in pa-
tient management: the moment when the 
rheumatologist considered the rheuma-
toid arthritis so active that the patient had 
to start treatment with or change slow 
acting drugs was marked as high disease 
activity. Conversely, patients who were 
not treated with slow acting antirheu-
matic drugs or continued to take the same 
slow acting antirheumatic drug during at 
least one year were placed in the group of 
low disease activity. In addition to disease 
activity other factors may lead to the start 
or withdrawal of a slow acting antirheu-
matic drug-for example, the refusal of 
the patient. These factors might have in-
terfered with the appropriate classifica-
tion of patients. This probably played a 
part in only a few patients, so we did not 
correct for possible misclassification as 
this might have introduced a subjective 
interpretation. 
We were able to describe the real pro-
cess of decision making in practice be-
cause the rhcumalologists were unaware 
that their decisions were part of an inves-
tigation. It was possible to develop the 
disease activity score because of the 
prospective monthly follow up of a large 
number of patients, during periods of up 
to more than three years. At each visit a 
large number of variables was collected 
by the same observer. 
A disease activity score based on the 
variables collected by the research nurses 
was composed using different statistical 
procedures. This disease activity score 
shows which variables best explain the 
decisions of the rhcumalologists. The dis-
ease activity score includes four vari-
ables: Ritchie score (semiobjective, clin-
ical variable), number of swollen joints 
(objective, clinical variable), ESR (labo-
ratory variable) and general health (sub-
jective variable). In practice, the variable, 
general health, is not always determined. 
Therefore we calculated a constant to be 
added to the equation of the disease ac-
tivity score with three variables so that the 
means of the scores based on three and 
four variables were equal, making the two 
disease activity scores interchangeable. 
Although not chosen for this reason, the 
variables are part of the whole spectrum: 
clinical, laboratory, objective and subjec-
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live. The Ritchie index gives most weight 
to the equation, indicating that a high 
Ritchie score plays a major part in the de-
cision about starting treatment with a 
slow acting antirheumatic drug. Sec-
ondly, swollen joints are important, fol-
lowed by ESR and general health. The 
rhcumatologisls of our department were 
guided more by joint symptoms than by 
laboratory abnormalities (Table VIII). 
This is in accordance with the results of 
structured workshops on preferences for 
endpoinl measures in clinical trials in 
Canada, where joint count, pain and 
overall scores accounted for 60% of the 
total score for all measures. These work-
shops ulili/cd (among other things) pa-
tients' profiles before and after a non-ste-
roidal anli-inflammalory drug trial. 
Recently, Anderson described the results 
of an analysis of pooled raw data from 
three placebo controlled trials of slow 
acting antirheumatic drugs in rheuma-
toid arthritis. Joint tenderness count, 
ESR, joint swelling score, doctor's as-
sessment ofdiscasc activity, and joint ten-
derness score showed, in descending or-
der, the highest rankings of adjusted t 
statist ic for all patients who took an active 
drug compared with all who took pla-
cebo. These results greatly resemble our 
disease activity score. 
The next step in the further develop-
ment of the disease activity score is vali-
dation: Do the rhcumatologisls' clinical 
judgments really reflect disease activity? 
One way of answering this is to use the 
disease activity score in a clinical trial 
comparing two slow acting antirheumatic 
drugs and relate the results to individual 
clinical and laboratory variables. Corre-
lation with radiological progression or 
functional capacity is another possible 
method of validation. If the disease activ-
ity score proves to be valid it may serve as 
a single outcome variable in a clinical trial 
comparing slow acting antirheumatic 
drugs. This would avoid conflicting re-
sults with various outcome variables. 
Moreover, smaller numbers of patients 
are needed since no correction has to be 
made for multiple statistical testing. In 
practice the validated disease activity 
score might be used to asses the disease 
activity of an individual patient and deter-
mine objectively when to start using a 
slow acting antirheumatic drug. In addi-
tion, the efficacy of the slow acting anti-
rheumatic drug may be determined· <m 
improvement of the score by 1.08 (2\ 
standard error) or more is a slat ist ii.illy 
significant improvement. This provides 
clear information, helpful in the manage-
ment of individual patients. 
The value of the disease activity score is 
currently under investigation and will be-
come apparent in the future. 
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Radiographic damage in trial SASP-HQ 
Summary 
The effects of hydroxychloroquine and sulphasalazine on progression of joint damage 
shown by X-rays were compared in a double-blind, randomised trial in 60 patients with 
rheumatoid arthritis not previously treated with slow-acting antirheumatic drugs. X-rays 
of the hands and feet at the start and after 24 and 48 weeks of treatment were available 
for 28 patients treated with hydroxychloroquine and 22 treated with sulphasalazine. 
Erosions and joint space narrowing were scored by a single observer unaware of 
treatment. At baseline there were no significant differences in demographic, clinical, or 
radiographic characteristics between the treatment groups. Patients withdrawn because 
of lack of effect were included in the analysis. The median number of erosions was lower 
in the sulphasalazine than the hydroxychloroquine group at 24 weeks of treatment (2.5 
vs 10) and the difference was significant at 48 weeks (5 vs 16;ρ < 0.02). TJie difference 
in median total score of joint damage was significant at 24 weeks (6.5 vs 17; ρ < 0.02) 
and at 48 weeks (8 vs 33; ρ < 0.02). Tiie increase in number of erosions and total score 
was significantly greater in the hydroxychloroquine than the sulphasalazine group, both 
after 24 weeks and after 48 weeks of treatment. 
Introduction 
The chronic joint inflammation of rheu­
matoid arthritis often leads to destruc­
tion of articular cartilage and subchon­
dral bone which is largely irreversible. 
The aim of treatment of rheumatoid ar­
thritis is, therefore, not only suppression 
of joint inflammation and relief of con­
comitant pain and stiffness, but also pre­
vention or retardation of joint damage. 
Non-steroidal anti-inflammatory drugs 
(NSAIDs) effectively suppress pain and 
stiffness, but do not change the course of 
the disease. Most patients need addi­
tional treatment with slow-acting anti­
rheumatic drugs such as hydroxychloro­
quine, gold salts, d-penicillamine, and 
cytotoxic drugs, which affect the disease 
more fundamentally and lead to suppres­
sion of inflammation and sometimes even 
to disease remission. Although control­
led studies have shown that these drugs 
can effectively suppress joint inflamma­
tion, there is hardly any evidence that 
they can prevent or slow down progres-
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sion of joint destruction. Only intra­
muscular gold has proved capable of sub­
stantially retarding progression of joint 
damage and a study on cyclophosphami­
de presented suggestive evidence of an 
effect of that drug. ' 
Sulphasalazine is an effective slow-act­
ing antirheumatic drug. However, no 
controlled studies have yet been pub­
lished that show whether this drug also 
favorably affects joint damage as shown 
by X-rays. One study has suggested that 
sulphasalazine reduces the rate of pro­
gression of joint destruction in the second 
year of treatment, but it was an open 
study and X-rays were available for eva­
luation from only 27% of the initial treat-
4 
ment group. 
We report here the evaluation of X-rays 
of hands and feel obtained during a dou­
ble-blind 48-wcck study of patients trea­
ted with either sulphasalazine or hy­
droxychloroquine. Results described 
elsewhere show that clinical response to 
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drug treatment occurred 8 weeks earlier 
in the sulphasalazine group than in the 
hydroxychloroquine group. The overall 
effect at 48 weeks, however, was not sig-
nificantly different. 
Patients and methods 
All consecutive patients with definite or 
classic rheumatoid arthritis, attending 
the outpatient clinic of the department of 
rheumatology, who had never previously 
received slow-acting antirheumatic 
drugs, and who had active disease not 
adequately controlled by NSAIDs, were 
asked to join the study. Only 2 patients 
refused and 1 patient started to take pre-
dnisolone and could not be included. 60 
patients participated in the study. Active 
disease was characterised by at least 
three of the following: seven or more 
painful joints on movement; four or more 
swollen joints; morning stiffness for at 
least 1 h; erythrocyte sedimentation rate 
(ESR) above 28 mm in the first hour; 
haemoglobin less than 8.7mmol/l (14.0 
g/dl) in men or less than 7.4mmol/l (11.9 
g/dl) in women. 
Patients randomised to receive sul-
phasalazine took an initial dose of 500 mg 
daily; the dose was increased by 500 mg 
every 4 days to the maintenance dose of 
2000 mg daily. Patients on hydroxychlo-
roquine received 200 mg twice daily for 
24 weeks and thereafter 200 mg once 
daily; this is the standard regimen in our 
clinic to reduce (especially ocular) toxic 
effects. No other concomitant drugs ex-
cept NSAIDs in a stable dose, or intra-ar-
ticular injections were allowed during the 
study. The patients received either hy-
droxychloroquine and a placebo for sul-
phasalazine or sulphasalazine and a pla-
cebo for hydroxychloroquine to ensure 
that the study was double blind. 
The randomisation was carried out by 
the hospital pharmacist after the patient 
agreed to participate. Clinical and labo-
ratory data were gathered prospectively 
by one observer (LH. N-Z) every 4 weeks 
for 48 weeks. Plain X-rays of hands, 
wrists, and feet were taken at the start and 
after 24 and 48 weeks of treatment. 
Films of the same quality and granula-
tion were used for all radiographic expo-
sures. After completion of the trial the X-
rays were assessed by one observer (D.M. 
v.d.H.) who was not aware of the treat-
ment the patient had received. The pa-
tients were scored in random order. All 
X-rays were viewed on the same lighlbox 
under identical conditions, in chronolog-
ical order for each patient. The hand X-
rays were scored in a modified way ac-
cording to Sharp . There is no agreement 
on scoring foot X-rays; we scored ero-
sions and joint space narrowing in the 
joints of the feet. In a pilot study the ero-
sive changes were much more pro-
nounced in foot than in hand X-rays. 
Therefore we decided to fix the maximum 
possible score of erosions in the feet at 10, 
compared with 5 in the joints of the 
hands. The scoring of the trial X-rays was 
preceded by extensive training in the 
method. Finally, to validate the scoring 
method, 30 pairs of X-rays for 5 patients 
in the trial, chosen at random, were sco-
red twice to measure the observer's inter-
nal correlation; this was 0.95 for the ero-
sions and 0.97 for the overall score. The 
same X-rays were scored by a second ob-
server (P.v.R.) after the same training. 
Correlation between the observers was 
0.96 and 0.94 for erosions and overall 
score, respectively. Since the scoring of 
X-rays is very lime-consuming and the 
correlations were good, all trial X-rays 
were scored by one observer. 
26 
Radiographic damage in trial SASP-HQ 
Erosions were counted in the ten meta- gular-navicular joints, right and left cap-
carpophalangeal joints, the eight proxi- itate-navicular-lunate joints, right and 
mal intcrphalangeal joints, the two inter- left radiocarpal joints, the ten metatarso-
phalangeal joints of the thumbs, the right phalangeal joints and the two inter-
and left first metacarpal bone, the right phalangeal joints of the big toes. Erosions 
and left radius and ulnar bones, the right were counted as score 1 if there was a dis-
and left trapezium and trapezoid (as one crete interruption of the cortical surface; 
unit; multangular), right and left navi- if there was a greater defect a score ac-
cular bones, right and left lunate bones, cording to the surface of the joint invol-
tile ten metatarsophalangeal joints, and ved was given (2-5). Consequently, for 
the two interphalangeal joints of the big confluent erosions the score could not 
toes. Joint space narrowing was assessed become smaller. In the hands the maxi-
in the ten metacarpophalangeal joints, mum erosion score in a joint was 5; in the 
the eight proximal intcrphalangeal joints, feet it was 10. Four grades of joint space 
right and left third, fourth and fifth carpo- narrowing were recognised: 1 = focal or 
metacarpal joints, right and left multan- doubtful; 2 = general, less than 50% of 
Table I. Demogrpahic, clinical, and laboratory characteristics at week 0 
Female/Male 
Mean age (range) in yr 
Mean disease duration in mo 
(median.range) 
No with ARA of anatomical stage: 
1 
2 
3 
4 
No with Stcinbrocker functional class: 
1 
2 
3 
4 
No with Rose Waaler litre >1:40 
No with subcutaneous nodules 
Mean (SD) 
Haemoglobin (g/di) 
ESR(mm/h) 
Morning stiffness (min) 
Ritchie articular index 
No of swollen joints 
Hydroxychloroquine 
(n = 28) 
16/12 
53.1 (22-72) 
15.6(8.0,3-120) 
14 
13 
1 
0 
1 
14 
13 
0 
27 
6 
13.0 (1.4) 
40 (24) 
122 (97) 
14(6) 
14(5) 
Sulphasala/inc 
(n = 22) 
15/7 
53.5 (22-75) 
12.8 (8 5, 3-165) 
15 
7 
0 
0 
3 
13 
6 
0 
20 
5 
13.0(1.8) 
43(33) 
154(108) 
12(5) 
13(5) 
ARA = American Rheumatism Association 
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the original joint space; 3 = general, 
more than 50% of the original joint space 
or subluxation; 4 = ankylosis. Thus, the 
maximum number of erosions in the 
hands was 160 and in the feet 120; and the 
maximum scores for joint space narrow­
ing were 120 and 48, respectively. Scores 
for erosions and joint space narrowing 
were added up to give the total score. 
Differences within treatment groups 
were tested with Wilcoxon's signed rank 
test; and differences between the groups 
with Mann-Whitney rank sum test. 
Differences in median changes between 
the two treatment groups were calculated 
after log transformation. The 95% confi­
dence intervals were determined with the 
Mann-Whitney rank sum lest. All tests 
were two-tailed and ρ = 0.05 was taken as 
the significance level. The Statistical 
Package for Social Sciences was used for 
the analysis. 
Results 
30 patients were randomised to each 
group. 1 patient was withdrawn from 
each treatment group because of proto­
col violation. In the hydroxychloroquine 
group 1 patient was withdrawn owing to 
side effects (borborygmi) and 9 owing to 
lack of clinical effect (5 patients after 24 
weeks, 1 after 30,2 after 32, and 1 after 40 
weeks of Irealment). Subsequently 5 of 
these patients received aurothioglucosc, 
1 oral gold, and 1 d-penicillamine; 2 pa­
tients refused further treatment. In the 
sulphasalazinc group, 1 patient was 
withdrawn because of lack of coopera­
tion, 4 patients because of side effects (3 
nausea/vomiting, 1 leukopenia which 
quickly disappeared after discontinuing 
the drug), and 3 because of lack of effect 
(2 after 24 weeks, 1 after 43 weeks). All 3 
patients were then treated with aurothio­
glucosc. X-rays were not available for 2 
patients treated with sulphasalazinc. All 
patients withdrawn because of lack of ef­
fect were included in the analysis, which 
therefore comprised 28 patients treated 
with hydroxychloroquine and 22 patients 
treated with sulphasalazinc. 
There were no significant differences 
between the groups in demographic, clin­
ical, or laboratory features at the start of 
the study (table I). The radiographic 
scores were similar in both treatment 
groups at the start of treatment (table II). 
The characteristics of the patients with­
drawn did not differ significantly from 
those of the patients in the analysis. In the 
Table II. Radiographic scores 
Median erosion score 
Median total score 
% of patients with erosions 
0 
1-10 
11-20 
20 
Hyd 
WkO 
1 
3 
43 
50 
7 
0 
roxychloroq 
Wk24 
10 
17 
21 
32 
29 
18 
nine 
Wk48 
16 
33 
12 
27 
23 
38 
Sulphasalazinc 
WkO 
1 
2 
50 
45 
5 
0 
Wk24 
2.5· 
6.5t 
32 
45 
14 
9 
Wk48 
St 
8t 
32 
41 
9 
18 
*p = 0.06; f < 0.02, for difference between treatment groups 
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patients withdrawn the median number 
of erosions was 0 and the median of the 
total score was 1; these scores were sim-
ilar to those in both treatment groups at 
week 0. 
The total number of erosions increased 
more in the hydroxychloroquine than in 
the sulphasala/ine group. At week 24 the 
difference was not significant (p = 0 06) 
but after 48 weeks it had reached signi-
ficance (p<0.02). The total score show-
ed a significant difference in progression 
between the treatment groups at 24 and 
48 weeks (p< 0.02). 
At the start of treatment the two treat-
ment groups showed the same distribu-
tion of patients according to the number 
of erosions (table II). After 48 weeks only 
12% of the patients in the hydroxychloro-
quine group had no erosions, compared 
with 32% in the sulphasalazinc group; 
only 27% of the sulphasala/ine group had 
more than 10 erosions compared with 
61% of the hydroxychloroquine group. 
Table III presents the increases in num-
ber of erosions and in total score during 
the study. Both were significantly greater 
in the hydroxychloroquine group, for the 
first 24 weeks and the second 24 weeks, 
as well as for the whole study period. 
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Discussion 
Several difficulties arise in measuring 
and judging the effect of slow-acting an-
tirheumatic drugs on the course of rheu-
matoid arthritis as shown by X-rays. First, 
the great variation in natural course of the 
disease makes a control group, prefera-
bly receiving placebo, necessary; how-
ever, because of the proven effect of slow-
acting antirheumatic drugs it is unethical 
to 'treat' patients with a placebo. By way 
of an intermediate solution Pullar et al 
used patients who consistently refused to 
start taking slow-acting antirheumatic 
drugs as a pscudocontrol group. Another 
difficulty is that many patients have to 
stop taking slow-acting antirheumatic 
drugs because of toxic effects or lack of 
efficacy, and it is difficult therefore to fol-
low patients for a long period. Lastly, it is 
important in studying the radiographic 
progression of joint damage that the dis-
ease duration of the patients is compara-
ble (and preferably short), because pro-
gression may not be linear, particularly in 
the early stages of the disease. This is sug-
gested by the findings of Brook and col-
leagues ' in a study of patients with early 
rheumatoid arthritis; they took annual X-
rays of hands and feet during 5-year fol-
New erosions 
Week 0-24 
Week 244« 
Week 048 
Total score 
Week 0-24 
Week 2448 
Week 048 
Median (95% confidence interval) 
Hydroxychloroquine 
5 1 ( 2 9-8 6) 
4 1(2 3-8 7) 
8 3(5 4-15 4) 
12 9(7.5-18 6) 
8 1 ( 6 3-12 0) 
17 3(12 1-28 6) 
Sulphasalazinc 
20 (0 9-3 8) 
12(0.5-2 4) 
21(14-6 0) 
4 3(3.5-7 0) 
3 J (2 0-5 6) 
73(4 4-110) 
Difference 
3 1 (0 1-8.5)· 
2 9(0 5-6 0)t 
6 2(15-14 2)1 
8 6 (2 5-16 2)t 
4 6 (1 l-9.1)t 
10 0(3 0-26 5)t 
*p<0 05, t p < 0 01, changes in scores compared after log transformation 
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low-up. The erosions occurred very early 
and soon stopped developing. Radio-
graphic features appeared in 71% of the 
patients; in 90% of these patients ero-
sions occurred within 2 years of the onset 
of joint symptoms. The erosive lesions ap-
peared much more commonly and much 
earlier in the feet than in the hands. 
Our data show significantly smaller 
numbers of erosions and joint space 
narrowing in the hands and feet of pa-
tients treated with sulphasalazine than in 
those of patients on hydroxychloroquine. 
This difference occurred in both the total 
amount of radiographic damage and the 
increase in radiographic defects. As far 
as we know, this is the first double-blind 
trial with sulphasalazine focusing on ra-
diographic progression of joint damage. 
Moreover, sulphasalazine is now one of 
the few slow-acting antirheumatic drugs 
with a proven efficacy against radio-
graphic progression. Admittedly, this 
trial was not carried out with placebo 
comparison, but it is unlikely that hydro-
xychloroquine would aggravate the joint 
damage. 
We carried out an intcnlion-to-trcat-
analysis for patients who received at least 
24 weeks of treatment. The inclusion or 
exclusion of patients who were with-
drawn because of lack of effect did not 
affect the results greatly. 
Pullar el al studied patients with differ-
ent disease duration and with a wide 
range of joint damage at the start. Most 
of their patients already had extensive 
deformities, with scores ranging from 15 
to 110 in the hands at the start of treat-
ment. This difference in study population 
is probably the main reason for their find-
ing of a slowing in progression only in the 
second year of treatment. Our groups 
consisted of early cases not previously 
treated with a slow-acting anti-rheumatic 
drug, and the radiographic score at the 
start was much lower. 
It is possible to criticise our results since 
only 7 of 22 sulphasalazine-trcated pa-
tients and 3 of 28 hydroxychloroquine-
treated patients were without erosions 
after 48 weeks (table HI). These patients 
could be a different subclass in whom no 
erosions develop (independent of treat-
ment), unequally divided over the two 
groups despite the randomisation. 
Therefore, we analysed the results after 
excluding patients in whom no erosions 
developed. This analysis showed a differ-
ence between the treatment groups; the 
new erosions in the second 24 weeks and 
the increase in total score in the first and 
second 24 weeks reached significance 
(p<0.05). 
Our results therefore show significant 
slowing of damage in joints of the hands 
and feet in patients treated with sulpha-
salazine compared with hydroxychlo-
roquine. Our groups consisted of early 
cases (except one patient in each treat-
ment group), and few radiographic ab-
normalities were present at the start of 
the study. This feature may be the main 
reason that we were able to document the 
slowing down of damage in the patients 
treated with sulphasalazine. The early 
onset of the clinical response to sulpha-
salazine may also be reflected in the re-
tardation of the lesions even within the 
first 24 weeks. This study emphasises the 
importance of starting an effective slow-
acting antirheumatic drug early in the 
course of rheumatoid arthritis. 
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3-year follow-up SASP-HQ 
Sir,-In a double-blind randomised trial 
of sulphasalazine and hydroxychloro­
quine in rheumatoid arthritis we found a 
significant difference in favour of sul­
phasalazine, in joint damage present 
after 48 weeks. In rheumatoid arthritis it 
is important to know if the benefit 
achieved short-term is sustained, so we 
decided to study outcome at about three 
years. 
After 48 weeks the trial code was bro­
ken and patients received slow-acting an­
tirheumatic drugs chosen by their physi­
cians. All 50 patients were invited for 
follow-up investigations after an average 
of 38 months (range 30-50). All but 1 at­
tended (27 hydroxychloroquine and 22 
sulphasalazine). The observer was as in 
the original trial and assessment included 
the Ritchie articular index, morning stiff­
ness, pain, grip strength, erythrocyte sed­
imentation rale (ESR), and plain X-rays 
of hands and feet. The X-rays were 
viewed exactly as before by the same ob­
server, who was blind to the patients' 
identity and treatment both in the trial 
and afterwards. As before, erosions and 
joint space narrowing were scored. Dif­
ferences between groups were tested sta­
tistically by Mann-Whitney rank-sum 
test. Differences in median changes were 
Table I Therapy during whole study penod 
Drug(s) used 
Hydroxychloroquine 
Sulphasalazine 
Gold 
Penicillamine 
Azathioprine or metho­
trexate 
Corticosteroids 
Reason for withdrawal 
trial therapy in years 1-3 
Lack of effect/exacerba­
tion 
Remission 
Toxicity 
Not drug related 
H 
H 
group 
. = 27) 
27 
10 
18 
3 
4 
2 
group 
17 
0 
0 
3 
S group 
(n = 22) 
4 
22 
7 
2 
5 
1 
S group 
9 
4 
0 
2 
calculated after log transformation. For 
95% confidence intervals (CI) we used 
the Mann-Whitney lest. All tests were 
two-tailed and the statistical Package for 
Social Sciences was used. 
At follow-up 7 patients were still on 
hydroxychloroquine and 7 were still tak­
ing sulphasalazine (table I). 6 patients in 
S and 4 in H no longer use a slow-acling 
antirheumatic drug: 4 S-trcalcd patients 
because of remission, 1 for therapy re­
fusal, and 1 for another, not drug related, 
reason, and 1 H-lreatcd patients because 
Table II Median radiographic scores, new erosions and total score 
Score 
Erosion 
Total 
M group 
WkO 
1 
3 
Wk48 
16 
33 
38 mo 
24 5 
55 
S group 
WkO 
1 
2 
Wk48 
5* 
8 ' 
38 mo 
ID-
IS· 
Wk048 Wk 48-38 mo Wk0-48 Wk 48-38 mo 
New erosions 
Increase in 
total score 
8 3 (5 4-15 4) 
17 3(121-28 6) 
5 5 (5 0-176) 
125(90 235) 
21(14-6 0)t 
7 3 ( 4 4-110)t 
2.5 (2 0-10 S)* 
6 0(3 5-175)t 
* p < 0 02 for differences between treatment groups 
t p < 0 0 1 and φ NS for belween-trcalment comparisons of changes in scores (compared afler log trans­
formation) 
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of partial remission (after treatment with 
another slow-acting drug), 2 for therapy 
refusal, and 1 for another not drug rela­
ted, reason. 
Clinical and laboratory variables at fol­
low-up time were not significantly differ­
ent in the period after the main trial 
(Table II). 
Thus 11 (38%) patients initially treated 
with S and 7 (24%) initially treated with 
H still experienced beneficial effects of 
the treatment after an average of over 3 
years. These figures are comparable with 
those published by others. ' The benefit 
achieved in the first year is sustained but 
not improved upon. 
The patients have been treated with a 
variety of slow-acting drugs, and the ef­
fect cannot be assigned to a particular 
one. This follow-up illustrates the impor­
tance of starting effective slow-acting an­
tirheumatic drugs early in rheumatoid ar­
thritis. The slowing of radiographic 
progression of joint damage attained with 
sulphasalazinc is still present 2 years 
later: the first blow is half the battle. 
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HAQ in trial SASP-HQ 
Summary 
To measure health status in Dutch rheumatoid arthritis patients, we have translated 
and revised the Health Assessment Questionnaire (HAQ) and added questions about 
psychosocial status from the Arthritis Impact Measurement Scales (AIMS). The resul-
tant questionnaire turned out to be reproducible and valid. In a double-blind trial 
comparing hydroxychloroquine and sulphasalazine, after 48 weeks the Physical Disabil-
ity score showed a significant difference in favour of the sulphasalazine group, reflecting 
the smaller deterioration in radiographic damage in this group. Thus the Physical 
Disability part of the questionnaire is sensitive to difference between two slow-acting 
anti-rheumatic drugs. 
Introduction 
Because Rheumatoid Arthritis (RA) is 
still an incurable disease, two important 
objectives of therapy are to prevent dis-
ability and to improve psychosocial well-
being. To examine whether these objec-
tives can be achieved, tools to measure 
these features arc needed. Over the last 
decade, a number of instruments have 
been developed to measure health status 
in arthritis patients. The most widely used 
are the Health Assessment Question-
naire (HAQ) and the Arthritis Impact 
Measurement Scales (AIMS). ' ' Both 
arc self-administered questionnaires. 
The HAQ, which deals only with Physical 
Disability and pain, is easy to use, while 
the AIMS is very extensive and also in-
cludes scales concerning depression, 
anxiety and social dimensions. Sicgcrt et 
al translated the HAQ literally into 
Dutch and tested it out on a small group 
of Dutch patients, but no measurement 
on sensitivity has been made. 
We have composed a Dutch health 
assessment questionnaire by combining 
questions from the HAQ (shortened ver-
sion) with questions from the AIMS 
about psychosocial status. In addition a 
few new questions especially for Dutch 
circumstances were added. We tested the 
questionnaire in hospitalized and ambu-
latory RA patients with a wide range of 
severity and correlated the questionnaire 
to other clinical endpoints in a double-
blind clinical trial comparing sulphasala-
zine vs. hydroxychloroquine to define the 
sensitivity of the questionnaire. 
Patients and methods 
Development of the questionnaire 
The physical part of the questionnaire 
consists of questions from the HAQ and 
a few new questions more relevant for the 
Dutch situation (for example the ability 
to ride a bicycle). This part of the ques-
tionnaire comprises the following eight 
components or subscales: Dressing and 
Grooming, Arising, Hygiene, Eating, 
Walking, Reaching, Grip and Outdoor 
pursuits. The subscales Depression and 
Anxiety from the AIMS, together with 3 
questions about Relations with spouse, 
children and friends, form the Psychoso-
cial part. In addition, questions about 
Profession, Housing and Transport form 
part of the questionnaire. These items arc 
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not included under Physical Disability or 
Psychosocial Status and are used for 
other purposes, for example to inves-
tigate the impact of RA in society. 
In a pilot study of 30 patients with defi-
nite or classical RA a pretest of the ques-
tionnaire with 44 questions was per-
formed. Spearman rank correlations 
were calculated for each question with 
every other question. If these exceeded 
0.9, the question has been excluded to 
eliminate redundancy. This resulted in 
the above-mentioned subscalcs and a 
total of 39 questions. Further elimination 
of questions caused loss of information. 
It is a self-administered questionnaire. 
Each component consists of 1-4 ques-
tions. The scores for the questions re-
garding functional activities range from 
0 = no difficulty, l = some difficulty, 
2 = great difficulty or with assistance, to 
3 = unable to perform. The responses to 
the anxiety and depression components 
are 0 = never, 1 = sometimes, 2 = often, 
3 = nearly always. The remaining ques-
tions have comparable answers: 0 for the 
normal and 3 for the worst situation. The 
mean score of the subscalc is the ultimate 
score for that component. Physical Dis-
ability and Psychosocial Status are com-
puted by adding the mean scores of the 
subscalcs of the corresponding index and 
dividing by the number of the categories, 
thus correcting for unanswered questions 
or components. These two overall scores 
or indexes (Physical Disability, Psychoso-
cial Status) have a continuous scale wilh 
a range from 0 to 3. 
Test of the questionnaire 
110 consecutive patients, 28 in- and 82 
outpatients (96% of the patients who 
were invited to participate) of the De-
partment of Rheumatology at the Uni-
versity Hospital Nijmegen and having 
classical or definite RA, completed the 
questionnaire. The response rate to all 
questions was 96-100%. All subscalcs 
ranged from the minimum score 0 to the 
maximum score 3, except the Relations 
subscale which reached 2.33 as maxi-
mum. Physical Disability ranged from 0 
to 2.97 (mean 0.92, SD 0.72) and Psycho-
social Status from 0 to 2.5 (mean 0.73, SD 
0.58). The time required to complete the 
questionnaire ranged between 2 and 8 
min. Thus the questionnaire covers the 
whole range of the scale and is quick to 
perform. 
To ascertain the internal consistency, 
Cronbach's alpha has been computed 
for the different indexes. Cronbach's 
alpha for the Physical Disability of the 8 
subscalcs was 0.92; for the Psychosocial 
Status with 3 subscalcs 0.71. Cronbach's 
alpha for the Psychosocial Status could 
be improved to 0.81 if the subscale about 
relations was excluded. 
Reproducibility of the questionnaire 
To study the reproducibility of the re-
sponses, 37 patients with stable disease 
(22 in-patients, 15 out-patients) com-
pleted the questionnaire twice with an 
interval of 12-24 days (mean 16.5). Pa-
tients with the same ESR and number of 
swollen and painful joints, who did not 
commence a new therapy during at least 
the last 3 months, were considered as hav-
ing stable disease. 
The test-retcst Spearman rank correla-
tions of the subscalcs range from 0.62 to 
0.92. The test-retcst correlation of Physi-
cal Disability is 0.89 and of Psychosocial 
Status 0.73. The measurement error of a 
single observation (see Statistical Melh-
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ods) is 0.26 for the Physical Disability and 
0.33 for the Psychosocial Status. Thus the 
reproducibility of the responses of the 
questionnaire was good. 
Validity of the questionnaire 
To assess validity, a different sample of 
20 hospitalized patients were asked to 
perform the tasks of the following com­
ponents of the Physical Disability in front 
of research nurses: Dressing and Groom­
ing, Arising, Hygiene, Eating, Walking, 
Reaching and Grip. All patients comple­
ted the questionnaire 1-3 days earlier, 
without knowing that they would have to 
repeat the tasks. 
The scores for the Physical Disability of 
these patients ranged from 0 to 2.47, 
meaning that this group too has a wide 
range of disease severity. The Spearman 
rank correlation between the Physical 
Disability questionnaire completed by 
the research nurses and the patients was 
0.85. The measurement error of a single 
observation was 0.04, ensuring that the 
validity of the responses regarding Phys­
ical Disability were good. 
Patients 
The questionnaire was used in a 48-
wcek double-blind study comparing sul-
phasala/inc with hydroxychloroquine to 
assess the sensitivity of the instrument. 
Sixty patients participated in the trial: 30 
in each treatment group. The question­
naire was tested in the last 41 consecutive 
patients of the trial because it had not 
been finali/cd in time for the first 19 pa­
tients in the trial. The questionnaire was 
completed at week 0, 24, and 48. The pa­
tients on hydroxychloroquine received 
400 mg daily during the first 24 weeks and 
200 mg daily thereafter. Patients on 
sulphasala/ine received 2000 mg daily. 
Clinical and laboratory parameters were 
determined every 4 weeks. Radiographs 
of hands and feet were made at the start 
and after 24 and 48 weeks. The complete 
design and the results of the trial has been 
described elsewhere. ' 
X-ray analysis 
After completion of the trial the radio­
graphs were scored by a single observer 
(DvdH). The reader was not informed of 
the therapy the patient had received. The 
patients were scored in random order. 
All radiographs were read on the same 
lightbox under identical conditions, in 
chronological order per patient. The 
hand radiographs were scored in a mod­
ified way according to Sharp. Analogous 
to Sharp's method for hand radiographs. 
we scored erosions and joint space nar­
rowing in the joints of the feel. To validate 
the method the inter- and inliaobservcr 
correlation was computed and turned out 
to be 0.96 and 0.94 respectively. 
Erosions were counted in the 10 meta­
carpophalangeal joints, the 8 proximal 
in lerphalangcal jo ints , the 2 inter-
phalangeal joints of the thumbs, the R 
and L 1st metacarpal bone, the R and L 
radius and ulnar bones, the R and L mul-
tangulars (as 1 unit), R and L navicular, 
R and L lunate, the 10 metatarsophalan­
geal joints and the 2 intcrphalangeal 
joints of the big toes. Joint space narro­
wing was assessed in the 10 metacar­
pophalangeal joints, the 8 proximal intcr­
phalangeal joints, R and L 3rd, 4th and 
5th carpometacarpal joints, R and L 
multangular-navicular, R and L capilale-
navicular-lunale, R and L radiocarpal 
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joints, the 10 metatarsophalangeal joints 
and the 2 interphalangcal joints of the big 
toes. Erosions were counted if a discrete 
interruption of the cortex surface existed; 
in case of a greater defect, a score accord-
ing to the surface of the joint involved was 
given. Consequently, for confluent ero-
sions the score could not become smaller. 
In the hands the maximum erosion score 
in a joint was 5; in the feet it was 10. Four 
grades of joint space narrowing were rec-
ognized: 1. focal or doubtful, 2. general-
ized < 50% of the original joint space, 3. 
generalized >50% of the original joint 
space or subluxation, 4. ankylosis. This 
made the maximum number of erosions 
in the hands 160 and in the feel 120; and 
the maximum score for joint space nar-
rowing 120 and 4ö respectively. The sum-
mation of the erosions and l.he joint soace 
narrowing gave the total score. 
Statistical Analysis 
Data have been analysed using Statisti-
cal Package for the Social Sciences X.9 
To generate test-retest reliability and va-
lidity, both Spearman rank correlations 
and the standard error fora single obser-
vation (уГ£(рі-р2)/2п ) have been 
computed. Two-tailed, unpaired T-tests 
and Mann-Whitney rank sum tests with 
α = 0.05 have been used to determine the 
significance level of the difference bet­
ween the means of the two treatment 
groups. 
Results 
The last 41 consecutive patients in a 
double-blind trial comparing hydroxy­
chloroquine (n = 20) with sulphasalazine 
(n = 21) were included in order to evalu­
ate the sensitivity of the questionnaire in 
measuring change over lime. Six patients 
dropped out in the first few weeks be­
cause OÍ side effects. From ihe remaining 
group; three questionnaires at week 24 
and week 48 wefC not completed. Only 
the patients who completed all question-
naires at weeks 0, 24 and 48 have been 
included in the analysis (n = 32). Nine-
teen patients received hydroxychloro-
quine and 13 patients sulphasalazine. 
Tabic I Basel^e characteristics of the patients in the Sulphasalazine and Hydroxychloroquine groups 
US(:d
 'Ti me analysis number, mean, SD and (range) 
Гетаіе/таіе 
Age (years) 
(range) 
Rheumafactor pos* 
Discase duration 
(month4) 
Stembrocker 1 
2 
3 
4 
Hydroxychloroquine 
(n = 19) 
9/10 
545 ± 1 3 0 
(22-72) 
18 
102 + 87 
(3-39) 
1 
9 
9 
0 
Sulphasalazine 
(n-13) 
10/3 
50.5 ± 1 5 4 
(22-76) 
12 
72 + 24 
(4-11) 
3 
6 
4 
0 
* Rose > 1 40 
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Table II. Spearman rank correlations between the change from baseline of the Physical Disability, 
Psychosocial Status and morning stiffness, pain, Ritchie score and ESR 
Change 24-0 
Physical Disability 
Psychosocial Status 
Change 48-0 
Physical Disability 
Psychosocial Status 
Morning stiffness 
0.31 
0.36 
0.26 
0.20 
Pain 
0.47 
0.32 
0.45 
0.15 
Ritchie score 
0.40 
0.10 
0.42 
0.34 
ESR 
0.52 
0.33 
0.61 
0.49 
The characteristics at baseline are given 
in Table I. The results of the question-
naire were evaluated independently of 
clinical features (tender joints, swollen 
joints, pain scale, morning stiffness, grip 
strength) and laboratory features (Eryth-
rocyte Sedimentation Rate, Haemogl-
obin). Thus the questionnaire has been 
analysed separately and not as one of the 
many possible parameters. 
The change from week 0 to weeks 24, 
and 48, respectively was computed for the 
following variables: morning stiffness, 
pain, Ritchie score, ESR, and the two in-
dexes. The Spearman rank correlation 
between the change in the various vari-
ables and also the change in Physical Dis-
ability and Psychosocial Status arc 
summarized in Table II. The correlations 
between the clinical and laboratory vari-
ables and the Physical Disability ranged 
between 0.26 and 0.61, and the Psycho-
social Status from 0.10 to 0.49. Overall, 
the correlations between the Physical 
Disability and the clinical and laboratory 
variables were closer than between the 
Psychosocial Status and these variables. 
The correlations were moderate to good, 
indicating that changes in the clinical and 
laboratory parameters can be found in 
changes in the indexes too. 
Unpaired t-tests have been conducted 
between the hydroxychloroquine and sul-
phasalazine group on the indexes at week 
0, week 24 and week 48. The results are 
summarized in Table III. At the start and 
after 24 weeks of therapy there were no 
significant differences between the two 
treatment groups. The Physical Disability 
at week 48 was significantly better in the 
sulphasalazine group than in the hydroxy-
chloroquine group. Psychosocial Status 
did not change in the hydroxychloroqui-
ne group and showed only a slight change 
in the sulphasalazine group at 48 weeks 
of study but did not reach statistical sig-
nificance. Although there were signifi-
cant improvements within both treatment 
groups, there was no significant differ-
ence in morning stiffness, Ritchie score, 
pain or ESR between the groups. On the 
contrary, the increase in radiographic 
progression was significantly smaller in 
the sulphasalazine than in the hydroxy-
chloroquine group. 
Discussion 
The main reason for devising a ques-
tionnaire to measure health status for the 
Dutch population is to have a reliable in-
strument to measure the impact of rheu-
matoid arthritis on patients' physical and 
psychosocial well-being. Especially in 
judging the efficacy of slow-acting anti-
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Table ΠΙ Physical Disability, Psychosocial Stalus, clinical, laboratoiy and radiographic variables of 
Hydroxychloroquine (IIQ) and Sulphasalazine (SASP) 
Physical Disability 
Psychosocial Status 
Morning stiffness 
Pain 
Ritchie 
ESR 
Median erosion score 
IIQ 
WeckO 
0 63 
0 57 
127 
43 
14 6 
43 
2 
Week 24 
050 
0 54 
56 
23 
10 
32 
10 
Week 48 
0.58 
0 56 
45 
35 
82 
26 
19 
SASP 
WeekO 
0 53 
0 31 
141 
43 
10 7 
36 
0 
Week 24 
0 27 
036 
16 
24 
5 2t 
23 
is* 
Week 48 
0 24' 
0 23 
31 
25 
5 3 
24 
2 5° 
* ρ = 0 03, tp = 0 05 (t-tcst, difference between the groups) 
φρ = 0 0 4 1
ο
ρ = 0 01 (Mann-Whitney rank sum lest, difference between the groups) 
rheumatic drugs it is of interest to have 
such a measure, which is sensitive enough 
to assess clinically important differences, 
in addition to the traditional process 
measurements. 
Mcenan et al. and Bombardier el al. 
have demonstrated the sensitivity of 
health status questionnaires in clinical 
trials with gold salts (between placebo, 
aurothiomalate and auranofin and be­
tween placebo and auranofin, respective­
ly). Mcenan used the AIMS question­
naire and found only a significant 
difference, in favour of the gold sails, in 
the psychological dimension of the health 
status, but not in the physical component 
after 21 weeks of Ircalmcnl. Bombar­
dier used the I IAO for ihe physical dis­
ability and several depression assess­
ments as a psychological component in a 
6-month trial. She showed a significant 
difference in the Η АО score between the 
placebo and auranofin group, in favour of 
ihe latter. There was no difference in the 
depression scores. 
In this paper we have described the 
evaluation of a double-blind clinical trial 
comparing hydroxychloroquine and sul­
phasalazine, versus a Health Status 
Measurement. The Physical Disability 
part of this questionnaire was mainly de­
rived from the shortened version of the 
HAQ, the part of the Psychosocial Status 
from the AIMS, expanded with three 
questions about relations. The question­
naire was tested in a Dutch population of 
RA patients and turned out to be valid. 
At the start of the trial the questionnaire 
was not yet available. In addition, a con­
siderable number of patients were ex­
cluded during the study as a result of 
which the evaluation with the health sta­
tus measure could only be done in 32 of 
the original 60 patients. Despite this, the 
results of the clinical, laboratory and 
radiological parameters are comparable 
to those of the original trial: significant 
improvement of clinical and laboratory 
variables within (but not between) the 
groups and significantly less radiographic 
damage in the sulphasalazine group ' 
(Table III). Thus the 32 patients in this 
investigation are a good reflection of the 
whole group. 
The evaluation of the health assessment 
questionnaire shows a significant differ­
ence in favour of sulphasalazine in the 
Physical Disability part, but not in Psy­
chosocial Status (Table Ш). Our results 
agree with those of Bombardier. The 
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lack of a significant difference in the Psy- tivity of the Physical Disability part of the 
chosocial Status may be due to the great health assessment questionnaire in a 
influence of factors not related to arthri- double-blind trial of 48 weeks, comparing 
tis, on psychosocial well-being. The two slow-acting anti-rheumatic drugs. 
correlations between the clinical vari- The significant difference between the 
ablcs and the indexes are somewhat two treatments is in accordance with the 
higher in our study than in the study of significant difference in radiographic 
Mecnan et al. (Table II). damage, whereas the clinical and labora-
This study has demonstrated the sensi- tory variables show only a trend. 
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Validity of process variables 
Summary 
Пеге is no agreement as to the best variable to follow disease activity in rheumatoid 
arthritis (RA). Moreover no studies on the validity of disease activity variables have been 
done. In this study we tested the validity of 10 frequently used single variables and 3 
composed indices. All patients participated in a large prospective follow-up in two 
clinics. The patients (n = 233) had a classical or definite RA and a disease duration 
shorter than 1 year at entry. Tlie mean follow-up was 30 months; the follow-up frequency 
four-weekly; 6011 records were used in the analysis. The validation criteria include 
correlations with the other variables (correlational validity), with the physical disability 
(criterion validity I), and with the radiographic damage of hands and feet (construct 
validity). Also the judgment of a group of rheumatologists in clinical practice has been 
used as a model of criterion validity (II). In this comparison the indices Disease Activity 
Score andMallya show the best validity. Tl\e best single variable is the number of swollen 
joints. Tlie validity of most single variables is poor and these variables are not suitable 
as single endpoint measures in clinical trials. 
Introduction 
Rheumatoid arthritis is a heterogene­
ous disease entity with greatly varying cli­
nical course and outcome. Two aspects 
are important in evaluating the disease: 
the disease activity and the ultimate out­
come. The assessments to evaluate these 
features are often called 'process' and 
'outcome' measurements, respectively. 
Radiographic abnormalities and physical 
disability are two tools to evaluate out­
come. Especially on these outcome mea­
surements a lot of research has been 
done. Methods to score radiographic 
damage are widely tested, e.g. for inter-
and intraobserver variation. ' Question­
naires to measure physical disability have 
been developed and tested extensively 
and these turned out to be valid assess­
ments for measuring outcome. ^ 
Process measurements arc widely used 
in the evaluation of short term clinical tri­
als. Although rheumatologists in work­
shops discussed the question which end-
point measures should be used in clinical 
trials, no agreement exists. ' Therefore 
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in most clinical trials many variables arc 
used for evaluation. This may cause con­
flicting results. Besides, correction for 
multiple testing is needed. This requires 
a larger group of patients to ensure 
enough power for the study. Single clini­
cal and laboratory variables are used 
most in measuring the disease process. 
Also some composed indices have been 
developed such as the Mallya and Riel 
index, and, the Disease Activity Score 
R I O 
(DAS). ' In contrast with the question­
naires, little research has been done on 
the validity of the various variables and 
indices. The validity of a variable means 
that the variable is measuring what it is 
supposed to do. In case of a process vari­
able in rheumatoid arthritis, this variable 
must measure 'disease activity'. This dis­
ease activity must be related with the ul­
timate result of the disease process. A 
problem in the study of validity of process 
variables of rheumatoid arthritis is that a 
golden standard for disease activity is 
lacking. Analogous to the validation of 
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questionnaires on physical disability, 
we have chosen for an explorative me­
thod, resulting in a combination of sev­
eral aspects of validity. This method for 
validation is widely used in social and be­
haviour sciences and advised by Tugwell 
and Bombardier for the selection of end-
point measures in clinical trials. The 
overall results of all these facets of valid­
ity gives the ultimate conclusion on the 
validity of a particular process variable. 
A lot of research has been done on dis­
ease activity variables and on judgment 
analysis. ' However, mostly only one 
aspect of disease activity has been evalu­
ated. For example the possible effect of 
measuring disease activity of a new as­
sessment was checked by the correlation 
with another disease activity variable 
such as the Ritchie score or the acute 
phase response. ' However, the reli­
ability of these'reference'disease activity 
variables is not well enough known. On 
the comparison of different laboratory 
and clinical disease activity variables little 
research has been done. ' As far as we 
know no study compared many labora­
tory and clinical disease activity variables 
and tested their ability to evaluate the ul­
timate outcome, measured as radio­
graphic damage and physical disability in 
a large database of patient records. 
The aim of this study was to compare 
the validity of 10 single variables and 3 
composed indices. The disease activity 
variables were chosen arbitrarily from 
the large amount of available assess­
ments. We selected especially those mea­
sures which are used frequently to mea­
sure disease activity in clinical trials and 
in clinical practice. Finally, the most valid 
variable to measure disease activity in 
clinical trials and clinical practice could 
be chosen. 
Patients and methods 
Patients 
All patients took part in an ongoing pro­
spective study of RA. Consecutive pa­
tients who met the following criteria were 
included in the study: classical or definite 
RA according to the ARA criteria, dis­
ease duration shorter than 1 year at entry 
of the study, not treated with slow-acting 
antirheumatic drugs (SAARDs) before. 
The whole project is a co-operation of the 
departments of rheumatology of the Uni­
versity Hospital Nijmegen and the Uni­
versity Hospital Groningen in the Neth­
erlands. At time of analysis 133 patients 
participated in the study in Nijmegen 
(clinic I). The follow-up ranged from 8 to 
57 months (mean 28; number of check­
ups =2937). In Groningen (clinic II) Ш) 
patients participated with a follow-up 
from 8 to 58 months (mean 31 ; number of 
check-ups = 3074). 
Ässessmenfs 
In both clinics three specially trained re-
search nurses assessed all the patienls in 
the outpatient department. The following 
assessments were carried out every 4 
weeks: number of lender joints, number 
of swollen joints: all the following joints 
were examined bilaterally for the pres-
ence or absence of swelling and tender-
ness: tcmpcromandibular, sternocla-
vicular, acromioclavicular, shoulder, 
elbow, wrist, each mclacarpophalangcal, 
each proximal inlcrphalangcal and inlcr-
phalangcal of the thumb, hip, knee, ankle, 
subtalar, midtarsal, metatarsophalan-
geal, intcrphalangeal of the big toe. 
Furthermore, Ritchie articular index, 
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Table I. Characteristics of Ihe patients at Ihe 
start of the follow-up 
Female (%) 
Age years (mean, SD) 
Disease duration months 
(mean, SD) 
IgM-RF > 5 IU (%) 
Physical Disability 
Erosions hands and feet 
(number) 
Total score hands and feet 
clinic I 
(n = 133) 
66 
54.3±14.5 
6.1+4.0 
80 
0.64 ±0.57 
2.9±4.7 
5.3±4.7 
clinic II 
(n = 100) 
65 
47.7±15.6 
6.9+4.6 
88 
morning stiffness (minutes), pain (on a 
Visual Analogue Scale (VAS) of 10 cm, 
0 = no pain, 10 = worst pain possible), 
general health (VAS of 10 cm, 0 = bcsl 
possible, 10 = worst possible), grip 
strength with a vigorimcter (kPa), ESR 
according lo Wcslcrgrcn (mm in 1 hour), 
haemoglobin (Hb, mmol/l), and C-Rcac-
livc Protein (CRP;mg/l). The normal 
range for haemoglobin in our clinics is 1 
mmol/l lower for women than for men. 
Therefore wc diminished the haemo-
globin value of the men by 1 mmol/l, en-
suring comparability regardless of sex. 
Wc calculated the Mallya index of dis-
ease activity for each patient at each visit. 
This index is composed of morning stiff-
ness, pain (VAS), grip strength, articular 
index, haemoglobin (uncorrected for 
sex) and ESR. Each variable is divided 
into four classes and the mean score of 
the six variables gives the final score 
(range 1 lo 4). The Riel index (a modified 
Mallya index) is made up of the variables 
morning stiffness, number of tender 
joints, haemoglobin (corrected for sex) 
and ESR and is calculated analogously lo 
the Mallya index. The disease activity 
score (DAS) is composed of Ritchie, 
number of swollen joints, ESR, and, gen-
eral health. In all 13 variables were an-
alysed in this study. 
Every six months the patients of clinic I 
completed a questionnaire on physical 
disability comparable with the HAQ. ' 
Also every six months plain anterior 
radiographs of ihe hands and feet were 
made. The number of erosions and the 
joint space narrowing in the hands were 
scored by a modified version of Sharp's 
method. The foot radiographs were 
scored in a similar way. These scoring 
methods have been described extensively 
before. Summation of Ihe erosions and 
joint space narrowing gives the total 
score. The scores of all 77 patients of cli-
nic I who were followed for at least two 
years were used in the analysis of radio-
graphic features. 
Validation 
As there is no golden standard available 
for the description of the quality of the 
variables considered for disease activity, 
a more explorative validai ion procedure 
was chosen. The following aspeéis of val-
idation were discerned. Correlational va-
lidity: does the measure correlali.' uit h 
other measures who are supposed to 
measure disease aclivity. For this analysis 
mutual correlations of the varialilcs 
under investigation have been calculated. 
Criterion validity: does the assessment fit 
with Ihe theory about the disease. Does 
the method measure the true clinical sta-
tus. Therefore correlations with Physical 
Disability have been determined. Besides 
the clinical judgement of rheumalologists 
on disease activity has been analysed. 
Construct validity: does the process vari-
able (disease activity) lead to the ultimate 
result, the oulcome. Correlations be-
tween the disease activity variables and 
radiographic damage have been calcu-
lated. 
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Table II Mean, standard deviation, minimum, maximum and skewness before and after transformation of 
the variables of clinic I (patients η = 133) and clinic II (patients η = 100) 
Variable 
1 DAS 
2 Mallya 
3 Riel 
4 General Health 
S Pain 
6 lender joints 
7 Swollen joints 
8 Ritchie 
9 Morning stiffness 
10 ESR 
11 CRP 
12 Haemoglobin 
13 Grip strength 
Mean 
3 35 
2 23 
197 
307 
316 
102 
121 
8 3 
40 
29 
28 
79 
40 
Clinic I (n 
SD 
123 
054 
0 62 
22 6 
230 
89 
7 3 
75 
67 
24 
39 
10 
22 
Mm 
0 32 
100 
100 
0 
0 
0 
0 
0 
0 
1 
1 
47 
0 
= 2937 check-ups) 
Max 
7 26 
3 83 
400 
100 
100 
44 
37 
46 
360 
140 
260 
10 8 
138 
Skewness 
before 
transfor­
mation 
.53 
S9 
.78 
.51 
1 1 
278 
142 
246 
-41 
90 
Skewness 
after 
transfor­
mation 
— 
— 
— 
-38 
-31 
- 1 1 
— 
-06 
16 
- 4 3 
-61 
— 
0 07 
Clinic 
Mean 
328 
2 18 
195 
285 
12 9 
75 
113 
36 
31 
24 
80 
47 
I (n = 3074 check-ups) 
SD 
128 
058 
064 
24 9 
12 3 
71 
10 9 
69 
26 
36 
10 
26 
Mm 
0 35 
100 
100 
0 
0 
0 
0 
0 
1 
1 
4 6 
0 
Max 
8 35 
400 
400 
100 
48 
40 
52 
360 
140 
398 
110 
184 
Statistical procedures Correlational validity 
Initially, all variables were assessed on 
their suitability for standard statistical 
analysis. If necessary, a transformation to 
'normality' was performed. The trans­
formed values were used in the further 
analysis. The study of validity was mainly 
based on correlations. 
Results 
Initial characteristics of the patients arc 
presented in Tabic I. The variables used 
in the analysis arc summarized in 
Table II. Because of a high skewness, 
some variables are transformed to ap­
proximate a normal distribution. The 
skewness for clinic II is comparable with 
that of clinic I. Therefore the same trans­
formations arc done. 
The mutual correlations of the different 
disease activity variables give the correla­
tional validity. A high correlation means 
that they arc all measuring the same pro­
cess. The first calculations are done on 
the individual data of the patients: the 
correlations between the variables within 
a patient and thereafter the mean over all 
patients arc computed, leading to a mean 
correlation matrix. The correlation ma­
trix is the basis on which the mean corre­
lations with the other 12 variables are 
then calculated. The results as to the 
correlational validity on the individual 
data arc fully comparable in both clinics 
(Table III). The mean correlations of the 
three composed indexes arc comparable 
and substantially higher than the single 
variables. Especially, the variable hae­
moglobin has a low correlational validity 
(0.29). The calculations arc also perfor-
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Table III Correlational validity mean Pearson correlation on the raw and the individual data of all 
patients of each variable with other 12 variables in both clinics 
Variable 
1 DAS 
2 Mallya 
3 Riel 
4 General Health 
5 Pain 
6 Tender joints 
7 Swollen joints 
8 Ritchie 
9 Morning stiff 
10 LSR 
11 CRP 
12 Haemoglobin 
13 Gnp strength 
Mean individual 
correlations 
clinic I (n = 133) 
Mean 
63 
65 
61 
38 
42 
SO 
43 
50 
42 
47 
41 
32 
41 
Range 
(35,89) 
(51,83) 
(39,83) 
(14,73) 
(18,73) 
( 18,92) 
(24,81) 
(19,92) 
(18,75) 
( 28, 70) 
(23,70) 
( 14,59) 
(32,61) 
Mean individual 
correlations 
clinic II ( 
Mean 
64 
64 
63 
42 
50 
41 
51 
35 
38 
40 
30 
46 
η = 100) 
Range 
(34,87) 
(43,87) 
(51,87) 
( 06,70) 
(13,93) 
(21,70) 
(11,93) 
( 02, 61) 
( 10, 74) 
(13,74) 
(02,58) 
(28,71) 
Raw correlations 
clinic I (n = 2937) 
Mean 
61 
62 
59 
36 
38 
47 
38 
48 
33 
36 
38 
29 
41 
Range 
(32,87) 
(44,86) 
( 40, 86) 
(06,80) 
( 03,80) 
( 09, 94) 
(18,72) 
( 08, 94) 
( 07, 64) 
( 09, 70) 
( 09, 70) 
( 03, 59) 
(23,64) 
med on the raw data. To start with, the 
correlation of each variable with every 
other variable is determined. Thereafter, 
for every variable we calculated the mean 
(minimum, maximum) correlation with 
the other variables. The overall correla­
tions arc similar to those on the individual 
data (Table III). 
Criterion validity 
Criterion validity implies that a good 
disease activity variable measures the 
true clinical status of the patient. Two 
theoretical aspects are distinguished. 
I. The first aspect of the criterion valid­
ity of all variables is determined by calcu­
lating the Pearson correlations between 
the variables and the Physical Disability 
on the individual data. This shows how 
the disease activity variables reveal what 
is the most important aspect for the pa­
tients. The mean and the median correla-
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tions are given in Table IV. The medians 
can be interpreted best. The DAS and the 
Ritchie have the highest median correla­
tions (0.70 and 0.68 respectively), haemo-
I'able IV Criterion validity I the mean and 
median individual Pearson correlation of each 
variable with the Physical disability (clinic I 
η = 133) 
Variable 
1 DAS 
2 Mallya 
3 Riel 
4 General Health 
5 Pain 
6 Tender joints 
7 Swollen joints 
8 Ritchie 
9 Morning stiffness 
10 ESR 
11 CRP 
12 Haemoglobin 
13 Gnp strength 
Mean 
44 
43 
33 
36 
39 
37 
36 
42 
29 
34 
38 
-16 
-35 
Median 
70 
60 
.50 
49 
58 
.58 
57 
68 
47 
45 
60 
- 3 2 
-58 
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Table V Cntcnon validity II mean and standard deviations for high and low disease activity in clinic II 
(patients η = 100) and standardised difference 
Variable 
1 DAS 
2 Mallya 
3 Rid 
5 Pain 
6 Tender joints 
7 Swollen joints 
8 Ritchie 
9 Morning sliffnes 
10 fcSR 
11 CRP 
12 Haemoglobin 
13 Grip strength 
High DA (n = 129) 
mean 
4 27 
2 62 
241 
614 
401 
12 60 
3 82 
221 
352 
2 27 
744 
7 18 
SD 
111 
0.58 
0 62 
230 
163 
725 
156 
131 
088 
0 80 
107 
178 
Low DA 
mean 
2 50 
189 
160 
334 
2 19 
4 16 
2 05 
106 
272 
159 
788 
5 48 
(n = 115) 
SD 
101 
0 48 
0 47 
279 
176 
4 93 
151 
114 
0 93 
0 62 
0 69 
2 32 
Standardised 
difference 
166 
137 
146 
1.10 
108 
135 
1.15 
0 93 
0 89 
094 
049 
0 82 
globin shows the lowest correlation 
(0 32). 
II. Clinical judgement by rhcumatolo-
gists is another procedure to evaluate ac­
tual disease activity. Therefore we used 
the decisions ot rheumatologists in clini­
cal practice to start or stop SAARDs. 
Decisions to start SAARDs or to stop 
SAARDs because of lack of efficacy were 
equated with moments of high disease ac­
tivity; withdrawal because of remission, 
or not starling or changing SAARDs for 
at least one year, with moments of low 
disease activity. The DAS is the 
formalisation of the decisions of rheuma­
tologists on the start and withdrawal of 
SAARDs in clinical practice and was 
constructed for the group of rheumatolo­
gists in clinic I. Therefore, only the re­
cords of the patients of clinic II were used 
for this analysis. Patients were divided 
into a group wilh high and one wilh low 
disease aclivily, according to the above 
explicit rules. The group wilh high dis­
ease activity comprises 129 records and 
the group with low disease activity 115. 
For all variables the mean and standard 
deviations of the groups wilh high and 
low disease activity are determined. The 
larger the difference between the means 
of the two groups, the larger the dis­
criminating power of the variable. To 
compare the various variables, the differ­
ences arc standardised (i.e. difference di­
vided by pooled standard deviation). 
The results are given in Table V. The 
DAS has by far the most discriminating 
power (SD score = 1.66), followed by the 
Riel (SD score = 1.46) and the Mallya 
(SD score = 1.37). The swollen joints 
count is the only single variable with a 
considerable discriminating power 
(SD score = 1.35). 
Construct validity 
Construct validity evaluates whether 
the variable which measures the process 
corresponds wilh the ultimate result of 
the process: the outcome. Longstanding 
disease aclivily leads lo (largely) irrcvers-
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ible joint damage, visible on radiographs 
as erosions and joint space narrowing. 
Thus the damage caused by the disease 
process and made visible on X-rays is 
cumulative. For this analysis only those 
patients of clinic I who have been fol­
lowed at least two years have been in­
cluded (n = 77). The mean of each vari­
able is calculated over adjacent periods 
of six months. This mean is correlated 
with the increase in joint damage in the 
same period. In all, 345 of those periods 
were available for analysis. Also the mean 
of the variables and the increase of the 
joint damage over a period of two years 
are calculated. The total of the 2-year pe­
riods in the analysis is 133. Table VI 
summarizes the results of the Spearman 
rank correlations of the mean of the vari­
ables with the increase in number of ero­
sions, joint space narrowing and total 
score. The results of the half-year periods 
and the two-year periods are compar­
able. The CRP, swollen joints, ESR, 
DAS, M ally a, Riel, and grip strength 
have the highest correlations. The other 
variables have substantially lower corre­
lations. 
Discussion 
Surprisingly, no systematic studies on 
the comparison of validity of 'process' 
measurements have been made, although 
these variables arc used widely in clinical 
trials and in clinical practice. In this study 
we were able to evaluate different aspects 
of the validity of 13 variables frequently 
used to measure disease activity. Not only 
single variables were included, but also 
indexes like the Mallya, Riel and DAS. 
Due to the lack of a golden standard for 
disease activity we used an explorative 
method to evaluate validity, as is used 
widely in social sciences. 
Physical disability and radiographic 
damage in hands and feet are mostly used 
Tabic V I Construct validity correlations between increase in joint damage in periods of one-half and 
of two years and mean clinical and laboratory variables over the same period (clinic 1,77 patients) 
Variable 
1. DAS 
2. Mallya 
3 Riel 
4. General Health 
S. Pain 
6. Tenderjoints 
7. Swollen joints 
8. Ritchie 
9. Morning stiffness 
10. ESR 
11. CRP 
12. Haemoglobin 
13. Grip strength 
halt-year periods (n 
E 
33 
.30 
30 
.07 
.12 
.18 
.42 
.17 
.15 
.29 
.35 
-.24 
-.29 
N 
28 
.30 
.25 
.17 
19 
.13 
.27 
.14 
.07 
.38 
.43 
-.19 
-.28 
= 345) 
Τ 
33 
.34 
32 
.13 
.17 
16 
.39 
.17 
.14 
.39 
.46 
-.25 
-.32 
lwo-years periods (n 
E 
.31 
.25 
.22 
.12 
18 
.15 
34 
13 
.10 
.19 
.40 
-.10 
-.32 
N 
26 
.30 
.21 
.23 
26 
.06 
.39 
07 
.03 
.36 
52 
-.14 
-.39 
= 133) 
Γ 
30 
31 
24 
.20 
26 
.12 
.48 
И 
.10 
29 
50 
-.14 
-.38 
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Table VII. Summary of validation entena for the 13 variables (+ + very good, + good, ±moderate, 
- poor) 
Vanablc 
1. DAS 
2. Mallya 
3. Riel 
4. General Health 
5. Pain 
6. Tender joints 
7. Swollen joints 
8. Ritchie 
9. Morning stiffness 
10. ESR 
11. CRP 
12 Haemoglobin 
13 Grip strength 
Correlational 
validity 
+ 
+ 
+ 
± 
± 
+ 
± 
+ 
± 
+ 
± 
-
± 
Cntenon 
validity I 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
± 
+ 
-
+ 
Criterion 
validity II 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
± 
± 
± 
-
± 
Construct 
validity 
+ 
+ 
+ 
-
-
-
+ 
-
-
+ 
+ 
± 
+ 
as Outcome' measurements. " Variables 
which measure the 'process' (disease ac-
tivity) have to correspond with the 'out-
come'. Therefore we used the physical 
disability and the radiographic damage in 
hands and feet to validate the disease ac-
tivity variables. 
Table VII summarizes all types of valid-
ity and gives a review of the relative qual-
ity of the variables. The limits of the ' + ' 
are determined arbitrarily. However, this 
was done to make an overall comparison 
of all aspects of validity of all variables 
more easily. This table provides a practi-
cal guide for the choice of a process vari-
able. The disease activity indexes (espe-
cially the DAS and the Mallya) score best 
overall. The validity of various single vari-
ables turned out to be very poor (espe-
cially haemoglobin, morning stiffness, 
general health, pain, and grip strength). 
The most valid single variable is the num-
ber of swollen joints. Particularly the re-
lation between swollen joints and radio-
graphic progression confirms earlier 
reports. "' The DAS is composed of the 
Ritchie, the number of swollen joints, the 
ESR and General Health.9 The Mallya 
index comprises morning stiffness, pain, 
grip strength, articular index, haemo-
globin and ESR. Thus the combination 
of a few variables, which have little value 
as single measurement, into an index 
greatly enhances the validity. 
The Disease Activity Score was based 
on judgements in clinical practice. This 
DAS turned out to be one of the most 
valid variables to measure disease activity 
in comparison with widely used variables. 
Therefore it might be concluded that 
clinical judgement by rheumatologisls 
correlate with the ultimate outcome, 
namely physical disability and radio-
graphic damage. 
In clinical trials of SAARDs, many dis-
ease activity variables are used to evalu-
ate the effect. This introduces the prob-
lem of multiple testing, which may lead to 
conflicting results in several variables. 
Besides, more patients arc needed to di-
minish a false positive result (type I 
error). The present study shows that a lot 
56 
Validity of process variables 
of the single variables have a (very) low uation, the indexes may also be helpful. 
validity in measuring disease activity and In conclusion, we recommend using a 
that the DAS and Mallya are the most disease activity index in evaluating trials 
valid variables in measuring disease activ- as well as in clinical practice. Most of the 
ity. Therefore these indexes may be used socalled disease activity variables mea-
as single endpoint measures in clinical surediseaseactivityonlypartly.lt is qucs-
trials, preventing conflicting results and lionable whether these variables, such as 
multiple testing (and fewer patients arc haemoglobin, morning stiffness etc. 
needed). Not only in trials but in patient should be used any longer as single dis-
management too, the problem arises of ease activity variables. However, in 
the discordance of the courses of individ- combination with others in a disease ac-
ual variables of disease activity. In this sit- livity index, these variables may be useful. 
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Prognostic features in RA: a review 
Summary 
Пе literature on profpwstic features on the final outcome in RA is reviewed. It is 
generally agreed that female sex and a positive RF are variables indicating a poor 
prognosis. Longstanding increased ESR and CRP values, decreased Hb, or the appear­
ance of subcutaneous nodules are indicators of a less favorable clinical course. No 
conclusions can be drawn regarding other factors due to the incomplete and heteroge­
neous study designs. 
Introduction 
Rheumatoid arthritis (RA) is a systemic 
disease with chronic, symmetrical polyar­
thritis as the most prominent clinical fea­
ture. The etiology of RA is still unknown. 
A genetic predisposition is strongly sug­
gested, because the frequency of HLA-
DR4 among seropositive RA patients is 
about twice that of the general popula­
tion. " A recent hypothesis is that an 
(unknown) initiating agent causes immu­
nological reactions and inflammation in 
the presence of a certain genetic make­
up. Environmental, social, psychological, 
economic and genetic factors may also 
play a role in the expression of the dis­
ease. 
Recent studies indicate that in nearly 
90% of the patients with erosive disease, 
these erosions occurred within 2 years of 
the onset of joint symptoms, indicating 
that it is important to select in a very ear­
ly stage those patients who are at risk to 
develop erosions. These patients are pos­
sible candidates for a more aggressive 
therapy. Little agreement exists in the lit­
erature as to which factors in early-stage 
disease predict an unfavorable final out­
come. For the sake of clarity, the progno­
sis of RA has to be divided into the prog­
nosis in terms of life expectancy and the 
prognosis as to disability. Survival in RA 
has been reviewed by Finals. We limit 
our review to the literature concerning 
the prognosis of the final outcome as 
measured by clinical and laboratory fea­
tures and radiological damage. 
Any study of predictive factors con­
cerning the outcome of newly-diagnosed 
RA patients has to fulfill various criteria: 
it should be a prospective study, includ­
ing RA patients early after onset of the 
disease; follow-up should be performed 
regularly for a minimum of several years, 
preferably by the same person; every 
check-up should include standardized 
clinical, laboratory, and radiological pa­
rameters. Radiological follow-up is es­
sential because it gives a cumulative index 
of the damage already established, and is 
not influenced by temporary flare-ups or 
remissions. Reviewing the literature, we 
found that no study fulfilled all these cri­
teria. Most studies arc performed in re­
trospect or in a prospective manner with 
well-established RA. Only a few studies 
had a follow-up period long enough to 
warrant conclusions, but their results 
were based on only a few measurement 
points during the observation period. 
Other studies did not include radiologi­
cal parameters and based their conclu­
sions on clinical or laboratory features 
only. The heterogeneous study designs 
and the above mentioned shortcomings 
may be the most important reasons for 
the conflicting results of different studies. 
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Some characteristics, such as age at 
onset, type of onset, race, sex, HLA sta-
tus, are invariable, and therefore it should 
be easier to draw conclusions from these 
characteristics than from variable param-
eters such as rheumatoid factor (RF), 
erythrocyte sedimentation rate (ESR), or 
the joint score. A few useful studies of 
these characteristics have been found. 
Nevertheless, there is no consensus about 
the influence of age, type of onset, etc, on 
the course of the disease. The most im-
portant reasons are the variance in out-
come parameters and the study duration, 
as well as the fact that many of these stud-
ies are performed in retrospect. 
Measurements at the real onset of the 
disease are hardly available; however, the 
data at the first visit within one year of 
onset may be regarded as the data of 
onset because of the chronicity of the dis-
ease. Little or nothing is known of the im-
plications on the final outcome of the ap-
pearance of clinical and laboratory 
parameters at the beginning of RA, but 
the existence of such parameters during 
the course is an indicator of an unfavor-
able outcome. An example is the ESR: an 
increased ESR at the beginning of RA 
has no prognostic importance, but pa-
tients with a persistently increased ESR 
have an unfavorable final outcome. An-
other example is a parameter such as RF, 
which might be negative at the start but 
become positive during the course: dif-
ferent measurements in the course of 
lime are needed to draw conclusions on 
the patients serological status. A pitfall in 
studies of prognostic factors during the 
course of the disease on the final outcome 
is the heterogeneous patient group: pa-
tients with varying disease duration are 
studied as one group during a defined pe-
riod. For example, patients with a disease 
duration of 2 years and 14 years are ob-
served for 3 years and regarded as being 
in the same period of disease. However, 
this is incorrect in principle, because RA 
has no linear course. 
Methods 
We reviewed articles in English since 
1940 on the prognosis of the final out-
come of RA with regard to disability. The 
studies were found through a review of 
the bibliographies of recent studies, re-
view articles, and inquiries from special-
ists on this subject, and was completed 
with a Medline computer search in En-
glish, French and German from 1975 to 
1987. Studies with a follow-up period of 
< 1 year or insufficient patient informa-
tion were excluded. Table I presents a 
summary of the study designs of the re-
ports on demographic, clinical, and labo-
ratory features used in our review. 
Demographic and clinical features 
Table II summarizes reports on vari-
ables in descriptive factors and disease 
manifestations. Little is known about dif-
ferent expressions of RA in the various 
races. A prospective study by Feigen-
baum et al concluded that white patients 
had a less favorable outcome. There are 
many contradictory reports about the re-
lation of sex to the subsequent course. 
Most studies " claim that males show a 
more favorable outcome, although other 
studies " found no correlation or even 
IR 
a more unfavorable outcome. Obvi-
ously, patient selection seriously influ-
ences such studies, and one might expect 
less sex difference in outcome if one 
starts with patients who already have es-
tablished disease. In fact, one report 
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Table I. Summary of study designs of reports investigating correlations of variables on the final out­
come in RA 
Refer­
ence 
4 
6 
7 
8 
9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
31 
32 
33 
35 
37 
38 
39 
65 
66 
67 
68 
69 
70 
71 
73 
74 
75 
76 
77 
P/R 
Ρ 
Ρ 
Ρ 
Ρ 
Ρ 
Ρ 
Ρ 
Ρ 
Ρ 
Ρ 
R 
R 
Ρ 
R 
R 
Ρ 
Ρ 
R 
Ρ 
Ρ 
Ρ 
Ρ 
Ρ 
Ρ 
R 
Ρ 
Ρ 
Ρ 
Ρ 
Ρ 
R 
Ρ 
Ρ 
Ρ 
Study 
duration 
(ут) 
5 
5 
3 
1-5 
10 
9 
±7 
3 
12 
11 
4.5 
5-10 
1 
6-9 
20 
2 
4.5 
15 
5 
1 
3 
1 
1 
2 4 
2 
1 
2 
5 
1 
10 
Follow-
up fre­
quency 
(vr) 
1-3 
1-2 
1-2 
Once 
Once 
1-2 
Once 
1-3-8 
0-5-10-20 
Once 
Once 
M 
3-11-15 
1-3 
1-4 
1-6 
1-2 
1-4 
1-4 
Once 
Once 
Once 
1-4 
1-2 
0-5-10 
No. of 
patients 
102 
50 
50 
141 
250 
200 
130 
77 
681 
100 
102 
500 
154 
45 
134>60 
78<60 
34/34 
200 
112 
235 
72 
102 
100 
102 
54 
142/142 
56 
57 
33 
33 
46 
30/90 
132 
103 
54 
15 
64 
112 
Disease 
duration 
(yr) 
< 1 
<l/2 
<l/2 
<l/2 
125<1 
±12.5 
<1 
10 ± 6 
< 1 
< 1 
1/2-25 
6 
1.1 + 19 
1.9 ± 2 5 
2/4.5 
<l/2 
±5.2 
recent 
<1.5 
< 1 
< 1 
< 1 
4.5 
<l/2 
5.7-10 
32<1 
< 1 
< 1 
±8 
12 
13 
12 
<5 
>15 
6 + 6 
5.2 
Agc(yr) 
±32 
30.4 
±57 
±50 
50.6 
544 
67 ± 4 
47+10 
71/40 
41 ± 1 4 
±45 2 
+41 
51 
49 2 
50.6 
55 
±37 
57 
35 + 9 
3 5 ± 9 
±55 
50.7 
56 
61 
38.5 
51.2 
47 
45.2 
F/M 
6.0 
6.0 
2.0 
2.7 
3.0 
1.8 
1.3 
± 3 
0.9 
3.0 
1.4 
22 
2.7 
2.5 
2.0 
1.3 
18 
2.9 
1.8 
1.8 
±2,5 
3.0 
2.5 
3.0 
3.0 
3.0 
2.2 
2.7 
Outcome 
parameters 
Rad 
Clin, rad 
Clin, rad 
Clin 
Clin, lab 
Rad 
Clin 
Clin, lab, rad 
Clin 
Clin 
Clin, lab 
Rad 
Clin 
Clin 
Clin, lab, rad 
Clin, lab, rad 
Rad 
Clin 
Clin 
Clin, lab, rad 
Rad 
Clin, lab 
Clin, rad 
Lab, rad 
Clin, rad 
Clin, lab, rad 
Clin, lab 
Lab, rad 
Clin, lab, rad 
Clin, rad 
Rad 
I.ab, rad 
Clin, lab, rad 
Clin, lab, rad 
Abbreviations: P/R, prospective/retrospective; F/M, female/male ratio; clin, clinical; lab, laboratocy; 
rad, radiological 
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concluded that initial attacks of RA oc­
cur with practically the same frequency in 
both sexes, but that the chronic form is 
more often found in females. A positive 
family history does not seem to influence 
the course of RA, as shown in different 
studies.1 3 - 1 5 
Characteristics at onset 
Studies of the prognosis with regard to 
age at onset are inconclusive. Deal et al 
found significantly greater clinical im­
provement in patients with RA onset at 
an older age than in younger RA controls 
matched for disease duration. A more 
favorable outcome of RA at an older age 
also has been reported in other -stud-
?Ω ^Ч 2 4 2Я 
ies. " Some investigators " found lit­
tle difference in course and prognosis in 
older patients, or even a more unfavor­
able outcome. 9 ' 1 3 , 1 5 , 2 9 - 3 2 In one study,19 
48% of the older-onset patients and 72% 
of the younger-onset patients were sero­
positive. This tendency of less scroposi-
tivity among RA patients with disease 
onset at an older age also has been estab­
lished in other studies. ' The data on 
scropositivity in other studies are insuffi­
cient. The difference in outcome may be 
attributable to the fact that older-onset 
patients suffer from a distinct subset of 
RA. Masi et al noticed that especially 
patients with a combination of younger 
age and acute onset showed a more favor­
able outcome. Various studies failed to 
show any difference in the course and 
prognosis of RA between an acute, sub­
acute, or gradual onset. ' ' Other 
studies reported a better outcome in pa­
tients with an acute onset. 8 , 9 , 1 5 , 2 7 , 3 6 
The studies of Feigenbaum el al and 
Fleming et al showed the influence of 
malaise and weight loss at onset on the 
overall prognosis. Patients with these 
general complaints showed a less favor­
able outcome. Sherrer et al did not find 
any difference between patients with or 
without weight loss at onset in terms of 
overall prognosis . Some investiga-
tors 6 , 9 , 1 5 , ^ 3 6 , have suggested that a 
particular site or pattern of early joint dis­
ease is of prognostic significance, but 
there is no agreement as to which partic­
ular site or pattern. On the other hand, 
Jacoby et al could not find a relation­
ship between the site of onset and the 
prognosis. Some studies ' have found a 
relationship between the number of af­
fected joints and overall prognosis: the 
more joints affected, the worse the final 
outcome. A few studies ' ' mention 
early symmetrical involvement of the 
joints as a predictor of a poor prognosis. 
Clinical and radiological features 
The existence of subcutaneous nodules 
has been considered by many investiga-
tors 7 , 1 0 , 1 1 , 1 3 , 1 6 " 1 8 , 3 6 , 3 8 to predict an unfa-
vorable prognosis. Feigenbaum et al 
found Raynaud-likc symptoms in 24% of 
their patients, and this was associated 
with an unfavorable outcome. According 
13 15 31 39 to some investigators, ' ' ' patients 
with early radiological features show an 
unfavorable outcome. This is not surpris­
ing because erosive disease as such is a 
sign of a more aggressive subgroup of 
RA, and these patients therefore have a 
less favorable prognosis. 
HLA and prognosis 
The human genes concerned with ex­
pression of the histocompatibility anti­
gens are located on the sixth chromo-
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some. The four principal loci are A,B,C 
and D. The gene products, or histocom-
patibility antigens A,B and C, are de-
tected serologically and the D antigen 
either serologically (HLA-DR) or by 
mixed lymphocyte reaction (HLA-D). In 
the mouse, genes concerned with the im-
mune response are found in association 
with the H-2 complex (analogue to the 
HLA complex in man), close to the 
D/DR locus. Perhaps this can be extrap-
olated to humans. An association has 
been noted between particular HLA 
groups and certain diseases. 
HLA-DR4 
At the 7lh International Histocompati-
bility Workshop, Staslny et al reported 
for the first time a relation between the 
HLA-DR4 antigen and RA. This has 
been confirmed, especially in the Cauca-
• · 341-44 
sian race, by many investigators. ' 
The relative risk of developing RA for 
DR4-positive individuals as compared 
with DR4-negative individuals ranges 
from 2.5 to 6.0 according to various inves-
tigators. ' * ' Not only in the popula-
tion, but also in families, has a positive 
correlation between RA and DR4 been 
reported . In Indian immigrants to the 
United Kingdom, DRl was correlated 
with RA . Recently, an association be-
tween the HLA class 2 determinant MCI 
on the one hand and DRl, DR4, and RA 
on the other has been described by 
Duquesnoy. ' A primary association of 
RA with this antigen would explain the 
increase in both DRl and DR4. More-
over, it has been suggested that DR4 is 
not primarily associated with susceptibil-
ity to RA, but correlates more with the 
clinical course. ' De Jongh et al 
found no difference in incidence of DR4 
between RA patients and non-RA pa-
tients in the Dutch population: in most 
studies the higher incidence of DR4 is es-
tablished in hospital populations of RA 
patients and therefore biased for more 
Table II. Summary of reports investigating the influence of clinical and demographic variables on the 
final outcome in RA 
Variables 
Race 
Male sex 
Family history 
Older age at onset 
Younger age at onset 
Acute onset 
Malaise at onset 
Weight loss at onset 
Site of onset 
Nodules 
Raynaud-likc symptoms 
Early radiological features 
Better 
6,7,8,9,10,11,12,13 
19,20,21,22,23,24 
7(acute)9 
8,9,15,27,36 
None 
14,15,16,17 
13,14,15 
25,26,27,28 
14,20,33,34,35 
13 
14 
Worse 
6 (White) 
18 
13,15,29,30,31,32 
6 
15 
6*9í;tl5t§31t36#37í 
7,10,11,13,16,17,18,36,38 
6 
13,15,31,39 
NOTE; Numbers in table refer to referenced studies. * More than two joints of the upper extremity af-
fected. fNumber of joints affected. ^Symmetrical involvement. §Metatarsophalangeal joints and wrist. 
#1 lands and feet 
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severe RA. Perhaps, iherfore, DR4 is 
correlated only with severe RA and not 
with milder subsets as present in the pop-
ulation. Young et al found more ero-
sions in patients with DR4 than in RA pa-
tients without DR4. Other investigators 
found only a relation between DR4 and 
seropositivity and not between DR4 and 
seronegativity. Dequeker et al 
found a high incidence of DR4 among 
RA patients, especially in men under 40 
years, but they found no correlation be-
tween DR4 and seropositivity, nodules, 
antinuclcar antibody (ANA), or kerato-
conjunctivitis. The same observations 
were made by Macda el al . Quciros el 
al established a positive correlation be-
tween DR4 and RF, but not with regard 
to radiological erosions, nodules, sicca 
syndrome or age at onset. Silman et al 
did not find DR4 a useful predictor of 
poor outcome at 3 years. On the other 
hand, Walker ci al reported less favor-
able clinical outcome in families with 
members with DR4 positivity. In this 
study, homozygotes for DR4 did not dif-
fer in outcome from heterozygotes. 
Brackertz and Wernet described a rap-
idly progressive, extraordinarily severe 
course of RA in homozygotes for DR4 in 
families. 
HLA-DR2 and HLA-DR7 
While the frequency of DR4 among RA 
patients is significantly high as compared 
with the population, DR2 is significantly 
low.3,42 ' '55*56 There is no agreement 
on the role of DR2 cither: docs DR2 play 
a role in susceptibility to RA or does it 
protect against an unfavorable outcome? 
Macda et al could not establish an asso-
ciation between DR2 and RF or clinical 
outcome. Ina study by Panayi et al DR2 
was correlated with seronegative RA. 
Griffin el ar found a correlation with a 
more favorable outcome: DR2-positive 
patients showed less nodules, Sjögren 
syndrome, and erosions, and a better out-
come in the Ritchie index. These patients 
also showed a belter response lo second-
line drugs. Less erosions in patients with 
DR2 were also reported by Young el ar . 
Barger et al noticed in a group of pa-
tients treated with gold a significantly 
lower frequency of DR2 than in RA pa-
tients never treated with gold. They pre-
sumed that DR2-positivc patients have a 
better prognosis and are therefore less in 
need of treatment with gold (and perhaps 
other second-line drugs?). 
There arc only a few reports about DR7 
in relation to RA. Quciros et ar found a 
lower frequency of DR7 in RA patients 
and Barger et ar noted a lower frequen-
cy in RA patients treated with gold. This 
last observation indicates that DR7 pos-
sibly protects against a more aggressive 
course of RA. 
Many studies established a correlation 
between certain HLA determinants 
(mostly DR3) and the response to and 
toxicity of second-line drugs. This item is 
left undiscussed here but will be consid-
ered in detail in another report. 
HLA-B27 
In Northern Sweden and in Finland a 
significant association between B27 and 
RA has been observed. ' ' Rantapaa 
et al found significantly more radiolog-
ical sacroiliilis in RA patients with HLA-
B27 than in HLA-B27-ncgative RA pa-
tients. The patients with HLA-B27 also 
showed more subcutaneous nodules and 
a less favorable functional class. They 
concluded that the presence of B27 is an 
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indicator of a less favorable final oucome. 
This has also been stated by other inves­
tigators, although there is a difference of 
opinion about the degree to which HLA-
B27 influences the prognosis. ' 
Laboratory variables 
RF and prognosis 
In Table HI the laboratory features cor­
related with the course and prognosis of 
RA are summarized. Since the introduc­
tion of the tests for RF, most reports state 
that the presence of RF is (strongly) pre­
dictive of an unfavorable course of the 
disease. There is an agreement to most 
• ., -.· ι « , 6-9,12-16,31,32,35,36,38.64-66 investigators 
about an unfavorable final outcome cor­
related to seropositivity, although differ­
ent variables are used, eg, the number of 
American Rheumatism Association 
(ARA) criteria and Ritchie index, total 
зя · 6 
joint count, and erosive changes. The 
studies of Amos et al, Dawes et al, and 
Jacoby et al revealed no correlation be­
tween seropositivity and radiological 
changes. A few studies mention a correla­
tion between the height of the RF titer 
and disease activity or final out­
come. ' ' A longitudinal study per­
formed by Weslcdt el al revealed that 
the RF correlated significantly with clin­
ical indices for joint activity, but had no 
prognostic value for the final outcome. 
The authors postulated that the RF is an 
epiphenomenon and not a pathogenetic 
factor. The same investigators found 
Tabic III Summary of reports investigating correlations of laboratory variables with the course of RA 
Variables 
RF 
IgA-RF 
IgM-RF 
IgG-RF 
ANA 
APF 
IgA-IC 
Clq>250ug/1 
Ilaptoglobulin 
Ceruloplasmin 
CRP 
HSR 
HB 
LDH 
AST 
Cholesterol 
Better None 
18,67,68 
69 
31 
75 
7,14,75 
Worse 
6,7,8.9,12.13.14,15,16,41. 
32,35,36.38 64•.65·.66.69. 
70 
69,70 
70 
73 
74 
68 
76 
75 
36,67,75 
10,11,13,15,31,32,67,77 
15,31,36 
18 
8,18 
18 
NOTE. Numbers in table refer to referenced studies Abbreviations: ANA, antinuclcar antibody, APF, 
antipennuclear factor, CRP, C-Rcactive Protein; III), hcmoglobulin; UDII, lactic dehydrogenase 
'Combined with DR4 
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IgA-containing immune complexes (IgA-
IC) to be a good marker of the develop-
ment of erosive disease. IgA-IC corre-
lated significantly with the appearance of 
extra-articular features but not with the 
joint disease activity. A combined effect 
of RF and DR4 on the severity of the dis-
ease is also suggested by some investiga-
SubtypesofRF 
With the further development of the en-
zymelinkcd immunoabsorbent assay 
(ELISA) and the radioimmunoassay 
technique, it is now possible to measure 
IgA, IgG and IgM isotypes of RF. The 
group of Teitsson and Wilhrington ' ' 
found that fluctuations in IgA-RF levels 
correlated significantly with correspond-
ing fluctuations in grip strength, ESR, 
and a composite index of disease activity. 
The IgG-RF was associated with changes 
in ESR and grip strength, but IgM-RF 
showed only a weak association with fluc-
tuations in ESR and none with any other 
clinical parameter. In the same prospec-
tive study they established that all seven 
patients who presented with increased 
IgA-RF developed erosions of the hands 
and wrists. By contrast, none of the five 
patients who presented with isolated in-
creased IgM-RF developed erosive dis-
ease. These data suggest that detection of 
IgA-RF in early RA indicates a poor 
prognosis. Some patients who are con-
ventionally seronegative have high serum 
IgA-RF values. Recent ly , Gioud-
Paquet et al published a study compar-
ing the Rose-Waaler test with the ELISA 
test for RF: 70% of patients seronegative 
in the Rose-Waaler test were seroposi-
tive in the ELISA test for one or more 
subtypes of the RF (IgM-, IgA-, IgG-, 
IgE-RF). Perhaps this is one of the rea-
sons why different investigators disagree 
on the clinical and radiological pattern of 
"seronegative" RA: in fact they are com-
paring heterogeneous groups of patients. 
Other laboratory variables 
Many laboratory features are consid-
ered to be of prognostic significance by 
one or a few research groups. ANA was 
considered to indicate a poor prognosis 
by Linn et al , but this autoantibody did 
not add any value to a positive RF: RF-
A N A - patients showed significantly 
fewer nodules and less destructive dis-
ease than RF-ANA +, RF + ANA- and 
RF-I-ANA+ patients (which groups 
were identical). Kaarela could not es-
tablish a relationship between ANA and 
final outcome. Westgeest et al found a 
strong relationship between RF and 
ANA and no relation between antipe-
rinuclear factor (APF) and ANA. They 
divided seronegative patients into two 
different groups, dependent on the APF 
status: the RF-APF-I- patients showed a 
more severe form of disease as measured 
by the ARA functional class, and more 
extra-articular features and radiological 
destruction than RF-APF- patients. 
In a report by Sjöblom et al , serum 
haptoglobulin was significantly related to 
the rate of destruction, whereas scrum 
ceruloplasmin (and other conventional 
acute-phase proteins) did not show such 
a relation. In a Japanese study by Ochi ct 
al, serum Clq levels turned out to be a 
prognostic guide to articular erosions. 
They found no correlation between the 
Clq level and ESR or C-reactive protein 
(CRP). However, patients with initial 
Clq levels above 250g/ml showed a per-
sistently increased CRP over a period of 
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years and had more erosive changes than 
patients with Clq levels below 250g/ml. 
The authors suggested that active RA can 
be classified into two subsets by Clq lev-
els: one with persistent inflammation and 
a large number of joints with erosions, 
and another without persistent inflam-
mation and with a small number of joints 
with erosions. A study by Dawes et al 
on the prediction of progressive joint 
damage in patients with RA receiving 
gold or d-pcnicillamine therapy, showed 
that patients without radiological de-
struction had lower serum antistrepto-
lysine liter (AST) levels and serum lactic 
dehydrogenase (LDH) levels but higher 
serum cholesterol levels. The study in-
cluded only a six-month period to estab-
lish the radiological progression. Ollen et 
al noticed a poor prognosis in seronega-
tive patients with a positive scrum AST. 
ESR, CRP and hemoglobin 
In various studies, an increase in 
ESR10·11·67·77 or CRP^·67·75 is correlated 
with a less favorable course of the dis-
ease. An increased ESR was one of the 
parameters predicting a poor prognosis 
according to Fleming et al, but Masi et 
al and Jacobyetal1 established that the 
level at an early point in the course did 
not seem to have prognostic implications. 
Patients with persistently low hemoglo-
bin (Hb) values had a less favorable prog-
nosis according to Wawrzynska-Pa-
gowska et al and Sjöblom et al. Most 
laboratory features such as CRP, ESR or 
Hb are just epiphenomena of active dis-
ease and in most studies correlate with 
clinical disease activity: an association 
with radiological progression is less often 
established. Whether CRP, ESR or Hb 
levels at the beginning of RA have any 
predictive value for the final outcome re-
mains uncertain due to the lack of pro-
spective studies of recently developed 
RA over a long follow-up period. 
Discussion 
RA is a heterogeneous disease in which 
subgroups show different courses. As de-
scribed above, there have been many at-
tempts to discover predictive features in 
order to select those subgroups with dif-
ferent prognoses. Most investigators 
studied patients with well-established 
RA in a retrospective way. Only a few 
based their results on a prospective study 
with newly diagnosed RA patients. This 
may be the main reason for the contradic-
tory results of the different reports. 
Moreover, it is difficult to untangle inde-
pendent correlations. Many studies, for 
instance, regard subcutaneous nodules as 
predictive of a poor prognosis; but sub-
cutaneous nodules arc strongly associ-
ated with a positive RF. Nearly all stud-
ies indicate a very strong correlation 
between a positive RF and more aggres-
sive disease. The question therefore 
arises whether there is a real correlation 
between subcutaneous nodules and prog-
nosis or whether there is only a seeming 
correlation due to the association of sub-
cutaneous nodules and RF. On the other 
hand, DR4 is associated with seropositive 
RA and a less favorable clinical course: is 
DR4 the cause of a poor prognosis and 
RF just one of the measurable parame-
ters? 
To summarize: only a few factors are 
known as predictors of an unfavorable 
clinical outcome in early RA: female sex 
and a positive RF, especially IgA-RF. 
During the course of the disease patients 
with the following characteristics show a 
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more unfavorable clinical course: persis- to be undertaken to assess the impor-
tently increased ESR or CRP, decreased tance of the other characteristics as pre-
Hb, or the appearance of subcutaneous diclive features in the early course of the 
nodules. A prospective study of newly di- disease. With this knowledge patients can 
agnosed RA patients over a long period be selected to ensure the best risk/benefit 
of time with frequent measurements has ratio of therapy with second-line drugs. 
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Radiographic progression 
Summary 
We studied the radiographic progression in hands and feet biannualfy in a prospective 
follow-up study of recent onset rheumatoid arthritis. The follow-up of 90 patients was 
three years, and the follow-up of another 57 patients two years. The radiographic damage 
was determined by a modified version of Sharp's method. The percentage of damage was 
determined by dividing the actual score by the maximum reachable score for that group 
of joints, ensuring comparability. After 3 years of follow-up radiographic damage was 
present in 70% of the patients and this group could already be selected after 1 year. 
Overall, 18-20% of the joints were affected after 3years, with relatively little abnormal-
ities per joint ( 8% of the maximum score was reached). During the whole follow-up 
more foot joints were affected than hand joints. Tlie rate of progression in the first year 
was significantly more than in the second and third years, indicating a flattening of the 
curve of radiographic progression. 
Introduction 
Chronic rheumatoid joint inflammation 
frequently leads to destructive lesions of 
articular tissues, namely cartilage and 
periarticular bone, which is largely 
irreversible and therefore should ideally 
be prevented. The degree and extent of 
joint damage, as visualized and scored by 
radiographic techniques, is an important 
outcome measure. However, little is 
known on the course of radiographic pro-
gression in rheumatoid arthritis (RA). 
Interpretation of the available studies is 
difficult. There are a few follow-up stud-
ies, but most investigations are cross-sec-
tional on patients with different disease 
duration. By connecting the radiographic 
scores of patients with various disease 
duration a radiographic course has been 
constructed. No agreement exists on the 
form of the curve of radiographic pro-
gression: it ranges from linear, S-shaped 
to a flattening of the curve after the first 
year(s). Especially the prospective fol-
low-up studies on patients with early RA 
show extensive radiographic damage 
even in the first few years. ' 
A problem in comparison of the studies 
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is the lack of standardization of the scor-
ing methods. Most widely used are the 
methods developed by Larsen and 
Sharp. ' However, other methods are 
also used. " The methods differ greatly 
in the type of abnormalities which are 
scored: juxtaarticular osteoporosis, joint 
space narrowing, erosions, malalignment 
or a combination. Some methods use a 
grading system with an ordinal scale, oth-
ers a count of the abnormalities with a 
continuous scale. The latter is much more 
useful for statistical analysis. Besides, 
some investigators report on number of 
patients with abnormalities, others on 
numbers of affected joints and some on 
radiographic damage. This makes the 
available studies difficult to compare. 
We used a modified version of Sharp's 
method to determine the course of radio-
graphic damage in a 3-ycar prospective 
follow-up study of patients with recent 
onset RA. Because of the clinical rele-
vance for the treatment of patients and 
the design of clinical trials, we tried to an-
swer the following questions: 1. how is the 
radiographic progression in hands and 
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feet during the first three years of RA; 
2. is there a difference in progression in 
the number of affected joints versus the 
progression in radiographic damage. In 
other words, is an already damaged joint 
more prone to show progression than an 
undamaged joint to become damaged; 
3. docs a difference exist in pattern of ra­
diographic damage in patients with a pos­
itive rheumatoid factor versus patients 
with a negative rheumatoid factor and in 
patients with or without HLA-DR4; 
4. docs more damage exist in the domi­
nant versus the nondominant hand. 
Patients and methods 
Patients 
All patients met the ARA criteria for 
classical or definite RA and look part in 
a prospective follow-up study. At entry 
disease duration was shorter than 1 year 
and the patients had not been treated 
with SAARDs before the start of the 
study. Patients have been followed up in 
the departments of rheumatology of the 
University Hospital Nijmegen and the 
University Hospital Groningen. All con­
secutive patients (n = 147) whose follow-
up was at least 2 years were included in 
this analysis; 90 patients had a follow-up 
duration of at least 3 years. Characteris­
tics at entry: 64% female, age 51 ± 15, 
82% IgM-RF >5 IU, 59% HLA-DR4, 
ESR 43 ± 31 mm after 1 hr, number of 
swollen joints 14 ± 8. 
Patients were treated with NSAIDs and 
several types ofSAARDs. Our policy was 
to start early with SAARDs in the follow­
ing order: hydroxychloroquine or sulfa­
salazine, thereafter auranofin or aurothi-
oglucosc, next penicillamine or metho­
trexate or azathioprinc. Corticosteroids 
could be added in all phases. Patients 
were treated with the following drugs: 
only NSAIDs η = 14, hydroxychloroquine 
η = 88, sulfasalazine η = 62, auranofin 
η = 10, aurothioglucose η = 63, methotre­
xate η = 20, azathioprinc η = 13, peni­
cillamine η = 23, corticosteroids η = 38. 
X-ray analysis 
Biannual X-rays of hands and feet were 
made. The X-rays were scored in random 
order by one observer in each depart­
ment, in chronological order per patient. 
The observers were not informed of the 
patients' identities. The number of ero­
sions (E) and joint space narrowing (N) 
were scored according to a modified ver­
sion of Sharp's method. This scoring 
method has been validated and described 
before.15 
Erosions were counted in the ten meta­
carpophalangeal joints, the eight proxi­
mal interphalangcal joints, the two intcr­
phalangeal joints of the thumbs, the right 
and left first metacarpal bone, the right 
and left radius and ulnar bones, the right 
and left trapezium and trapezoid (as one 
unit; multangular), right and left navi­
cular bones, right and left lunate bones, 
the ten metatarsophalangeal joints, and 
the two intcrphalangeal joints of the big 
toes. Joint space narrowing was assessed 
in the ten metacarpophalangeal joints, 
the eight proximal interphalangcal joints, 
right and left third, fourth and fifth carpo­
metacarpal joints, right and left multan-
gular-navicular joints, right and left cap-
itate-navicular-lunate joints, right and 
left radiocarpal joints, the ten metatar­
sophalangeal joints and the two intcrpha­
langeal joints of the big toes. Erosions 
were counted as score 1 if there was a dis-
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crete interruption of the cortical surface; 
if there was a greater defect, a score ac­
cording to the surface of the joint in­
volved was given. Consequently, for 
confluent erosions the score could not 
decrease. In the hands the maximum ero­
sion score in a joint was 5; in the feet it 
was 10. Four grades of joint space nar­
rowing were recognized: 1 = focal or 
doubtful; 2 = general, less than 50% of 
the original joint space; 3 = general, 
more than 50% of the original joint space 
or subluxation; 4 = ankylosis. Thus, the 
maximum number of erosions in the 
hands was 160 and in the feet 120; and the 
maximum scores for joint space narrow­
ing were 120 and 48, respectively. Scores 
for erosions and joint space narrowing 
were added up to give the total score. 
The number of erosions (E) and joint 
space narrowing (N) of the various 
groups of joints were analyzed sepa­
rately. The percentage of damage was 
determined by dividing the actual score 
by the maximum reachable score for that 
group of joints, ensuring comparability 
between the various group of joints and 
between the erosions and narrowing. Be­
side the percentages of the maximum 
score, the number of affected joints (sep­
arate for E and N) were counted. This 
was again expressed as the percentage of 
the corresponding number of joints. 
The following groups of joints were an­
alyzed separately and in combination: 
proximal interphalangeal joints (PIPs), 
metacarpophalangeal joints (MCPs), 
carpometacarpal, multangular-navicu-
lar, capitate-navicular-lunatc and radio­
carpal joints (WRIST), metatarsopha­
langeal and the two interphalangeal 
jo ints ( M T P s ) , H A N D S (PIPs + 
MCPS +WRIST), TOTN (narrowing of 
all groups of joints), TOTE (erosions of 
all groups of joints), TOTE + N (erosions 
and narrowing of all groups of joints). 
To evaluate the interobserver variation, 
96 pairs of X-rays of hands and feet have 
been scored by both observers of this 
study. The Spearman correlations be­
tween the two observers were TOTE 
0.92, TOTN 0.80, TOTE + N 0.90. High 
correlations do not rule out the possibility 
of systematic differences. Wilcoxon 
signed rank tests have been performed 
between the scores of the two observers 
to check this. One observer scored signif­
icantly more narrowing than the other ob­
server (mean 15.1 vs 12.1). No systematic 
differences could be found in any of the 
other scores. 
The intraobserver variation for both ob­
servers has been computed in the same 
way. Observer 1 scored 25 randomly cho­
sen pairs of X-rays twice with a minimum 
time of 6 months between the two scores 
and observer 2 scored 27 pairs. The 
Spearman correlations were for TOTE 
0.94 and 0.99, for TOTN 0.94 and 0.99, 
and for TOTE + N 0.96 and 0.99 for the 
two observers respectively. No systematic 
differences were present in any of the 
scores. 
Statistical analysis 
Spearman rank correlations, Chi-squa-
re test, t-test (Student), Mann-Whitney 
and Wilcoxon signed rank test were used 
for the statistical analysis. All tests were 
two-sided and а = 0.05 was considered as 
level of significance. 
To study the difference between the 
dominant versus the non-dominant hand, 
the paired t-test was used. The Wilcoxon 
signed rank test was used to test the dif­
ference between various groups of joints 
and between erosions and narrowing. 
Radiographic damage measured with 
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Table I Radiographic progression of groups of joints in hands and feet (0,0.5,10,1.5 and 2 yr η = 147 
2 J and 30yr η = 90, mean values) 
Year 
PIPE 
PIPN 
MCPE 
MCPN 
WRISTH 
WRJSTN 
HANDE 
HANDN 
HANDE+N 
M1PE 
MTW 
MTPE + N 
TOTE 
TOTN 
TOTE+N 
% of maximum 
0 
04 
04 
0 6 
0 9 
0 3 
11 
04 
0 9 
06 
15 
21 
16 
0 9 
12 
10 
OS 
21 
IS 
19 
27 
11 
4 2 
17 
30 
22 
31 
37 
32 
2 3 
32 
26 
10 
34 
21 
32 
4 2 
23 
76 
29 
5 0 
38 
4.5 
5 6 
4 8 
36 
5 2 
4 2 
radiographic damage 
1.5 
41 
27 
4 4 
5.5 
31 
101 
38 
66 
5 0 
5 6 
67 
5 9 
4 6 
66 
54 
20 
47 
32 
56 
64 
39 
124 
47 
79 
61 
63 
72 
66 
54 
77 
63 
25 
54 
37 
70 
78 
5 0 
14 7 
5 7 
94 
73 
73 
82 
76 
64 
91 
74 
30 
60 
41 
82 
8.5 
62 
168 
67 
10 6 
84 
81 
90 
84 
73 
10 2 
84 
%of 
0 
14 
14 
18 
22 
14 
32 
1.5 
24 
19 
5 7 
41 
4 9 
27 
29 
28 
maximum number of affected joints 
0.5 
72 
5 0 
67 
76 
37 
100 
57 
79 
68 
12 6 
84 
10.5 
76 
80 
78 
10 
10.5 
6 8 
9 9 
110 
7.5 
17 7 
9 2 
126 
10 8 
18 9 
12 2 
15 5 
118 
125 
121 
15 
12 2 
86 
12 3 
13.5 
9 9 
219 
114 
15.5 
134 
23 0 
14 0 
18 5 
14 5 
151 
14 8 
20 
13 7 
9.5 
15 2 
14 6 
113 
256 
13 3 
176 
15 4 
24.5 
15 2 
19 9 
16 4 
16 9 
16 6 
25 
15 2 
10 2 
17 2 
16 6 
13.5 
287 
15 2 
19 7 
174 
267 
17 2 
22 0 
18 3 
190 
18 7 
30 
16 5 
104 
18 3 
177 
15.5 
303 
16 7 
20 8 
18 7 
281 
184 
23 2 
19 8 
201 
20 0 
PIPE = erosions of PIP joints, PIPN = narrowing of PIP joints, MCPE = erosions of MCP joints, 
MCPN = narrowing of MCP joints, WRISTE = erosions of wnst joints, WRISTN = narrowing of 
wnst joints, HANDE = erosions of PIP, MCP and wnst joints, HANDN = narrowing of PIP, MCP 
and wnst joints, HANDP + N = summation of erosions and narrowing in PIP, MCP and wnst joints, 
MTPE = erosions of MTP and 1st IP joints, MTPN = narrowing of MTP and Ist IP joints, 
MTPE + N = summation of erosions and narrowing of MTP and 1st IP joint, 1 0 ГЕ = erosions of all 
hand and foot joints, TOTN = narrowing of all hand and feet joints, TOTE + N = summation of ero­
sions and narrowing of all hand and foot joints 
this method may be static or progress, but 
not decline. In order to obtain a smooth 
curve with duration of disease from the 
57 patients over only 2 years and the 90 
patients over 3 years of follow-up, the fol­
lowing procedure was used to combine 
the data of the two periods. The means of 
all data of 147 patients were calculated 
for t = 0 to t = 2 yr The same was done for 
the 90 patients for t = 0 to t = 3 yr. The 
increment of this group from t = 2 to t = 3 
was attached to the level at t = 2 for all 
patients. Following the above approach 
prevented a dip in the curve, which was 
not a real dip but only a consequence of 
a difference in study population. The 
curves arc presented as a table. 
Results 
Course of radiographic progression 
The radiographic progression in terms 
of both the percentage of maximum score 
and the percentage of maximum number 
of affected joints is summarized in Ta­
ble I. This is split for erosions and nar­
rowing and various groups of joints. 
On average, at 3-year follow-up most 
groups of joints show about 8% of the 
maximum score. The narrowing of the 
PIPs is somewhat less (4%) and the nar­
rowing of the wrist much higher (17%). 
The percentage of maximum number of 
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joints is about 18-20% for most groups of 
joints. Again fewer PIPs show narrowing 
(10%) and more joints in the wrist show 
narrowing and more MTPs show ero­
sions (30% and 28% resp.) in comparison 
with the other groups of joints. In general, 
the percentage of number of affected 
joints is 2-3 times the percentage of maxi­
mum score, meaning that many joints 
show little damage. 
In Table II the medians with 90% con­
fidence intervals are given for the percen­
tage of maximum score for some overall 
scores. The medians give information 
supplementary to the means. The medi­
ans are substantially lower than the 
means (Table I, i.e. negative skewncss). 
This indicates that many patients have 
few or no radiographic abnormalities, 
while patients who show radiographic 
damage have many abnormalities. 
Erosions vs narrowing 
The average percentage of total nar­
rowing (TOTN) over all time points was 
significantly larger than the average per­
centage of total erosions (TOTE, signed 
rank test ρ = 0.007), meaning that the 
TOTN was higher than the TOTE during 
the whole follow-up period. This was 
mostly a consequence of the evident 
narrowing in the wrist. 
The increase in radiographic damage is 
given in Table III, split up for the first, 
second and third years. The increase over 
the whole period was again more in the 
percentage of total narrowing compared 
with the percentage of total erosions 
(signed rank test p). 
Hands vs feet 
The mean total score of the hands 
(HANDE + N) during the whole period 
was not significantly different from the 
mean total score of the feet (MTPE + N). 
On the contrary, more foot joints than 
hand joints were affected (Table I, signed 
rank test ρ = 0.01). This was the same if 
only MCPs were compared with MTPs. 
The increase in score and in number of 
affected joints was similar for both hands 
and feet. This means that the predomi­
nance of affected foot joints present at 
the start did not increase or decrease. 
Table II. Medians and 90% confidence intervals of the radiographic damage in groups of joints of 
hands and feet (0,0.5,1.0,1.5, and 2.0 yr η = 147,2.5 and 3.0 yr η = 90) 
HANDE+N 
M1FE + N 
TOTE 
TOTN 
TOTE+N 
0 
0 
(0-0.2) 
0 
(0-0.2) 
0 
(0-0.2) 
0 
(0-0.3) 
0.2 
(0-0-5) 
OS 
0.4 
(0.2-1.1) 
0.6 
(0-1.2) 
0.7 
(0.3-1.1) 
0.6 
(0.3-1.8) 
1.1 
(0.5-1.6) 
1.0 
1.4 
(0.4-2.5) 
1.8 
(0.3-2.4) 
1.4 
(0.6-2.5) 
1.8 
(0.6-3.6) 
2.0 
(1.4-3.2) 
15 
2.5 
(0.8-3.3) 
2.4 
(1.3-3.0) 
2.9 
(1.1-3.3) 
3.0 
(1.2-Í.2) 
3.1 
(2.Ы.1) 
2.0 
3.2 
(1.5-4.0) 
2.4 
(1.2-3.6) 
3.2 
(1.54.3) 
3.6 
(1.8-7.2) 
4.2 
(2.4-5.0) 
25 
3.8 
(0.5-5.5) 
3.0 
(1.2-4.8) 
3.9 
(1.8-6.1) 
4.5 
(1.2-8.4) 
4.6 
(2.5-7.0) 
3.0 
3.2 
(0.8-6.5) 
3.6 
(1.8-5.4) 
5 
(1.8-6.8) 
3.6 
(0.6-6.6) 
4.4 
(1.6-7.9) 
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Tabic III Progression in first, second (n = 147) and third years (n = 90) and comparison of the 
progression in the first with the progression in the second and third years (Wilcoxon Signed Rank tesi) 
Progression 
HANDE 
IIANDN 
MANDE+N 
MTPE 
MTPN 
MTPE + N 
TOTN 
TOTE 
TOIli + N 
mean 
0-1 yr 
25 
4 1 
32 
30 
3.5 
32 
4 0 
27 
32 
% of maximum score 
1-2 yr 
18-
2 9-
2 3-
1 β­
ίο­
ι 8* 
2 5-
18-
2 1-
2-3 yr 
2 0-
27-
2 3 ' 
1 Β-
Ι 9-
18* 
25-
19* 
2 1 · · 
mean % of maximum number joints 
0-1 yr 
77 
102 
89 
13 2 
80 
10 6 
96 
92 
94 
1-2 yr 
41* 
5 1 ' 
4 6* 
5 6·* 
3 1 " 
4 3 " 
4.5* 
4 5 " 
4 5 " 
2-3 yr 
3 4 " 
3 1 " 
3 3 " 
3 6 " 
3 1 · 
3 4 " 
3 1 " 
3 .5" 
3 3 " 
•p<0 05, " p < 0 01,-NS 
Progression of radiographic damage 
inyr 1,2,3 
We tested if there was a difference in 
progression of radiographic damage in 
the first, second or third year of RA 
(Table III). The increase in percentage of 
maximum of the total score of the hands 
and of the feet was significantly less in the 
third year compared with the first year. 
The increase in the feet was also signifi­
cantly less in the second year. The pro­
gression of the number of affected joints 
was significantly less in the second and 
the third year in comparison with the first 
year in all groups of joints. The lesser pro­
gression in the second and the third year 
concerned the number of affected joints 
much more than the degree of damage. 
This decline of progression is demon­
strated in figure 1, which gives an exam­
ple of the overall score of narrowing and 
erosions in both hands and feet. 
IgM-RF and HLA-DR4 
The wrist showed a predominance of 
narrowing in both the seropositive and 
the seronegative patients. No different 
pattern of erosions or narrowing could be 
found in the seronegative vs seropositive 
patients, nor in DR4 + vs DR4- patients. 
RF + patients had significantly more ra­
diographic damage compared with R F -
paticnts 
To study the combined influence of 
both RF and DR4, patients were divided 
according to their RF and DR4 status. 
The mean r a d i o g r a p h i c scores 
(TOTE + N) for the various subclasses 
were RF-DR4- 1.0 (n = 19), RF-DR4 + 
2.3 (n = 8), RF + DR4- 6.6 (n = 39) and 
R F + D R 4 + 7.4 (n = 77). These data 
show a small synergistic effect of DR4 
and RF. 
Dominant hand 
The damage in the dominant versus the 
nondominant hand was compared for 
erosions and narrowing in PIPs, MCPs 
and wrist. No statistically significant dif­
ference existed in any group of joints at 
any time during the 3-year follow-up. The 
Spearman correlations between the dom­
inant and non-dominant hand at t = 3 ran-
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Figure 1. Tolal score expressed as % of maximum 
score ( H- )and lolal score expressed as % of 
maximum of affected joints ( - · - ) during three 
years of follow-up 
ged from 0.71 to 0.96 for the various 
groups of joints. 
Discussion 
Radiographic damage is the (irrevers-
ible) result of chronic joint inflammation 
and is often considered as an important 
factor in judging the course of the disease 
and efficacy of SAARDs. Curiously, the 
natural course of the radiographic dam-
age is not known. Ideally, a prospective 
follow-up of early RA is needed to study 
the 'natural' course. However, this is not 
the natural course sensu strictu, because 
medication is always included. Many 
cross-sectional studies on this item are 
based on RA with a wide range of disease 
duration. Especially, if these investiga-
tions are carried out in a department of 
rheumatic diseases, selection bias may 
play an important role: e.g. patients with 
a good prognosis, and accordingly little 
radiographic damage, may not longer at-
tend the rheumatic clinic, paticnls with 
very severe disease may have died and 
therefore not been included in the analy-
sis. 
We agree with Sharp that it is a miscon-
ception that, to be useful, the same radio-
logical scores must be found when ap-
plied by different individuals or when 
used repeatedly by the same observer. 
Papers on the reproducibility of radio-
graphic scoring reveal that differences 
between observers may be quite large but 
that these differences arc generally con-
sistent. Therefore interobserver correla-
tions are usually high. In our study, the 
correlations between the two observers 
for the narrowing score, erosion score 
and total score were 0.80, 0.92, and 0.90 
respectively. These correlations are quite 
high and fully in accordance with the lit-
erature. In a study by Sharp et al on the 
reproducibility of multiple-observer 
scoring of radiologic abnormalities, cor-
relations ranged from 0.53 to 0.96. The 
high correlations between the two ob-
servers and the very high consistency of 
each observer (correlations ranging from 
0.94 to 0.99), indicate that the results of 
the radiographic progression may be 
considered reliable. The absolute figures 
of the radiographic abnormalities arc 
more indicative, particularly for the nar-
rowing score as there was a significant 
difference in scoring between the two ob-
servers. According to the pitfalls of radio-
graphic scoring, this study gives a good 
indication of radiographic progression 
whereas the absolute figures of the scores 
might be different if read by other observ-
ers. 
In our prospective follow-up of 147 pa-
tients with early RA, we found a con-
siderable percentage of radiographic 
damage. After 3 years 20% of the total 
numbers of hand and foot joints were af-
fected. The percentage of maximum 
81 
Chapter Vili 
damage was 8.4%, meaning that many 
joints were affected with relatively little 
damage per joint. Möttönen found 2.3% 
of the small joints of the hands and feet 
eroded at the start and 13.1% after 2 
years of follow-up of 58 patients with 
early RA. These figures are very similar 
to our results: 2.7% at the start and 16.4% 
after 2 years (Table I). 
The medians, as presented in Table II, 
give some (indirect) information on the 
number of patients with abnormalities. 
The medians are considerably lower than 
the means, indicating that many patients 
have lillle radiographic damage. How-
ever, if patients have radiographic abnor-
malities, they show considerable damage. 
In our group 30% of the patients 
showed < 1% joint damage in hands and 
feet after 3 years' follow-up. This figure 
was the same after 2 years. Only 1 patient 
(out of 90) who had < 1 % damage at year 
1 showed substantial progression in the 
next 2 years. Therefore, patients with lit-
tle radiographic damage can already be 
selected after 1 year of follow-up. The 
percentages of palicnls without abnor-
malities in the literature arc similar to our 
study: Brook and Corbctt 23%,2 Möt-
tönen 24%,3 Ebcrhardl 28%.18 In two 
cross-sectional studies on longstanding 
RA by Thould and Fuchs, these per-
centages of patients without abnormali-
ties were only 9% and 4.5% respectively. 
However, this may be due to selection of 
patients: patients with good prognosis do 
not longer attend the rheumatological 
department. 
Some studies included only the radio-
graphic progression of hands, although 
several studies indicate that fool joints 
may be affected at an early stage of the 
disease ' and erosiveness was found 
even twice as much in feet as in fingers. 
We also found that more foot joints than 
hand joints were affected during the total 
follow-up period. At the start this differ-
ence was already present. The progres-
sion in the feet and hands was similar, so 
that the difference did not increase dur-
ing the 3-year follow-up. This means lhat 
the damage in the foot joints developed 
in an earlier stage than in the hand joints. 
The distinct narrowing in the wrist is 
striking. As a consequence of this pro-
nounced narrowing in the wrist, the per-
centage of narrowing is larger than the 
percentage ofcrosions over the whole pe-
riod. 
A different pattern of radiographic 
damage in RF + versus RF- patients or 
an association between HLA-DR4 and 
the severity of radiographic changes has 
been suggested. Therefore we evaluated 
the effect of IgM-RF+ andHLA-DR4-(-
on erosions and narrowing in the wrist, 
hands, feet and total score. No difference 
in pattern of radiographic abnormalities 
could be found in RF- patients. On the 
other hand RF + patients showed more 
damage than R F - palicnls. The differ-
ence between DR4 + and DR4- patients 
was less pronounced. DR4 and RF have 
a small synergistic effect on the severity 
of the radiographic damage. Seroposili-
vily was the most important factor, but 
DR4 was also related to severity. The re-
lation of DR4 with severity of radiogra-
phic damage is in accordance with obser-
vations by others. "" 
Some investigators found more damage 
in the dominant hand, ' while this could 
not be confirmed by others. We 
found no significant difference in radio-
graphic damage in both hands. This was 
not present in summarized hand score, 
nor in various groups of joints or in ero-
sions or narrowing analyzed separately. 
It is striking that most progression was 
seen in the first year. The increase in da-
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mage was less in the second and third 
years. This declining progression in the 
second and third years was more pro-
nounced in the number of affected joints 
than in the radiographic score. Thus in 
the second and third year relatively few 
new joints became damaged but the in-
crease in joint damage continued on a rel-
atively higher level (but less than in the 
first year). This observation means that a 
damaged joint is more prone to become 
more seriously damaged than an unaffec-
ted joint to become damaged. This pro-
gression of the severity of an affected 
joint may be due to several factors. First, 
it may be much harder to diminish the 
pannus in a joint than to prevent a new 
inflammation in a 'virgin' joint. Second, 
biomechanical factors may play a role in 
the progression, independently of infiam-
mai ion. 
The decline in progression after the first 
year causes a flattening curve of the ra-
diographic course. In our study, also, a 
relatively large amount of radiographic 
damage in the first 3 years is present. 
Both these observations arc in disagree-
ment with 1 he S-shaped curve of Sharp ct 
al. Other studies also found a consider-
able quantity of radiographic damage in 
the first few years and a flattening of the 
progression thereafter. ' *' Moltonen 
et al found in the hands a linear progres-
sion and in the feet the greatest progres-
sion between 6 and 18 months during a 
follow-up of 2 years. 
We can only speculate on ihe cause of 
ihe decline of the progression rate. One 
of the possibilities is the effect of 
29 
SAARDs. In our group, most patients 
have been treated with SAARDs in the 
very early phase of the disease. This ap-
proach may have been ihe cause of the 
diminishing progression of radiographic 
damage. However, this can only be an-
swered definitely in controlled, random-
ized clinical trials. 
As long as we do not know the cause of 
this difference in progression rale of ra-
diographic abnormalities, this has impor-
tant implications for the use of X-rays as 
an outcome variable in trials of SAARDs. 
It is of great importance in the design of 
such a study thai Ihe patients have a com-
parable disease duration. Especially in 
the early phase of ihe disease, a (relalive-
ly small) difference in disease duration 
may be confounding. 
In conclusion, 70% of the palients sho-
wed radiographic damage after 3 years of 
follow-up and this group could already be 
selected after 1 year. Overall, 18-20% of 
Ihe joints were affccled after 3 years, with 
relatively lillle abnormalilics per joinl 
( 8% of the maximum score was 
reached). The rate of progression in ihe 
first year was significanlly more than in 
the second and third years, indicating a 
flattening of the curve of radiographic 
progression. 
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Older vs younger age at onset RA 
Summary 
The influence of age at onset was studied in a prospective follow-up of early RA. 
Patients >60yr (ORA, η = 71) showed significantly more often onset in the large joints 
and higher disease activity at the start compared with patients <60yr (YRA, η = 142). 
Tlie higher disease activity was still present after two years of follow-up as well as more 
radiographic damage in both hands and feet (NS, ORA η = 46, YRA η = 101). Rheuma­
toid factor and DR4 were comparable in both age groups. Our data show a more severe 
course in older age RA. This disagreement with the literature is probably due to the fact 
that many studies are cross-sectional with unbalance of rheumatoid factor in the two age 
groups. 
Introduction 
Patients who develop rheumatoid ar­
thritis (RA) at an older age are often 
thought to belong to a different subclass. 
Several aspects arc described which 
should distinguish this subgroup from 
younger age RA: a more equal sex distri­
bution, more large joints involvement and 
systemic complaints, more often an acute 
onset and less rheumatoid factor po-
silivity, and a higher erythrocyte sedi­
mentation rate (ESR) at onset. " There 
arc two possibilities to explain the ob­
served differences: older age at onset RA 
(ORA) is another disease in comparison 
with younger age at onset (YRA) or 
ORA is the same disease but with another 
expression due to the age. 
Opinions differ if these variations in 
characteristics cause a difference in 
prognosis of ORA. Some studies on this 
subject claim a better prognosis, some 
found no difference, " and others even 
a worse prognosis for ORA.' In studies on 
prognosis of RA, which were not espe­
cially focused on age at onset, a worse 
prognosis with increasing age has been 
found. 1 6 1 9 
Many investigations are from the four-
ties, fifties and sixties and describe only 
patients with ORA without a direct com­
parison with YRA. Only a few studies 
compare ORA and YRA directly.1"3,13'14 
Most studies are cross-sectional and 
based on patients with a wide variety of 
disease duration. 
In the present study we compared ORA 
with YRA in patients of a prospective fol­
low-up study of early RA. Demographic, 
clinical, laboratory, and radiographic 
characteristics at onset and after a follow-
up of 2 years arc presented. 
Patients and methods 
Patients 
Patients with classical or definite RA 
(ARA criteria) and disease duration less 
than one year at entry were selected. No 
patient had been treated with slow-acting 
antirheumatic drugs (SAARDs) before 
entry. All consecutive patients who met 
these inclusion criteria were asked to 
take part in a prospective follow-up study 
ongoing since 1985. All patients have 
been seen in the departments of rheum­
atology at the University Hospital Nijme­
gen and the University Hospital Gro-
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ningen in the Netherlands. Clinical and 
laboratory variables were collected every 
month by a research nurse. X-rays of 
hands and feet were made every six 
months. In this analysis the data at onset 
and after two years of follow-up have 
been used. 
Although limits of 50 to 65 years are 
used for the older age group, in the ma­
jority of the studies ORA is defined as 
onset of RA after the 60th birthday. 
Therefore we defined ORA as age at 
onset after the 60th birthday and YRA as 
age at onset between 16 and 60 years. The 
demographic, clinical, and laboratory 
variables of all patients in the follow-up 
study could be used for the comparison 
at the start (YRA η = 142, ORA η =71). 
147 patients had a follow-up of at least 2 
years (YRA η = 101, ORA η = 46). X-
rays of these patients from the start and 
after 2 years were included in the analysis. 
The therapy the patients received dur­
ing the 2-year follow-up is shown in Table 
I. Except for corticosteroids, therapy was 
very similar for the YRA and ORA. More 
ORA patients used corticosteroids. 
Ässess/nenfs 
At the start the following information 
was collected: prodromal events such as 
infections, psychologic stress, trauma 
etc.; joint complaints in the past; type of 
onset (acute = within 1 day, subacute = 
within 1 week, insidious = ranging from 
weeks to months ) ; site of onset 
(monarthritis, small joints, large joints, 
small as well as large joints); symmetry at 
onset; weight loss in kilograms in the First 
few months after onset; family history di-
vided into first degree relatives and other 
relatives; fever; IgM-rheumatoid factor 
(IgM RF, ELISA, < 5 IU/ml negative).20 
Table I Therapy during the 2-year follow-up in 
numbers of patients (%), many patients used 
more drugs (YRA η = 101, ORA η = 46) 
Only NSAID 
Hydroxychloroquine 
Sulfasalazine 
Auranofin 
Aurothioglucose 
Penicillamine 
Azathioprine 
Methotrexate 
Corticosteroids 
YRA 
10(10) 
58 (58) 
39 (39) 
9(9) 
40 (40) 
13(13) 
8(8) 
10(10) 
19(19) 
ORA 
4(9) 
27 (56) 
18(37) 
1(2) 
21(44) 
9(19) 
4(8) 
5(10) 
18(37) 
The sera of 128 YRA and 65 ORA pa­
tients were typed for HLA-DR4. 
The following variables were collected 
at the start and after two years: ESR 
(Westcrgrcn, mm/l hr), C-reaclive pro­
tein (mg/1), Ritchie articular index, num­
ber of swollen joints, disease activity 
score (DAS, a composed score of Ritchie 
articular index, number of swollen joints, 
ESR, and general health). '" Physical 
Disability was investigated by the Dutch 
version of the Health Assessment Ques­
tionnaire in the patients with 2-year fol­
low-up at the start and after 2 years. 
The number of erosions and joint space 
narrowing of hands and feet were scored 
by means of a modified version of Sharp's 
method as described before. ' The X-
rays were scored by one observer in each 
department without information on the 
patient's identity. 
Statistical analysis 
Statistical analysis was performed by 
Chi-squarc test and Mann-Whitney rank 
sum test. Due to the great skewness, 
mean and standard deviation are not ap­
propriate to describe the variables well. 
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Table I I Demographic, clinical, and laboratoiy characteristics at onset of Y R A (n = 142 )and O R A 
(η = 71) 
Demographic characteristics 
Age mean (range) 
Females (%) 
HLA-DR4 (%) 
IgM-RF >5 lU/ml (%) 
subcutaneous nodules (%) 
Anamnestic characteristics (%) 
Prodromes 
Joint complaints in the past 
Weight loss 
Fever 
Type of onset 
acute 
subacute 
insidious 
Site of onset 
monarthntis 
small joints 
large joints 
small and large joints 
Symmetrical onset 
Positive family history for RA 
only 1st degree relatives 
Laboratory and clinical characteristics 
median (lOlh-SHHh percentile) 
ESR 
CRP 
Ritchie 
Swollen joints 
DAS 
YRA 
435(16-59) 
67 
60 
78 
11 
33 
54 
20 
17 
28 
17 
55 
17 
56 
13 
13 
74 
42 
18 
28 (7-76) 
14 (11-93) 
12(2-21) 
13(2-23) 
4 0 (2 4-5 4) 
ORA 
68 3 (60-86) 
5 7 
52 
89 
7 
41 
42 
33 
8 
41 
17 
42 
8 
48 
8 
35 
69 
32 
15 
56 (21-100) 
47 (8-182) 
12 (3-30) 
15 (6-28) 
4 4 ( 2 8-6 2) 
Ρ' 
-
-
-
-
-
-
03 
-
-
002 
-
-
-
0000 
0000 
-
-
004 
* Mann-Whitney test for continuous variables and Chi-Square test for cross tabulations, 
- = non-significant 
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Table III Clinical, laboralory, and radiographic characteristics of YRA (n = 101) and ORA (n = 46) at 
onset (t = 0) and after 2-year follow-up (t = 2) median (10lh.90th percentile) 
Variable 
ESR 
CRP 
Ritchie 
Swollen joints 
DAS 
Physical Disability 
Hands erosions 
Hands narrowing 
Feet erosions 
Feet narrowing 
Hands total score 
Feet total score 
Total erosions 
Total narrowing 
Total score 
t = 
YRA 
31(7-70) 
12(0 8-89) 
lió (3-21) 
13 (2-28) 
4 0(24-5 4) 
0 32(0-145) 
0(0-1) 
0(0-3) 
0(0-6) 
o(o^) 
0(0-2) 
0(0-5) 
0(0-4) 
0 (0-3) 
2(0-3) 
= 0 
ORA 
67(22-100) 
36 (7-191) 
12(4-36) 
15 (5-28) 
46 (2 8-62) 
045(0-166) 
0(0-3) 
0(0-5) 
0 (04) 
0(0-12) 
0 (04) 
0(0-5) 
0(0-2) 
1(0-5) 
1(04) 
ρ· 
0001 
0003 
-
-
001 
-
-
003 
-
-
007 
-
-
005 
-
t = 
YRA 
18 (4-51) 
5 8 (0 6-82) 
4(0-19) 
5(0-18) 
2 6 (1445) 
016(0-0 90) 
1 3(0-12) 
17(0-28) 
25(0-21) 
0(0-23) 
25 (0-18) 
24(0-19) 
32(0-16) 
3 0(0-22) 
36(0-17) 
= 2 
ORA 
32(8-67) 
19 (2-69) 
6(0-20) 
7(2-18) 
3 0(16-5 0) 
022(0-128) 
25 (0-15) 
54(0-21) 
29(0-16) 
2 1 (0-25) 
4 1 (0-16) 
3 0(0-21) 
36(0-19) 
5 4(0-23) 
4 6 (0-18) 
Ρ* 
0001 
001 
-
-
01 
-
-
-
-
-
-
-
-
-
-
*p Mann-Whitney rank sum test, - = non-significant 
Therefore the 10,h, 50 t h and 90 t h percen­
tiles are given. All tests were two-sided 
with α = 0.05 as level of significance. 
Analyses were performed with SAS 
Results 
26 
(p = 0 002) Besides, more ORA patients 
presented with an acute onset (41% vs 
28%, NS). 
The disease activity at onset was signif­
icantly higher in the ORA patients. This 
was especially pronounced in the ESR, 
CRP and DAS (p< 0.005). 
Characteristics at onset 
Table II summarizes the characteristics 
at onset of the whole group (YRA 
η = 142, ORA η = 71). No significant dif­
ferences existed in the demographic 
characteristics. The percentage females 
was 67% in the YRA compared to 57% 
in the ORA. 
Anamncstically the ORA more often 
showed weight loss in the early phase of 
the disease (p = 0.03). Site of onset was 
also more frequent in this group in both 
small and large joints from the start 
2-year follow-up 
The same demographic, laboratory and 
clinical findings at onset as described for 
the whole group could be found for the 
group with 2-year follow-up (partly 
shown in Table III). The disease activity 
of both YRA and ORA was diminished 
after 2 years of follow-up. Nevertheless, 
the higher disease activity of the ORA 
seen at the start was still present after 2 
years (Table III, ESR, CRP, and DAS). 
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Radiographic damage 
The radiographic score at onset was 
very low for both groups. The only differ-
ence is that ORA showed more joint 
space narrowing in the hands, resulting 
also in a difference in the total narrowing 
of hands and feet and the total score of 
the hands. After 2 years no statistically 
significant differences existed. The ran-
ges of abnormalities were very wide for 
both groups. The increase in radiogra-
phic damage was not significantly differ-
ent, either (data not shown). 
Discussion 
There is no unanimity in the literature 
on the course of ORA, which is mostly 
considered as a mild subgroup of RA. 
These results are mostly collected in ol-
der, cross-sectional studies on longstan-
ding RA, some without a control group of 
YRA. This study was intended to investi-
gate if ORA is really a different subgroup 
of RA. We had the opportunity to ob-
serve prospectively a large group of YRA 
and ORA patients with disease duration 
of less than 1 year at entry of the study, 
who had not been treated with SAARDs 
before. In this study bias (e.g. selection 
bias) played a much smaller role than in 
the other studies, because all patients 
were seen prospectively from the onset of 
the disease. 
The most striking difference from the 
literature is the equal and high percent-
age of IgM-RF-positivity in YRA and 
ORA. Most studies provide insufficient 
information to draw conclusions on the 
percentage of RF-positivity. However, 
several studies found a lower percentage 
of RF-positivity in ORA, · others more 
equal proportions (Table IV).3,13'14 Al-
though three studies describe only a 
group of ORA patients, they conclude 
that the course of ORA is better or equal 
to YRA. ' ' Four cross-sectional studies 
compared ORA with YRA.1'3,14 All con-
clude that ORA is a better subgroup. 
However, one study based this con-
clusion only on the data at onset. Only 
one study beside the present one in-
cluded a follow-up of several years from 
which to draw conclusions on the course 
of ORA in comparison with YRA. Both 
studies found an equal percentage of se-
ropositivity and a worse prognosis in 
ORA. The study design may play a major 
role in the contrasting findings of the var-
ious investigations. The fact that the 
cross-sectional studies found a belter or 
equal prognosis in contrast to the worse 
course in the follow-up studies, may be 
due to patient selection. Patients with a 
good overall prognosis no longer attend 
the department of rheumatology. On the 
other hand patients with a bad prognosis 
may have died and therefore not included 
in the analysis. The percentage of pa-
tients not included due to death may be 
especially large in older patients. The se-
lection of patients may not be equal in 
both age groups and this may influence 
the comparison of ORA and YRA. The 
lower rate of scropositivity in ORA in 
several studies can be a result of this se-
lection bias. Because scropositivity is a 
wellknown unfavorable prognostic fac-
tor, the difference in RF might be a cause 
of the conflicting findings. 
The high percentage of RF-positivc pa-
tients in our study may be due to the fact 
that the study was performed in two spe-
cialized departments of Rheumatology in 
University hospitals. Another explana-
tion may be that we have used a very sen-
sitive method for the determination of the 
IgM-RF with a low cut-off point for 
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seropositivity ( < 5% of normal controls 
above cut-off point). However, the lat­
ter possibility does not influence the 
comparison of the two groups because 
the proportion of patients with border­
line RF-titers was equal in both groups. 
The percentage of DR4 + (58%) is in 
the same range as reported by other stud­
ies, higher in comparison with normal 
controls. ' The percentage of HLA-
DR4 is not different in the two age 
groups. Terkeltaub et al in 32 patients 
with O R A found 3 8 % D R 4 + in 
comparison with 17% in normal con­
trols. However, 7/10 R F + patients 
were DR4 + . Thus, if restricted to sero­
positive patients, a high frequency of 
DR4 was found. The frequency of DR4 
in relation to age has been studied by sev­
eral investigators. I noue et al found less 
DR4 in ORA, viz. 44% vs 64% in YRA 
which was not significantly different 
(n = 107, ρ = 0.08). Jaraquemada found 
a declining trend in DR4 frequency with 
28 
advancing age of onset of the disease in 
female but not in male patients. The in­
fluence of seropositivity and age on the 
DR4 prevalence has been studied by 
Hazes et al in a well-defined group of fe 
male patients with recent onset RA 
DR4 was similar in all age groups of RA 
if corrected for RF-positivily and higher 
in comparison with a control population. 
59% of their R F + patients and 50% of 
the whole group were DR4 + . This is fully 
comparable with our study on a group of 
males as well as females. 
Some of our results are in accordance 
with the literature: a relatively more 
equal sex distribution, more often an 
acute onset and onset in the small as well 
as the large joints and a higher ESR in the 
ORA group. Not only the ESR is higher 
in ORA, but also the CRP, DAS, and 
number of swollen joints (p = 0.08). Both 
the YRA and the ORA group improved 
in disease activity. Nevertheless, the 
higher disease activity in ORA is still 
Tabic IV. Summary of reports on ORA and YRA with regard to seropositivity 
Reference 
Present study 
Fcrraccioli13 
Terkeltaub2 
Deal1 
Ehrlich3 
Inoue" 
Moesman 
Adler4 
Brown 
Study design 
follow-up 2yr 
follow-up 3 yr 
cross-sectional 
cross-sectional 
cross-sectional 
cross-sectional 
descriptive 
descriptive 
cross-sectional 
Number of 
patients 
>60n = 46 
<60n = 101 
>65n = 34 
<65n = 38 
г60п = 34 
<60n = 34 
>60n = 78 
<60n = 134 
5:60 η = 43 
<60n = 36 
&60n = 79 
<60n=414 
>50n = 85 
>55n = 20 
>65n = 156 
Mean dis­
ease dura­
tion 
< l y r 
6yr 
2yr 
4.1 yr 
5.3 yr 
4.1 yr 
12.5 yr 
0.5-5 yr 
YRA % RI·-
78% 
50% 
59% 
72% 
67% 
76% 
ORA % RI' 
89% 
55% 
32% 
48% 
58% 
66% 
65% 
65% 
45% (13/29) 
Conclusion 
author 
ORA worse 
ORA worse 
ORA belter 
ORA better 
not due to RF 
ORA better 
ORA belter 
at onset 
ORA = YRA 
ORA better 
ORA = YRA 
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Older vs younger age at onset RA 
present after two years. tis. 
The narrowing of the hands at the start In conclusion, in our study with a good 
is more pronounced in ORA, resulting in balance of RF-positivity, the ORA pa-
a difference in the total score of the hands tients showed a higher disease activity at 
and the total score of the hands and feet, onset, which was still present after 2 
After two years, the ORA patients years. Consequently, ORA patients suf-
tendcd to have more radiographic dam- fered from more active inflammation 
age, and a worse Physical disability, al- during the 2 years of follow-up. There was 
though there were no statistically signifi- also a tendency to a higher radiographic 
cant differences anymore, mostly due to score and a slightly worse Physical Dis-
tile wide range of abnormalities in both ability in ORA. The disagreement with 
groups. A more destructive arthritis as we the literature may be mostly due to the 
found in older human beings was also fact that our results are based on a follow-
seen in old adult mice compared with up study. 
young adult mice in experimental arthri-
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Prognostic factors 
Summary 
We studied the influence of demographic, clinical, laboratory and genetic features and 
radiographic damage at onset on the outcome after two years in a prospective study of 
147 patients with classical or definite RA with disease duration shorter than one year at 
entry. Outcome was determined by physical disability and by radiographic damage of 
hands and feet. By means of multiple regression analysis and discriminant analysis 
outcome was explained from variables at the start and during the first 6 months. No 
clinically relevant conclusions could be made for physical disability due to the low 
explained variance and small number of patients with bad physical disability. Radio-
graphic damage after two years was predicted by high disease activity at the start 
(measured as erythrocyte sedimentation rate, C-reaclive protein or Disease Activity 
Score) combined with DR4 or DR2 (as a prognostically favorable factor) and rheuma-
toid factor positivity. Radiographic damage could be better predicted if disease activity 
during the first 6 months was included. Absence or presence of progression of radio-
graphic damage could be correctly predicted in 83% of the patients. 
Introduction 
Rheumatoid arthritis (RA) is a hetero-
geneous disease of unknown etiology. As 
long as curative therapy is not available it 
would be advantageous to know factors 
to predict prognosis. The value of knowl-
edge of prognostic factors is threefold: 
firstly, this might provide insights into dis-
ease mechanisms of RA. Secondly, it 
could improve the best choice of therapy 
for a particular patient; more effective 
but more toxic drugs could be reserved 
for patients with a high risk of a bad fìnal 
outcome, thus increasing the benefit/risk 
ratio. Finally, prognostic factors might be 
used in clinical trials to indicate sub-
groups of therapeutic rcsponders. ' 
Many investigators have tried to find 
factors which correlate with the final out-
come of RA. We have summarized these 
reports in a review article. In general, fe-
male sex and positive rheumatoid factor 
were variables indicating a poor progno-
sis. Results on other possible prognostic 
factors were conflicting. This might be 
mostly due to the heterogeneous and in-
99 
complete study designs. Many investiga-
tions were cross-scclional, in a retrospec-
tive way, on patients with varying disease 
duration, with poor outcome measures. 
In our opinion, prognosis can only be stu-
died reliably in a prospective follow-up 
study of patients with recent onset RA, 
with regular check-ups, preferably by the 
same person with standardized clinical, 
laboratory and radiographic measures. 
Such prospective study design is lime-
consuming but excludes many types of 
bias. This report describes prognostic 
factors in a 2-ycar follow-up study of a co-
hort of 147 patients with recent onset RA. 
Patients and methods 
Patients 
Patients were seen in the departments 
of Rheumatology of the University Hos-
pital Nijmegen and the University Hospi-
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tal Groningen in the Netherlands. All 
consecutive patients who met the ARA 
criteria for definite or classical RA with 
a disease duration shorter than one year 
at entry, and who had not been treated 
with slow acting antirheumatic drugs 
(SAARDs) before were included. Pa­
tients were followed up at four-weekly in­
tervals. All 147 patients whose follow-up 
was at least two years were used for this 
analysis. 
Patients were treated with nonsteroidal 
anli-inflammalory drugs (NSAIDs) and 
several types of SAARDs. Our policy was 
to start early with SAARDs in the follow­
ing order: hydroxychloroquine or sulfas­
alazine, thereafter auranofin or auro-
thioglucosc, next penicillamine or 
methotrexate or azathioprine. Cortico­
steroids could be added at all stages. Pa­
tients were treated with the following 
drugs: only NSAIDs η = 14, hydroxy­
chloroquine η = 85, sulfasalazine η = 57, 
auranofin η = 10, aurothioglucose η = 61, 
penicillamine n —22, methotrexate 
η = 15, azathioprine η = 12, corticoste­
roids η = 37. 
Assessmenfs 
At the start of the follow-up, the follow­
ing anamnestic information on the onset 
of the disease was collected: type of onset 
(1 = acute = within one day, 2= sub­
acute = within one week, 3 = insidious = 
ranging from weeks to months); site of 
onset (monarlhritis, small joints, large 
joints, both small and large joints); sym­
metry at onset; a patient was classified as 
having malaise at onset if he had either 
fever or weight loss in the first few months 
after onset; family history: two variables 
were created: firstly, the presence or ab­
sence of a family member with RA and 
secondly, presence or absence of first de­
gree relatives with RA; educational level 
expressed as the number of years of edu­
cation. 
The following clinical and laboratory 
variables were collected at the start: IgM 
rheumatoid factor4 (IgM RF, ELISA, 
< 5 lU/ml negative), Antinuclcar Anti­
gen (ANA), erythrocyte sedimentation 
rate (ESR, Westergren, mm/1 hr), C-re-
activc protein (CRP, mg/l), Ritchie artic­
ular index, number of swollen joints, dis­
ease activity score (DAS, a score com­
posed of Ritchie articular index, number 
of swollen joints, ESR, and general 
health ' ) and presence of subcutaneous 
nodules. The sera of 145 patients were 
typed for HLA-DR locus. H LA-DR 1, 
DR2, DR3 and DR4 were included as 
possible prognostic factors. 
Physical disability was investigated by 
the Dutch version of the Health Assess-
ment Questionnaire at 2 years' follow-
up. The range of the possible score is 
from 0 to 3. 
X-ray analysis 
Biannual X-rays of hands and feet were 
made. The X-rays were scored by one ob­
server in each department, in chronolog­
ical order per patient. The observers 
were not informed of the patients' iden­
tity. The number of erosions (E) and joint 
space narrowing (N) were scored in a 
modified way according to Sharp. This 
scoring method has been validated and 
described before. The Spearman 
correlation of the narrowing, erosion and 
total score between the two observers 
ranged from 0.80 to 0.92 (determined on 
96 pairs of X-rays of hands and feet). The 
intraobserver correlations for both ob­
servers ranged from 0.94 to 0.99 (deter-
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mined on 25 and 27 pairs of X-rays). 
Erosions were counted in the ten meta-
carpophalangeal joints, the eight proxi-
mal interphalangcal joints, the two inter-
phalangeal joints of the thumbs, the right 
and left first metacarpal bone, the right 
and left radius and ulnar bones, the right 
and left trapezium and trapezoid (as one 
unit; multangular), right and left navi-
cular bones, right and left lunate bones, 
the ten metatarsophalangeal joints, and 
the two interphalangcal joints of the big 
toes. Joint space narrowing was assessed 
in the ten metacarpophalangeal joints, 
the eight proximal interphalangcal joints, 
right and left third, fourth and fifth carpo-
metacarpal joints, right and left multan-
gular-navicular joints, right and left cap-
itate-navicular-lunate joints, right and 
left radiocarpal joints, the ten metatar-
sophalangeal joints and the two interpha-
langcal joints of the big toes. Erosions 
were counted as score 1 if there was a dis-
crete interruption of the cortical surface; 
if there was a greater defect, a score ac-
cording to the jointsurface involved was 
given. Consequently, for confluent ero-
sions the score could not become smaller. 
In the hands the maximum erosion score 
in a joint was 5; in the feet it was 10. Four 
grades of joint space narrowing were rec-
ognized: 1 = focal or doubtful; 2 = gen-
eral, less than 50% of the original joint 
space; 3 = general, more than 50% of the 
original joint space or subluxation; 4 = 
ankylosis. Thus, the maximum number of 
erosions in the hands was 160 and in the 
feet 120; and the maximum scores for 
joint space narrowing were 120 and 48, 
respectively. Scores for erosions and joint 
space narrowing were added up to give 
the total score (X-damage). 
Statistical analysis 
Discriminant analysis and multiple re-
gression analysis were performed. By 
means of discriminant analysis a discrimi-
nant function was developed to predict 
the category of abnormality. Multiple re-
gression analysis tries to explain a contin-
uous variable: the extent of abnormalities. 
The following variables were used as in-
dependent variables in both types of anal-
ysis: type of onset, site of onset, symmetry, 
malaise at onset, positive family history 
for RA, first degree relatives with RA, 
IgM RF, ANA, ESR, CRP, Ritchie artic-
ular index, number of swollen joints, sub-
cutaneous nodules, age at onset, sex, ed-
ucational level, the department of 
investigation, HLA-DR1, DR2, DR3 and 
DR4, DAS, and the radiographic damage 
at the start. In some analyses a measure 
for the disease activity during (he first 6 
months was included. For this purpose 
we calculated the mean DAS during 
months 0-3,3-6 and 0-6 (DAS03, DAS36 
and DAS06 resp.). The reason was to 
evaluate if inclusion of measures of dis-
ease activity during the first six months 
could enhance the prognostic value. Be-
cause of the high negative skewness, the 
radiographic score (X-damagc) and its 
increase were transformed to approxi-
mate a normal distribution (root trans-
formation). 
For the discriminant analysis the total 
score of hands and feet at 2 years was di-
vided in < 1 % versus > 1 % abnor-
malities, the progression in < 3 versus 
>3 new abnormalilies, and the physical 
disability in <1.0 versus >1.0. The de-
pendent variables for the multiple regres-
sion analysis were the total score of hands 
and feet at 2 years, the increase in total 
score in 2 years, and the physical disabil-
ity at 2 years. Both forward and backward 
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Table I Charactenstics at the start of the follow-up, used as independent vanables in the discnminant 
and multiple regression analyses in percentages or mean (SU) 
Age mean yr 
(range) 
Females % 
Clinic I 
Subcutaneous nodules % 
Malaise % 
Type of onset % 
acute 
subacute 
insidious 
Site of onset % 
monarthnlis 
small joints 
large joints 
small and large joints 
Symmetrical onset % 
Family history pos for RA % 
only 1st degree relatives % 
Education % 
0-6 yr 
6-12 yr 
12 yr 
IIIA-DR1% 
DR2 
DR3 
DR4 
IgM-RF >5 lU/ml % 
ANA% 
ESR (SD) (mm in 1st hr) 
CRP (SD) (mg/l) 
Ritchie (SD) 
Number of swollen joints (SD) 
DASO (SD) 
DAS03 (SD) 
DAS06 (SD) 
DAS36 (SD) 
total 
(n = 147) 
50 9 
(16-78) 
64 
54 
10 
27 
34 
20 
46 
14 
54 
11 
21 
27 
43 
18 
34 
30 
36 
27 
19 
18 
59 
82 
53 
43(31) 
42(57) 
14(9) 
14(8) 
4 2 ( 1 2 ) 
3 9 ( 1 0 ) 
3 8(10) 
3 5 ( 1 1 ) 
< 1 % 
X-damage 
(n = 43) 
46.5 
(16-77) 
65 
46 
9 
12 
39 
26 
35 
16 
44 
14 
26 
30 
40 
19 
19 
32 
48 
27 
32 
20 
37 
65 
38 
28 
16 
13 
12 
38 
34 
32 
30 
гі% 
X-damage 
(n = 104) 
52 8 
(17-78) 
64 
57 
10 
33 
32 
18 
50 
12 
59 
10 
19 
26 
45 
17 
39 
30 
31 
28 
13 
17 
69 
89 
60 
50 
53 
14 
15 
4 3 
41 
4 0 
38 
<3prog 
X-damage 
(n = 46) 
472 
(16-77) 
72 
50 
11 
15 
41 
24 
35 
17 
48 
13 
22 
33 
37 
17 
22 
31 
47 
21 
32 
21 
36 
59 
36 
32 
20 
13 
13 
39 
3.5 
33 
30 
>3prog 
X-damage 
(n = 101) 
52 6 
(17-78) 
60 
50 
9 
32 
31 
19 
50 
12 
57 
10 
21 
25 
46 
18 
39 
30 
30 
30 
12 
16 
70 
92 
61 
49 
53 
14 
14 
4 3 
41 
4 0 
38 
RI· rheumatoid factor, ANA antinuclcar antigen, K R erylhrocyle sedimentation rale, CRP C-reaclive 
protein, DASO disease activity score at the start, DAS03, DAS06, DAS36 mean disease activity score 
months 0 to 3,0 to 6,3 to 6 
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multiple regression analyses were per-
formed, leading to the same regression 
equation in all situations. Regression di-
agnostics were applied to check the qual-
ity of the regression results. No serious 
influential points could be detected. 
Results 
Table I shows the characteristics of the 
patients and the independent variables 
used in the analyses, both for the total 
group and subgroups with high and low 
X-damage. Table II summarizes the out-
come variables at two years of follow-up. 
Both subdivisions on X-damagc (at 2 
years and progression) are highly corre-
lated. 
To check if the participating center in-
fluenced the outcome, the department 
where the patient was seen was included 
as independent variable in all analysis. In 
no analysis did the department of investi-
gation show a significant contribution to 
the outcome. 
First of all a discriminant analysis was 
done to determine which variables distin-
guish the group of patients with < 1% of 
abnormalities versus the group of pa-
tients with > 1% abnormalities after two 
years of follow-up (Table III). All vari-
ables at the start including X-damage 
were included as independent variables. 
ESR, X-damagc and DR4 were deter-
mined as the variables with the greatest 
explained variance. The canonical corre-
lation (a measure for the explained vari-
ance) was 0.47. This set of three variables 
classified 79% of the patients in the cor-
rect group. Because of the cumulative ef-
fect of radiographic damage, the radio-
graphic damage after two years is directly 
related to that at the start. Therefore we 
did the same analysis without X-damage 
Table II Dependent variables in discriminant 
and multiple regression analyses (n = 147) 
X-damage t = 0 yr (range) 
X-damage t = 2 yr (range) 
Increase in X-damage 
Physical disability 1 = 2 yr 
mean 
(range) 
5 (0-97) 
29 (0-202) 
24 (0-198) 
0 35(0-2 12) 
median 
1 
19 
15 
028 
as independent variable. Again ESR and 
DR4 were the variables with the greatest 
explained variance. The canonical corre-
lation was only slightly less (0.42) and 
75% of the patients were classified cor-
rectly. Thereafter, all available variables 
from the start and from the first six 
months of follow-up were included, with 
and without X-damage at the start. If X-
damage was not included the combina-
tion of DAS of month 0 to month 6 
(DAS06), positive rheumatoid factor and 
DR2 (negatively correlated) showed a 
canonical correlation of 0.55 with 80% of 
the patients correctly classified. After in-
clusion of X-damage, DAS06 combined 
with X-damagc and DR4 resullcd in a ca-
nonical correlation of 0.55 with 82% of 
the patients correctly classified. The 
proportion with radiographic damage 
correctly identified with this last discrim-
inant function was 92% and the propor-
tion without radiographic damage cor-
rectly classified was 59%. The positive 
prognostic value was 85% and the nega-
tive prognostic value 73%. The above-de-
scribed conceptions arc comparable to 
the terms sensitivity, specificity, positive 
predictive value, and negative predictive 
value in diagnostic tests. However, we 
prefer to restrict these terms to diagnos-
tic tests to prevent confusion. 
Table IH also presents the pooled with-
in-groups correlations between several 
independent variables and the discrimi-
nant function. These correlations en-
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Table III Discriminant analysis of groups with < 1 % ( 
Vanables included in 
discriminant function 
Canonical correlation 
Correctly classified 
Correlations with 
discriminant function 
(r;>0 20) 
all vanables at 
t = 0 
ESR 
X-damage 
DR4 
047 
79% 
ESR 
DR4 
X-damage 
CRP 
Age 
IgMRF 
DASO 
060 
059 
055 
036 
025 
023 
0 20 
1=41) versus > 1 % (n = 102) 
all vanables at 
t = 0, cxcl X-dam­
age 
ESR 
DR4 
042 
75% 
ESR 
DR4 
CRP 
DASO 
Age 
Malaise 
IgMRF 
DR2 
0 70 
068 
048 
034 
0 29 
025 
023 
- 0 22 
all vanables at 
t = 0andt = 6 
months 
DAS06 
X-damage 
DR4 
0.55 
82% 
DAS06 
DAS03 
DAS36 
DR4 
DASO 
X-damage 
ESR 
Swoll j 
Age 
CRP 
0 61 
0.56 
051 
049 
046 
045 
030 
024 
0 21 
0 20 
abnormalities 
all vanables at 
t = 0 a n d t = 6 
months, exel X-
damage 
DAS06 
IgMRF 
DR2 
0.55 
80% 
DAS06 
DAS03 
DAS36 
IgMRF 
DASO 
DR2 
ESR 
CRP 
DR4 
Age 
Swoll j 
0 61 
0.57 
051 
0 45 
042 
-0 37 
0 31 
027 
0 26 
0 21 
021 
ESR erythrocyte sedimentation rate, X-damage total radiographic damage at the start, CRP C-reactive 
protein RF rheumatoid factor, Swoll j number of swollen joints, DASO disease activity score at the 
start, DAS03, DAS06, DAS36 mean disease activity score months 0 to 3, 0 to 6, 3 to 6 
hance the information on which variables 
are important. Some variables are not in­
cluded in the discriminant function be­
cause they correlate strongly with vari­
ables already entered in the discriminant 
equation. For example, in the analysis of 
all variables, DAS06 is included in the 
discriminant function. Owing to the high 
correlation between the DAS03, DAS36 
and DASO and both the discrinant func­
tion and DAS06, the above-mentioned 
variables were no longer included. 
Discriminant analysis on the progres­
sion of radiographic abnormalities was 
also performed. Patients were divided 
into two groups: < 3 new abnormalities 
versus >3 new abnormalities in the two 
years of follow-up. Table IV shows these 
results. From this analysis it is apparent 
that the radiographic damage at the start 
does not predict the progression in the 
next two years. The correlation between 
X-damage and the discriminant function 
was only 0.03. IgM RF and DR2 in com­
bination with either CRP or DAS06 re­
sulted in canonical correlations of 0.53 
and 0.58 respectively, with 83% and 79% 
of the patients classified correctly. The 
discriminant function based on all avail­
able data of the start and first six months 
revealed a proportion with radiographic 
damage correctly identified of 88% and a 
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proportion without radiographic damage 
correctly classified of 59%. The positive 
prognostic value was 83% and the nega­
tive prognostic value 68%. 
Finally, physical disability was used as a 
dependent variable in discriminant anal­
ysis (physical disability < 1 versus > ! ) . 
Physical disability was known for 144 pa­
tients; only 15 patients had a score >1. A 
combination of large joints affected at 
onset and high DAS during months 3-6 
resulted in a canonical correlation of 0.38 
with 92% of the patients correctly classi­
fied. The explained variance is too low to 
be of clinical relevance. 
Table V shows a summary of multiple 
regression analysis. These results are 
roughly comparable to those of the dis­
criminant analysis. Only the number of 
swollen joints and malaise at onset were 
included now. Again the physical disabil­
ity was explained by a different subset of 
variables compared with the radiogra­
phic damage, namely DAS06 and type of 
onset: an acute onset results in a more fa­
vorable physical disability. However, the 
multiple R is very low and consequently 
the results are of little clinical relevance. 
Discussion 
Knowledge of prognostic factors might 
provide important information in many 
areas. Prognostic factors might enhance 
insights into disease mechanisms, in­
crease the benefit/risk ratio for SAARDs 
for a particular patient, reveal therapeu­
tic subgroups in clinical trials. Besides, a 
set of easily applied and accurate prog-
Tablc IV Discnmmanl analysis of groups wilh < 3 ( n = 44) versus >3 (n = 99) new abnormalities 
during 2 years of follow-up 
Variables included in 
discriminant function 
Canonical correlation 
Correctly classified 
Correlations with discrimi­
nant function 
(raO 20) 
all variables at t = 0 
IgMRF 
CRP 
DR2 
0.53 
83% 
IgMRF 
CRP 
DR2 
LSR 
DR4 
Age 
0.72 
043 
-040 
0 39 
0 29 
0 23 
all variables at t = 
months 
IgMRF 
ПАЬОб 
DR2 
038 
79% 
IgMRF 
DAS06 
DAS03 
DAS36 
DASO 
DR2 
ESR 
DR4 
Age 
 0 and t = 6 
064 
0 49 
0 47 
0 39 
0 37 
-0 36 
0 31 
0 27 
0 26 
ESR erythrocyte sedimentation rate, CRP C-reaclivc protein, RF rheumatoid factor, DASO disease ac­
tivity score at the start, DAS03, DAS06, DAS36 mean disease activity score months 0 to 3,0 to 6,3 to 6 
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nostic factors of outcome might also con­
tribute to more economical and effective 
evaluation and management of patients. 
Many investigators studied correlation of 
possible prognostic factors with out­
come, but with a wide variety of conclu­
sions. The conflicting results are proba­
bly due to the heterogeneous study de­
signs. In many studies outcome was not 
well defined, patients with longstanding 
RA were included, or results were based 
on cross-sectional or retrospective stud­
ies. In our opinion prognosis can only be 
studied reliably in patients with recent 
onset RA, in a prospective manner with 
well-defined outcome variables. Radio­
graphic damage is essential as outcome 
parameter because this is a cumulative ef­
fect of the disease process. Physical dis­
ability is another important outcome vari­
able. Clinical and laboratory variables 
are temporary disease activity variables 
and not useful as outcome measure. Even 
in the first years of the disease a con­
siderable number of patients may show 
radiographic damage. Therefore it is 
essential to know prognostic factors early 
in the course of the disease. Few studies 
met the above-mentioned criteria and 
performed a study design comparable to 
ours.
2
·
1 1
"
1 4 
Discriminant analysis and multiple re­
gression analysis arc statistical methods 
which simultaneously evaluate interac­
tions among multiple variables. Variables 
with redundant information are elimi­
nated and variables which are less signif­
icant in univariate analysis, may make im­
portant contributions to a prognostic 
function in second instance. ' These 
methods provide the most efficient use of 
data which are studied as possible prog­
nostic factors. We used both discriminant 
analyses and multiple regression analyses 
because these may give additional infor­
mation. Discriminant analysis is only an 
on/off phenomenon: a patient can belong 
two one or the other category, in our 
study absence or presence of radiogra­
phic damage. Multiple regression analy­
sis also includes the extent of radiogra­
phic damage. 
Two years of follow-up is a relatively 
short period for a chronic disease such as 
Fdblc V Multiple regression analysis of radiographic damage al two years, the increase in radiographic 
Jamagc in I wo years and the physical disability at two years (n = 147) 
Dependent variable 
Variables included in 
multiple regression 
Multiple R2 
all variables at 
1 = 0 
X-damagc I = 2 yr 
I g M R F 
X-damagc 
Swollen joints 
Malaise 
D R 2 -
042 
all variables at 
t = 0, 
exel X-damagc 
X-damage t = 2 yr 
I g M R F 
ESR 
Swollen joinls 
D R 2 -
031 
all variables at 
l = 0 a n d t = 6 
months 
Increase in 
X-damage 
DAS36 
I g M R F 
X-damage -
D R 2 -
0 39 
all variables at 
t = 0andt = 6 
months 
Physical disability 
t = 2yr 
DAS06 
lypcof onset-
0 23 
I3SR erythrocyte sedimentation rate, X-damage total radiographic damage at the start, CRP C-reactive 
protein, КГ rheumatoid factor, - means a negative correlation, ι e a prognostically favorable factor 
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rheumatoid arthritis, although one study 
indicates that 90% of the patients who 
will develop erosions will do so in the first 
two years of the disease. In our group 
only 1 patient (out of 90) with no radio-
graphic damage after one year of follow-
up showed radiographic progression 
during the next two years of follow-up 
(data not shown). Therefore we think it is 
a realistic goal to determine prognostic 
factors for radiographic damage after 
only two years of follow-up. However, 
physical disability as an outcome variable 
after two years of follow-up is a major 
problem, as only 15 patients in our group 
showed a score >1 . This means that the 
range of physical disability in this group 
of early RA is very small and most pa-
tients still have a moderate to good phys-
ical function. For this reason it is hard to 
determine reliable prognostic factors for 
a worse physical disability. Furthermore, 
the explained variance in the analyses was 
very low. Therefore we think that 2 years 
of follow-up is too short to draw reliable 
conclusions on prognostic factors for 
physical disability. The subsequent para-
graphs are solely based on radiographic 
damage as outcome variable. 
All discriminant and multiple regres-
sion functions in our study included a 
measure of disease activity (ESR, CRP or 
DAS). If information on the first six 
months was included as an independent 
variable, the canonical correlation was 
higher. This means that more of the vari-
ation of prognosis could be explained. In 
addition each discriminant and multiple 
regression function contained a genetic 
marker: either DR4 as a prognostically 
unfavorable or DR2 as a prognostically 
favorable factor. Rheumatoid factor was 
also included in many functions. Of the 
demographic characteristics and the fea-
tures of the onset of the disease, only mal-
aise at onset was included once in a mul-
tiple regression function. Age at onset 
showed a moderate correlation with most 
functions, indicating that a higher age at 
onset was a relatively unfavorable prog-
nostic factor. 
The prognostic significance of DR4 and 
DR2 is in accordance with other re-
In 17 
ports, ' although this could not be con-
firmed by all. Young et al found no ad-
ditive information of HLA data to discri-
minate between a group with and without 
13 
erosions. 
The radiographic damage at the start 
contributed significantly to the functions 
of the absolute radiographic damage at 
two years. This comes fully up to expec-
tations as radiographic damage is a cu-
mulative process. The patients with a 
high initial X-damage will consequently 
have a high X-damage at two years' fol-
low-up. However, if only the progression 
of radiographic damage during the two 
years of follow-up was studied, the initial 
X-damage did not predict progression of 
radiographic abnormalities. Moreover, 
in the multiple regression analysis a high 
initial X-damage was even negatively as-
sociated with the radiographic progres-
sion. This, however, is probably not a real 
negative relationship but an artefact in-
troduced by measurement errors (i.e. 
'regression to the mean' phenomenon). 
These seemingly conflicting results of the 
initial X-damage on the outcome were 
described earlier by two investigators in 
two different papers. In one report Luuk-
kaincn et al described the absolute radio-
graphic damage at three years' follow-up 
and noticed a positive correlation with 
the initial X-damage. On the other 
hand Moltonen et al studied the increase 
in Larsen index and found a negative cor-
relation with the initial Larsen index and 
noted the difference in results with the 
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study of Luukkainen. However, these 
differences might probably be interpre­
ted in the same way as we described for 
our study. 
The explained variance in the multiple 
regression analyses was about 40% with 
4 or 5 variables (Table V). These figures 
were comparable with those from the lit­
erature, although with fewer variables. 
Luukkainen et al found an explained vari­
ance of 29% for three years' Larsen index 
with 5 variables and of 43% with 10 vari­
ables (joint space narrowing at the start, 
serum iron, ANA, grip strength, tenosy­
novitis, Rheumatoid factor, CI esterase 
inhibitor, functional disability, number of 
symmetrically involved small joint 
groups). Kaarela divided patients into 
5 categories of X-damage after a mean 
follow-up of 7.6 years. Seven variables 
revealed an explained variance of 43% in 
the multiple regression analysis (number 
of diseased peripheral joints, Waaler-
Rose, grip strength, American Rheuma­
tism Association criterion on radiogra­
phic abnormalities, ESR, number of 
diseased central joints, number of sym­
metrically swollen joints). The explained 
variance is relatively low in all these stud­
ies. Hence other variables, not included 
in the analyses, and yet unknown, are 
important in the prediction of radio­
graphic damage. 
A discriminant analysis was performed 
in two other studies. Feigenbaum et al 
studied 50 patients during an average of 
5 years and divided the patients into three 
outcome groups. The group under study 
was a mild group because only 10 (20%) 
patients developed erosions, in compari­
son with about 70% in other papers in­
cluding the present study. ' A combi­
nation of 6 variables classified 82% of the 
patients in the correct category (Rheu­
matoid factor, malaise or weakness, white 
versus black race, Raynauds-like sympto­
matology, two or more swollen upper 
joints, female sex). Young et al classified 
76% of 149 patients correctly with 4 vari­
ables in a category with or without ero­
sions after three years of follow-up (Latex 
titer, RAHA titer, hemoglobin, platelet 
count). The percentage of both correct­
ly classified patients with radiographic 
damage and positive prognostic value in 
our study was somewhat higher (92% ver­
sus 82%, and 85% versus 8 1 % resp.) and 
the percentage correctly classified with­
out radiographic damage somewhat lo­
wer (59% versus 64%). The percentage 
correctly classified with radiographic da­
mage is inversely related to the percen­
tage of patients without radiographic da­
mage, depending on the choice of a priori 
chances in the discriminant analyses. The 
higher the one, the lower the other. 
Our results reveal that genetic markers 
such as DR4 and DR2 are not only in­
volved in susceptibility but also in scvcrily 
of rheumatoid arthritis. In addition, high 
disease activity measured as ESR, CRP 
or DAS and a positive rheumatoid factor 
was significantly associated with radio­
graphic damage after two years of follow-
up. 
Although the percentage of patients 
classified in the radiographic category 
correctly is too low to rely on fully in clin­
ical practice, patients with the above-
mentioned unfavorable prognostic fac­
tors are prone to more radiographic 
damage. Accordingly they might be 
treated more aggressively early in the 
course of the disease. Besides, these vari­
ables might be used in clinical trials for 
stratified randomization and to indicate 
subgroups of therapeutic responders. 
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Summary and conclusions 

Summary and conclusions 
Rheumaloid arthritis (RA) is a hetero-
geneous disease with unknown aetiology. 
Symmetrical Polyarthritis is the most 
common feature. Longstanding RA may 
lead to marked limited functional capac-
ity and to irreversible joint damage, vis-
ible on X-rays as erosions and joint space 
narrowing. The course of the disease is 
variable and capricious, ranging from one 
episode of (mild) Polyarthritis with spon-
taneous remission to (rapidly) progress-
ive and destructive polyarthritis with ex-
tensive extra-articular manifestations. 
Drug therapy is the cornerstone of treat-
ment and may be divided in first-line 
drugs and second-line drugs. First-line 
drugs (Non-Stcroidal-Anti-Inflamma-
tory-Drugs) relief pain and stiffness, sec-
ond-line drugs (e.g. sulphasala/inc, 
aurothiomalate) have the capability to in-
fluence the course of the disease. How-
ever, a curative therapy is not known. 
Most second-line drugs may cause seri-
ous side-effects, in general the more ef-
fective the more toxic. Knowledge of 
prognostic factors could improve the best 
choice of therapy for a particular patient; 
more effective but more toxic drugs could 
be reserved for patients wilh a high risk 
of a bad final oulcome, thus increasing 
the benefit/risk ratio. Besides prognostic 
factors might provide insights into dis-
ease mechanisms of RA, and might be 
used in clinical trials to indicate sub-
groups of thcrapculic rcspondcrs. 
Process and outcome variables 
The disease process of RA can be char-
acterized by two types of variables: pro-
cess and outcome variables. Process vari-
ables measure actual disease activity and 
ideally correlate with the ultimate out-
come, measured by oulcome variables. 
The main problem in defining ihe value 
of process variables is that a golden stan-
dard for disease activity is lacking. In clin-
ical praclice and in clinical trials, many 
process variables are used. The use of a 
lot of variables may cause problems in 
judgment of efficacy of a second-line 
drug in a particular patient and in the 
analysis of clinical trials. If some assess-
ments improve and others detoriate il is 
hard to draw a final conclusion on effi-
cacy. If more effect variables are used in 
clinical trials, a correction has to be made 
in statistical analysis and conscqucnlly 
more patients arc needed lo determine 
the same effect. 
In this thesis we tried to define a mea-
sure for disease activity and validated two 
methods to be used as outcome variables. 
Thereafter we could apply these process 
and oulcome variables in a prospective 
follow-up study of patients wilh recent 
onset RA. 
Disease activity score 
Chapter II described ihe definition ol .1 
disease activity score. Clinical jiulgmcnt 
is an overall impression of the doctor ol 
disease activity. This judgment is implit-il 
and investigations demonstrated (hat 
doctors arc not able lo describe exactly 
on which impressions or symptoms their 
clinical judgment is based. Therefore we 
analysed the way doctors behave in prac-
lice, in particular the decision making of 
the start or withdrawal of second-line 
drugs. We studied 113 patients with clas-
sical or definite rheumatoid arthritis in a 
prospective follow-up. Disease duration 
was less then 1 year and patients were not 
treated before with second-line drugs. 
Follow-up ranged from 2 lo 39 months 
wilh 1816 check-ups. Many clinic.il and 
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laboratory variables were assessed four-
weekly by two research nurses. 
Patients were divided in groups with 
high and low disease activity according to 
explicit rules. By various statistical meth-
ods a disease activity score (DAS) could 
be defined. This DAS is a continuous 
measure including the variables Ritchie 
articular index, number of swollen joints, 
erythrocyte sedimentation rate and gen-
eral health measured on a visual analogue 
scale. The variable general health can be 
replaced by a constant if this measure is 
lacking. The mean DAS in the group 
under study was 3.57 (SD 1.18, range 
0.51-7.26). Because of the complexity of 
the formula to calculate the DAS, a no-
mogram was constructed to facilitate the 
use of the DAS in clinical practice. 
Radiographic scoring 
In addition the development of a pro-
cess measure (DAS) we defined and val-
idated outcome measures in Chapter III, 
IV, and V. Therefore we used a randomi-
sed, double-blind, parallel trial compar-
ing hydroxychloroquine and sul-
phasalazine. 
Chapter III described the results of ra-
diographic progression after 48 weeks of 
follow-up of 50 patients. Sharp's method 
formed the basis for the scoring method 
of radiographic abnormalities. This me-
thod scores the number of erosions and 
the amount of joint space narrowing in 
hands. Because various studies indicate 
that already in the early phase of the dis-
ease feet may be seriously affected, we as-
signed this method for X-rays of the feet 
too. This method turned out to be sensi-
tive to differentiate the amount of radio-
graphic progression between patients 
treated with hydroxychloroquine and sul-
phasalazine. Patients on sulphasalazine 
showed significantly less radiographic 
progression after 24 and 48 weeks of 
treatment. 
After 48 weeks the trial was unblinded 
and patients received second-line treat-
ment according to the judgment of their 
rheumatologists. Patients were evaluated 
after a mean of 3.2 years. The difference 
in radiographic damage in favour of sul-
phasalazine was still present, but did not 
improve upon (Chapter IV). 
Physical disability 
Chapter V reported the use of a ques-
tionnaire in the above-described trial. 
This questionnaire was intended to mea-
sure the physical and psychosocial well-
being of patients. The physical part was 
mainly based on the Health Assessment 
Questionnaire (HAQ) expanded with a 
few questions especially related to the 
Dutch situation. Psychosocial well-being 
was measured by questions derived from 
the Arthritis Impact Measurements Sca-
les (AIMS). The reliability, reproducibil-
ity and validity of the questionnaire was 
tested in a large amount of inpatients and 
outpatients. Thereafter the sensitivity of 
the questionnaire was investigated in the 
trial comparing hydroxychloroquine and 
sulphasalazine. Because the develop-
ment of the questionnaire was not fin-
ished in time at the start of the trial, only 
the last 32 consecutive patients of the trial 
could be evaluated. 
The physical disability part turned out 
to be sensitive to differentiate between 
patients treated with hydroxychloro-
quine and sulphasalazine in accordance 
with the difference in radiographic pro-
gression. On the contrary, the psychoso-
cial part could not detect a difference. In 
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the following procedures only the physi-
cal part of the questionnaire was used. 
Validity of process variables 
After the validationo of methods for ra-
diographic scoring and measuring physi-
cal disability as outcome measures, these 
could be used to compare the validity of 
process measures (Chapter VI). We in-
cluded 10 single variables and 3 com-
posed indexes frequently used in clinical 
practice and clinical trials to measure dis-
ease activity. Patients with early RA fol-
lowed prospectively in two centers 
formed the basis for these analyses. In all 
233 patients were assessed four-weekly 
with a follow-up ranging from 8 to 58 
months (mean 30 months). Mutual 
correlations between the process vari-
ables, correlations between process vari-
ables and both physical disability and ra-
diographic damage, and the sensitivity to 
discriminate between high and low dis-
ease activity formed the basis for the va-
lidity judgment. Most single variables 
correlated poor wilh the outcome mea-
sures and showed little discriminative 
power. The DAS and Mallya turned out 
to be most valid in measuring disease ac-
tivity. We prefer the use of the DAS be-
cause this is, in contrast with the Mallya 
index, a continuous variable, which is 
much easier to use in statistical analysis. 
Review on prognostic factors 
Chapter VII described a review of the 
literature on prognostic factors of the 
final outcome in RA. Most results are 
contradictory. The main reason might be 
the heterogeneous study designs. Many 
studies were cross-sectional, based on 
longstanding RA with poor outcome 
variables. Only rheumatoid factor posi-
tivity and female sex were found as prog-
nostic unfavourable factors in most stud-
ies. Many studies did not include 'real' 
outcome measures such as physical dis-
ability and radiographic damage but 
based there results only on clinical and 
laboratory variables (i.e. process mea-
sures). 
Course of radiographic progression 
Surprisingly little is known on the pro-
gression of radiographic damage in RA. 
Opinions differ from a linear, S-shaped 
to a flattening form of the curve of radio-
graphic progression. We studied the ra-
diographic progression of hands and feet 
during a three year prospective follow-up 
of early RA (Chapter VIII). The follow-
up of 90 patients was two years and of an-
other 57 patients three years. 
After 3 years of follow-up radiographic 
damage was present in 70% of the pa-
tients and this group could already be se-
lected after 1 year. Overall, 18-20% of 
thcjoinls were affected after 3 years, with 
relatively little abnormalities per joint 
( 8% of the maximum score was 
reached). During the whole follow-up 
more foot joints were affected than hand 
joints. No difference could be found be-
tween the dominant and the nondomi-
nant hand. The rate of progression in the 
first year was significantly more than in 
the second and third years, indicating a 
flattening of the curve of radiographic 
progression. These results demonstrate 
that already early in the course of the dis-
ease a lot of radiographic damage maybe 
present. Therefore it is important to start 
early with effective second-line antirheu-
matic drugs. 
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Older versus younger onset RA 
Patients who develop rheumatoid ar­
thritis (RA) at an older age are often 
thought to belong to a different subclass. 
However, no unanimity exists whether 
older patients have a better or a worse 
prognosis. We studied the influence of 
age at onset in a prospective follow-up of 
early RA (Chapter IX). Both the charac­
teristics at onset (61 patients 60 years, 142 
patients < years) and after a follow-up of 
two years (46 patients 60 years, 101 pa­
tients < years) were included. 
Older age onset patients showed more 
often both large and small joints affected 
from the beginning. Besides older pa­
tients had more often weight loss. The 
most striking difference was the higher 
disease activity at the start in the older 
group. Both age groups improved during 
the two years of follow-up, but the differ­
ence in disease activity was still present at 
the end of the follow-up. Moreover, older 
patients showed significantly more radio­
graphic damage in the hands at the start. 
After two years older patients demon­
strated still more radiographic damage 
but this did not reach significance any-
niorc. The rheumatoid factor positivity 
and the ι ILA-DR4 percentage was equal 
in both groups. An unbalance of these 
lactors in many cross-sectional studies 
might be the main reason for conflicting 
results of severity in older age RA. Most 
studies with fewer rheumatoid factor 
positivity in older age patients found a 
belter prognosis in old patients. 
Prognostic factors 
Evaluation of prognostic factors of phy­
sical disability and radiographic damage 
was done in the same follow-up study of 
early RA as described above. In all 147 
patients with a follow-up of two years 
were available for analysis. Many demo­
graphic, clinical, laboratory and genetic 
features at the start and during the first 
six months of follow-up were included as 
possible prognostic factors in multiple re­
gression and discriminant analysis. 
No clinically relevant conclusions could 
be made for physical disability due to the 
low explained variance and small number 
of patients with bad physical disability. 
Radiographic damage after two years 
was predicted by high disease activity at 
the start (measured as erythrocyte se­
dimentation rate, C-reactive protein or 
Disease Activity Score) combined with 
DR4 or DR2 (as a prognostically favour­
able factor) and rheumatoid factor posi­
tivity. Radiographic damage could be 
better predicted if disease activity during 
the first six months was included. Ab­
sence or presence of progression of ra­
diographic damage could be correctly 
predicted in 83% of the patients. 
Early treatment with effective second-
line agents is especially important in 
those patients with the above-mentioned 
prognostic unfavourable factors. 
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Samenvatting en conclusies 
Dit hoofdstuk is een Nederlandse uiteenze 
voor niet-medici begrijpelijke bewoordingen, 
Reumatoïde artritis 
Reumatoïde artritis, ook chronisch ge-
wrichtsreuma of kortweg RA genoemd, 
is een onstekingsziekte van de gewrich-
ten. Het meest op de voorgrond staan 
warme, gezwollen, pijnlijke gewrichten. 
Vrijwel altijd zijn de kleine gewrichten 
van handen en/of voeten aangedaan. 
Ieder gewricht kan ontstoken raken en de 
meeste ontstekingen zijn symmetrisch: 
bijvoorbeeld beide knieën. Naast ontste-
kingen in de gewrichten kunnen er bij 
reumatoïde artritis ook afwijkingen ont-
staan in onder andere hart, longen en 
kleine bloedvaten. Reumatoïde artritis 
kan op elke leeftijd ontslaan en komt on-
geveer tweemaal zo vaak voor bij vrou-
wen als bij mannen. In Nederland lijdt 
1.5-2% van de bevolking aan reumatoïde 
artritis. Het beloop van de ziekte kan heel 
wisselend zijn. Dit varieert van een een-
malige aanval zonder restverschijnselen 
tot een snel verergerend ziektebeeld met 
blijvende beschadiging aan gewrichten 
en organen. Het merendeel van de pa-
tiënten heeft afwisselend goede en slech-
te periodes. Binnen slechte periodes kun-
nen de klachten ook van dag tot dag 
wisselen. De meeste patiënten hebben 
's ochtends de meeste klachten. Deze 
klachten bestaan uit stijfheid en pijn. 
Hierdoor kunnen ook bepaalde bewegin-
gen niet of moeilijker uitgevoerd worden. 
Indien er blijvende beschadigingen ont-
staan kan ook de stand van een gewricht 
veranderen. 
In het beginstadium van de ontsteking 
van een gewricht is het gewricht gezwol-
len en pijnlijk. Het kraakbeen van het ge-
wricht is dan nog niet aangetast en het 
van de voorafgaande hoofdstukken in 
gewricht kan nog volledig restloos gene-
zen. Wanneer de ontsteking langer blijft 
bestaan kunnen er beschadigingen in het 
gewrichtskraakbeen en het eronder lig-
gende bot ontstaan. Kraakbeen kan zich 
bijna niet herstellen. Daarom zijn be-
schadigingen in het kraakbeen ook blij-
vend. Op de röntgenfoto's kun je dit zien 
aan een versmalling van de gewrichts-
spleet. Tevens kun je kleine aanvretingen 
in hel bot aangrenzend aan hel kraak-
been zien (zogenaamde erosies). 
Behandeling 
Het doel van de behandeling van reu-
matoïde artritis is vermindering van pijn 
en stijfheid, behoud van optimale functie 
en voorkoming van blijvende bescha-
digingen. De hoeksteen van de behande-
ling van reumatoïde artritis is geneesmid-
delen. Het volledige pakket van de be-
handeling bestaat onder andere uit: voor-
lichting, fysiotherapie, oefentherapie, 
ergotherapie, orthopedische ingrepen et-
cetera. De medicamenteuze behandeling 
kan ingedeeld worden in twee hoofd-
groepen: de ecrstelijnsmid-delen (ook 
Non-S teroidal-Ant i - I η fiamma tory 
Drugs, NSAIDs, genoemd) en de twee-
delijnsmiddelen (ook Slow-Acting-Anti-
rheumalic Drugs, SAARDs, ge-noemd). 
Voorbeelden van NSAIDs zijn indome-
thacine, naprosyne. Deze middelen gaan 
wel de pijn en de stijfheid tegen maar 
kunnen niet het ziekteproces tot rust 
brengen. De SAARDs daarentegen heb­
ben wel de potentie het ziekteproces afte 
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remmen. Voorbeelden van SAARDs 
zijn: sulfasalazine, hydroxychloroquine, 
goudinjecties, methotrexaat. In het al-
gemeen hebben de SAARDs echter 
enige nadelen. Ten eerste duurt het 
geruime tijd voordat de werking intreedt. 
Dit kan bij sommige middelen drie tot zes 
maanden duren. Ten tweede kunnen 
SAARDs leiden tot ernstige bijwerkin-
gen. In grote lijnen geldt: hoc effectiever 
het middel des te meer kans op bijwer-
kingen. Indien bekend zou zijn welke 
patiënten een slechte prognose hebben, 
zouden deze patiënten met de meest ef-
fectieve, dus ook meest risicovolle medi-
cijnen behandeld kunnen worden. Te-
vens hoeven patiënten met een goede 
prognose niet aan potentiële risico's van 
geneesmiddelen bloot gesteld te worden. 
Hierdoor zou het mogelijke voordeel van 
de medicatie ten opzichte van de poten-
tiële risico's verbeterd kunnen worden. 
Literatuuroverzicht 
Een van de doelen van dit proefschrift 
was om factoren in het begin van de ziekte 
te vinden die de prognose kunnen voor-
spellen. Hel voordeel van prognostische 
factoren is meerledig. Ten eerste kunnen 
patiënten met een gunstige prognose 
gerustgeslcld worden. Ten tweede kan bij 
patiënten met een slechte prognose in 
een vroeg stadium begonnen worden met 
een effectief tweedelijns antireuma-
ticum. Tenslotte kunnen prognostische 
factoren gebruikt worden bij het testen 
van nieuwe geneesmiddelen. Sommigen 
geneesmiddelen kunnen geen effect laten 
zien als je naar een niet geselecteerde 
groep patiënten kijkt. Verdeel je deze pa-
tiënten in groepen met bepaalde prog-
nostische kenmerken dan kun je mogelijk 
in de ene groep wel en in de andere geen 
effect zien. Dit geeft dan tevens een in-
dicatie welke patiënten succesvol met dit 
middel behandeld kunnen worden. 
Er is reeds veel onderzoek gedaan naar 
het bestaan van mogelijke prognostische 
factoren. In hoofdstuk VII is hiervan een 
overzicht gegeven. Het is opvallend dat 
er veel tegenstrijdige resultaten in de 
literatuur beschreven worden. De oor-
zaak hiervan ligt waarschijnlijk in het feit 
dat vele studies niet goed opgezet waren. 
Een van de mankementen in de onder-
zoeken was dat het eindresultaat waaraan 
de prognose afgemeten werd niet goed 
gedefinieerd was. Vaak werden metingen 
bedoeld om de activiteit van de ziekte op 
een bepaald moment vast te leggen (zo-
genaamde ziekteactivitcits- of 'proces-
variabelen') gebruikt om het eindre-
sultaat van het proces (de zogenaamde 
'outcome') vast te stellen. Bovendien 
werden vele verschillende proecsvari-
abelen naast elkaar gebruikt 
Onderzoeksgroepen 
Voor dit proefschrift werden twee groe-
pen patiënten onderzocht. Ten eerste 
werd gebruikt gemaakt van een vergelij-
kend onderzoek (trial) van twee genees-
middelen. Gedurende 48 weken werden 
60 patiënten behandeld met of hydroxy-
chloroquine òf sulfasalazine. Er werd 
geloot welke patient welk geneesmiddel 
kreeg. Noch de onderzoeker, noch de 
patient was op de hoogte welk medica-
ment gebruikt werd. 
Ten tweede werden RA-patienten met 
een ziekteduur korter dan 1 jaar gezien in 
een vervolgonderzoek. Deze patiënten 
waren voor de start van het onderzoek 
nog niet behandeld met SAARDs. De 
patiënten werden iedere 4 weken op de 
polikliniek onderzocht in het Acadc-
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misch Ziekenhuis Nijmegen en het Aca-
demisch Ziekenhuis Groningen. Vele 
klinische en laboratorium variabelen 
werden verzameld door gespecialiseerde 
research verpleegkundigen. Tevens wer-
den ieder zes maanden röntgenfoto's 
gemaakt van handen en voeten en een 
vragenlijst over de functionele capaciteit 
ingevuld. 
Proces- en outcomevariabelen 
Het eerste deel van dit onderzoek heeft 
zich toegespitst op het ontwikkelen en 
valideren van proces- en outcomevari-
abelen. Valideren wil zeggen dat nage-
gaan wordt of het meetinstrument ook 
werkelijk meet wat beoogd wordt te me-
ten. Hoofdstuk II is gewijd aan de ontwik-
keling van een ziekteactivitcitsscore 
(Discase Activity Score DAS), dus een 
procesvariabele. Vele procesvariabelcn 
worden gebruikt bij de evaluatie van 
klinisch geneesmiddelenonderzoek en in 
de klinische praktijk. Hierbij doet zich 
vaak het probleem voor dat sommige 
variabelen verbeteren, terwijl anderen 
niet reageren of zelfs verslechteren. Het 
is dan moeilijk een eindconclusie over het 
beloop van de ziekteactiviteit te trekken. 
Daarnaast bestaat het probleem van het 
gebruik van vele cvaluatievariabelen in 
een onderzoek: alleen al door het toeval 
kan er een verschil gevonden worden. 
Om dit "vals positieve" resultaat te voor-
komen moet in de statistische analyse een 
correctie aangebracht worden. Dit heeft 
echter tot consequentie dat er meer pa-
tiënten aan een onderzoek moeten mee-
doen om eenzelfde effect te kunnen 
meten. 
Ziekteactiviteitsscore (DAS) 
Er bestaat geen gouden standaard voor 
ziekteactiviteit. In de algemene praktijk 
baseert de arts zich op een algemene in-
druk. Dit is een (onbewuste) samenvoe-
ging van meerdere factoren. Uit onder-
zoek is gebleken dat artsen niet kunnen 
aangeven hoe de vorming van een alge-
mene indruk plaats vindt. Daarom heb-
ben we besloten naar het handelen van 
artsen in de praktijk te kijken. Het onder-
zoek is uitgevoerd bij 113 patiënten van 
het vervolgonderzoek uit Nijmegen. De 
patiënten werden variërend van 2 tot 39 
maanden vervolgd. In totaal waren 1816 
meetpunten beschikbaar. Beslissingen 
over het al dan niet starten van SAARDs 
werden genomen door zes reumatologen. 
Als hoge ziekteactiviteit werd gekozen 
het moment waarop een SAARD werd 
gestart. Patiënten die gedurende mini-
maal eenjaar niet behandeld werden met 
een SAARD werden beschouwd als 
hebbende een lage ziekteactiviteit. Zo 
werden twee groepen gevormd: een met 
hoge ziekteactiviteit en een met lage 
ziekteactiviteit. Door middel van diverse 
statistische methoden werd nagegaan 
hoe die twee groepen het beste onder-
scheiden konden worden. Dit resulteer-
de in een samengestelde ziekteactivi-
teitsscore. Deze bestaat uit de Ritchie 
score (een maat voor het aantal pijnlijke 
gewrichten), het aantal gezwollen ge-
wrichten, de bezinking (een maat voor 
ontsteking in het bloed) en het algemeen 
welbevinden van de patiënt (aangegeven 
op een lijn van 0 tot 10 cm). Omdat de 
formule om de ziekteactivitcitsscore te 
meten moeilijk uit te rekenen is zonder 
een rekenmachine werd een nomogram 
ontwikkeld waarop de waarde gemak-
kelijk afgelezen kan worden. 
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Röntgenscore 
In hoofdstuk III en IV wordt de waarde 
getest van een methode om röntgenfoto's 
te scoren. Zowel de gewrichtsspleet-
versmalling als erosies op hand- en voet-
foto's werden gemeten. Deze methode 
werd toegepast in het vergelijkend on-
derzoek van hydroxychloroquine en sul-
fasalazine. Bij het begin, na 24 en na 48 
weken werden foto's gemaakt van han-
den en voeten. Patiënten behandeld met 
sulfasalazine hadden significant minder 
toename van de röntgenafwijkingen. Na 
48 weken werd de code verbroken en 
werden patiënten met diverse medica-
menten behandeld. Een naonderzock na 
ruim 3 jaar liet zien dat het verschil dat na 
48 weken aanwezig was nog steeds be-
stond: de eerste klap is een daalder 
waard. Uil deze onderzoeken blijkt dat 
de methode voor het scoren van de rönt-
genafwijkingen goed bruikbaar is en vol-
doende gevoelig om verschillen te kun-
nen melen. 
Functionele capaciteit 
In dezelfde trial werd eveneens een vra-
genlijst getest om de functionele capa-
citeit en psychosociale situatie te melen 
(hoofdstuk V). De vragenlijst bestond uit 
vragen over aankleden en verzorging, op-
staan, hygiëne, eten, lopen, reiken, grip, 
activiteiten buitenshuis (functionele 
capaciteit) en depressiviteit, bezorgd-
heid en relaties (psychosociale situatie). 
Deze vragenlijst was reeds ontwikkeld in 
een andere groep patiënten. Hierbij werd 
gekeken of de vragenlijst reproduceer-
baar was en overeenkwam met wat de 
patiënten werkelijk kunnen. Vervolgens 
werd gekeken hoe gevoelig de lijst was 
om veranderingen te meten in de trial. 
Patiënten behandeld met sulfasalazine 
hadden een betere functionele capaciteit 
aan het einde van de trial in vergelijking 
met patiënten behandeld met hydroxy-
chloroquine. Tussen de twee groepen 
kon geen verschil vastgesteld worden in 
psychosociale toestand. 
Validering procesvariabelen 
Nadat de twee oulcomcvariabclen (na-
melijk de röntgenscore en de functionele 
capaciteit) gedefinieerd en gelest waren, 
konden deze gebruikt worden om de 
validiteit van diverse proccsvariabclcn na 
te gaan (hoofdstuk VI). Procesvariabelen 
zijn alleen dan 'echte' proccsvariabclcn 
als ze correleren met het uiteindelijk re-
sultaat van hel proces, de outcome. Tien 
veel gebruikte individuele en drie samen-
gestelde proccsvariabclcn werden getest 
in het boven beschreven vervolgon-
derzoek van patiënten met een begin-
nende RA. De gegevens van Nijmegen en 
Groningen werden gebruikt. De vari-
abelen werden getest op de onderlinge 
correlaties, de correlatie met de funclio-
nele capaciteit en met de röntgenafwij-
kingen. Tevens werd nagegaan of de vari-
abelen konden differentiëren lussen 
patiënten met hoge en lage zicklcacli-
viteit. Patiënten werden hiervoor op de-
zelfde manier ingedeeld naar zickte-
activiteit zoals beschreven voor het 
opstellen van de ziekteactivitcilsscore 
(DAS). Omdat de DAS ïn Nijmegen om-
wikkeld was, werden voor deze analyse 
alleen de patiënten uit Groningen ge-
bruikt. De samengestelde scores (waar-
onder de DAS) bleken in totaliteit beter 
te voldoen als procesvariabele dan de in-
dividuele variabelen. De klinische indruk 
van de artsen in de praktijk (uitgedrukt in 
de DAS) bleek een valide mectinstru-
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ment te zijn. 
Beloop röntgenafwijkingen 
Hoofdstuk VIII beschrijft het beloop 
van de röntgenafwijkingen in handen en 
voeten gedurende de eerste drie jaar van 
RA. Alle 147 patiënten die minstens twee 
jaar vervolgd waren, werden geana-
lyseerd; 90 patiënten hadden een studie-
duur van meer dan 3 jaar. De halfjaar-
lijkse röntgenfoto's van handen en voeten 
werden gescoord voor gewrichtssplect-
vcrsmalling en erosies. Na 3 jaar hadden 
70% van de patiënten röntgenafwijkin-
gen in handen en/of voeten. Slechts één 
patiënt die na één jaar geen röntgenafwij-
kingen had ontwikkeld, kreeg in de vol-
gende twee jaar afwijkingen. Dus al in een 
vroeg stadium kunnen patiënten onder-
scheiden worden die wel en geen rönt-
genafwijkingen ontwikkelen. Over het 
geheel genomen waren 18-20% van de 
gewrichten in handen en voeten na 3 jaar 
beschadigd. Per gewricht was er door-
gaans een geringe mate van beschadiging. 
Gedurende de 3 jaar waren er meer voet-
gewrichten met afwijkingen dan hand-
gewrichten. Tevens werd gekeken naar 
de hoeveelheid afwijkingen die in het 
eerste, het tweede en het derde jaar ont-
stonden. In het eerste jaar kwamen be-
duidend meer afwijkingen tot stand in 
vergelijking met het tweede en derde 
jaar. Deze afname in progressie kwam 
vooral tot uiting in het aantal gewrichten 
dat beschadigd was, en minder in de ernst 
van de beschadigingen. Dit geeft aan dat 
vooral gewrichten die reeds beschadigd 
waren verder aangetast werden. Terwijl 
gewrichten zonder afwijkingen in het 
eerste jaar ook minder vaak beschadigd 
werden in het tweede en derdejaar. Deze 
resultaten geven aan dat reeds vroeg 
tijdens de ziekte röntgenafwijkingen 
ontstaan. 
RA op oudere versus jongere 
leeftijd 
Hoofdstuk IX beschrijft de vergelijking 
van RA ontstaan na en voor de zestigste 
verjaardag. De patiënten uit het vervolg-
onderzoek werden bestudeerd. Voor de 
vergelijking van het ontstaan van de ziek-
te waren 142 patiënten onder de 60 jaar 
en 71 patiënten boven de 60 jaar beschik-
baar. Reumatoïde artritis begon bij de 
oudere patiënten vaker in zowel kleine 
als grote gewrichten. Bij de jongere 
patiënten was dit overwegend in de kleine 
gewrichten. Daarnaast hadden oudere 
patiënten een duidelijk actievere ziekte 
bij het begin. Van 101 jongere patiënten 
en 46 oudere patiënten waren röntgen-
foto's, gegevens over functionele capa-
citeit en ziekteactiviteit beschikbaar van 
de start en na twee jaar. Hoewel beide 
leeftijdsgroepen verbeterd waren in de 
twee jaar vervolg, hadden de oudere pa-
tiënten na twee jaar nog steeds een hoge-
re ziekteactiviteit. Bij het begin van de 
ziekte hadden de oudere patiënten signi-
ficant meer gewrichtsspleelvcrsmalling 
in de handen. Na twee jaar was er wel een 
tendens tot meer röntgenafwijkingen bij 
de oudere patiënten, maar dit was niet 
meer significant verschillend. 
Oudere patiënten hadden gedurende 
de twee jaar van het onderzoek een ho-
gere ziekteactiviteit. Dit kwam ook tot 
uiting in een tendens tot meer röntgenaf-
wijkingen. Eerdere onderzoeken lieten 
geen verschil of juist een beter beloop bij 
oudere patiënten zien. Echter bij deze 
onderzoeken bestond er vaak cen lager 
percentage reumafactor bij de oudere 
patiënten. In ons onderzoek waren beide 
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groepen volledig vergelijkbaar wat be-
treft de rcumafactor en genetische ken-
merken (HLA-DR4). Dit verschil zou de 
discrepantie met eerder onderzoek kun-
nen verklaren. 
Prognostische factoren 
Hoofdstuk X geeft het onderzoek naar 
prognostische factoren weer. Het onder-
zoek werd uitgevoerd bij 147 patiënten 
uit het vervolgonderzoek die minimaal 
twee jaar vervolgd waren. Door middel 
van diverse statistische methoden werd 
getracht de functionele capaciteit en de 
röntgenschade na twee jaar te voorspel-
len met gegevens die bij de start aanwezig 
waren. Ook de ziektcacliviteit gedurende 
hel eerste halfjaar en de röntgentocname 
in deze periode werden als mogelijke 
voorspellende factoren toegevoegd. De 
functionele capaciteit van het overgrote 
deel van de patiënten was na twee jaar 
redelijk tol goed. De groep met een 
slechte functionele capaciteit was te klein 
om betrouwbare analyses te kunnen 
doen. Daarom werd besloten alleen de 
röntgenschade te voorspellen. De ver-
schillende analyses lieten hetzelfde beeld 
zien. Hoge ziektcacliviteit aan het begin, 
gecombineerd met bepaalde genetische 
kenmerken (HLA-DR4) en een positieve 
reumafactor in het bloed waren prog-
nostisch ongunstige factoren. De aan-
wezigheid van HLA-DR2 was juist prog-
nostisch gunstig. De röntgenafwijkingen 
konden beter voorspeld worden als 
levens de gegevens over de ziekteacti-
viteit van de eerste zes maanden gebruikt 
werden. De aan- of afwezigheid van rönt-
genafwijkingen kon met bovengenoemde 
prognostische factoren goed voorspeld 
worden bij 83% van de patiënten. Dil 
percentage is te laag om het klinisch be-
leid volledig op af te stemmen. Wel is het 
van belang om patiënten met deze prog-
nostisch factoren in een vroeg sladium 
van de ziekte te behandelen met een 
effcclicfSAARD. 
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based on four variables 
Nomogram DAS 
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Nomogram to estimate disease activity in rheumatoid arthritis. 
Use of the nomogram: 
Connect the Ritchie score with the number of swollen joints. Mark the intersection 
on axis 1. Connect the ESR (mm/l hr) with the general health (VAS mm). Mark the 
intersection on axis 2. The connection of the marks on axis 1 and axis 2 gives the DAS. 
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DAS based on three variables 
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Nomogram to estimate disease activity in rheumatoid arthritis. 
Use of the nomogram: 
Connect the Ritchie score with the number of swollen joints. Mark the intersection 
on the intersectionline R. Connect the ESR (mm/1 hr) with this mark to obtain the 
DAS. 
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Graag maak ik van deze gelegenheid gebruik de vele personen te bedanken die op 
enigerlei wijze bijgedragen hebben aan het tot stand komen van dit proefschrift. Met 
name wil ik mijn dank uitspreken aan de patiënten die zo trouw vele malen de 
polikliniek bezocht hebben en steeds bereid waren wat extra tijd en bloed aan het 
onderzoek te spenderen. De researchvcrpleegkundigen Leny Theunisse, Marijke 
Sanderson en Dini Lubberts hebben een belangrijk deel van de poliklinische taak voor 
hun rekening genomen. Zonder jullie was dit onderzoek niet mogelijk geweest. Het 
was altijd prettig samenwerken met de medewerkers op unit A van de polikliniek 
interne geneeskunde. Monique Helsen verzorgde het invriezen van het spijtbloed. 
Sonja van Oosterhout en Carien Verstccgden voerden de gegevens op accurate wijze 
in de computer in. Erik Brummelkamp schreef hiervoor de benodigde programma's 
en was altijd bereid mij met raad en daad bij te slaan bij problemen met soft- dan wel 
hardware. Anja Koster verzorgde een deel van de statistische analyses. 
Een gedeelte van de gegevens werd verzameld op de afdeling reumatische /ickten 
van het Academisch Ziekenhuis Groningen. De hele Groningse ploeg: drs. Miek van 
Leeuwen, Hermicn Kaplcin-Demkes, Wictie Lolkcma en Hannie Wcstra onder 
leiding van prof.dr. Martin van Rijswijk, ben ik hiervoor zeer erkentelijk. Miek, 
ondanks jouw geweldig drukke werkzaamheden zorgde je steeds voor aanvoer van 
nieuwe gegevens. 
Mijn dank gaat uit naar Ike Nuver-Zwarl die alle patiënten in de vergelijkende trial 
van hydroxychloroquine en sulfasalazine vervolgde. Tevens ben ik de reumatologen 
uit de Maartenskliniek Nijmegen, hel Mariaziekenhuis Tilburg en het Medisch Spec-
trum Twente erkentelijk voor de verwijzing van patiënten voor deze trial. 
I gratefully acknowledge the support of Torsten Johansson, Uppsala Sweden, for 
producing the DAS-nomogram. Many ideas, phone calls, and faxes all over the world 
passed in review before the final nomogram could be produced. Thank you for the 
very pleasant co-operation. 
Dr. Piel van Riel stond aan de wieg van dit hele project. Beste Piet, jij was de eerste 
die mijn interesse wekte voor de reumatologie. Vele discussies hebben wc gevoerd 
op zeer uiteenlopende terreinen. Geleidelijk aan heb je mij wegwijs gemaakt in het 
doen van onderzoek. Dank je voor de prettige, stimulerende samenwerking en de 
ruimte die je mij bood om zelfstandig te werken. Dr. Martin van 't Hof was de 
begeleider op statistisch gebied vanaf hel eerste uur. Heel veel lijd hebben wc samen 
doorgebracht achter de computer. Veel van mijn kennis op het gebied van pro-
grammeren en statistiek heb ik zodoende van je kunnen afkijken. Jouw vrolijke aard 
en plezierige samenwerking maakten dat ik steeds uitkeek naar onze volgende 
afspraak. Prof. dr. Leo van de Putte was altijd op de achtergrond aanwezig om op de 
juiste momenten met de juiste adviezen te komen. Leo, dankjc voor de ruimte die je 
gaf om ervaring en kennis te vergaren in het doen en het uitdragen van onderzoek. 
Alle collegae en secretaresses werkzaam op de afdeling Reumatische ziekten dank 
ik langs deze weg voor de prettige werksfeer. Samen hebben wc heel wat gezellige 
uren doorgebracht keuvelend over onderzoek, afdeling en alles wat daar totaal los 
van staat. 
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Lieve Bram, dank je voor alle zichtbare en onzichtbare steun. 
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Stellingen 
behorende bij het proefschrift 
'Disease activity and outcome in rheumatoid arthritis 
A methodological study' 
Désirée M.F.M, van der Heijde, 8 maart 1991 
1. Het gebruik van een samengestelde ziekteactiviteitsscore heeft vele 
voordelen boven het toepassen van aparte klinische en laboratoriumvariabelen. 
Dit proefschrift 
2. Sulfasalazine is in staat de toename van erosies en gewrichtsspleetver-
smalling in hand- en voetgewrichten te remmen. 
Dit proefschrift 
3. Vroeg starten van de behandeling van reumatoïde arthritis met effectieve 
tweedelijns antireumatica is van belang om irreversibele gewrichtsbescha-
diging te voorkomen. 
Dit proefschrift 
4. Zeventig procent van de patiënten met reumatoïde arthritis die zijn verwezen 
naar een specialist, krijgt erosies en gewrichtsspleel versmalling in handen en/of 
voeten. 
Dit proefschrift 
5. De combinatie van HLA-DR4, een positieve reumafactor en een hoge 
ziekteacliviteit in het begin van de ziekte voorspellen een slechter ziektebeloop, 
gemeten aan afwijkingen zichtbaar op röntgenfoto's. 
Dit proefschrift 
6. Het is algemeen bekend dat geneesmiddelen bijwerkingen kunnen ver-
oorzaken. Vaak wordt echter miskend dat zogenaamde 'natuurlijke' stoffen 
zoals bijvoorbeeld vitamines eveneens toxisch kunnen zijn. 
Kerstens et al: Megadoses vitamine D: progressieve geneeskunde? 
Ned Tijdschr Geneeskd 1990;134:1959-61 
7. Het bagatelliserend gebruik van verkleinwoorden zoals aspirientje, wijntje, 
sherrytje geeft vaak de houding van de gebruiker aan ten aanzien van deze 
stoffen. 
8. De opkomst van computers met bijbehorende printers betekent een 
toenemende verspilling van papier. Deze extra aanslag op onze bossen kan 
gemakkelijk gereduceerd worden door eenzijdig bedrukt papier te gebruiken 
voor proefafdrukken. 
9. Het ligt meer voor de hand het maximaal aantal koffers voor een vliegreis 
vast te stellen in plaats van het gewicht, analoog aan het feit dat het ticket 
bestemd is voor een bepaald aantal personen ongeacht hun lichaamsgewicht. 
10. Patiënten met een overvloedig gebruik van parfum tijdens hun bezoek aan 
de polikliniek zettten artsen in een kwalijke geur. 
11. Het op de hoogte zijn van methodologie en statistiek door de onderzoeker 
maakt de hulp van epidemioloog of statisticus niet overbodig maar vergroot de 
kans aanzienlijk om zoveel mogelijk antwoorden uit de gegevens te halen. 
12. Niet een toenemend emancipatoir besef maar economische noodzaak zal 
het aantal werkende vrouwen de komende jaren doen toenemen. 
13. Ik heb een heel eenvoudige smaak, ik ben tevreden met het beste. 
Oscar Wilde 
14. Het DAS-nomogram is gemaakt om het gebruik van de DAS in de praktijk 
te vergemakkelijken zodat het uitrekenen van de DAS, de DAS niet de das 
omdoet. 
15. Deze promotie op 8 maart door een vrouw op een aandoening die over-
wegend bij vrouwen voorkomt, past geheel in het kader van internationale 
vrouwendag. 



